



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/01/09
(87) Date publication PCT/PCT Publication Date: 2018/07/12
(85) Entrée phase nationale/National Entry: 2019/06/26
(86) N° demande PCT/PCT Application No.: US 2018/012998
(87) N° publication PCT/PCT Publication No.: 2018/129540
(30) Priorité/Priority: 2017/01/09 (US62/444,147)

(51) Cl.Int./Int.Cl. *A61K 31/7088* (2006.01),
A61K 35/17 (2015.01), *A61K 35/76* (2015.01),
A61P 31/18 (2006.01)
(71) Demandeur/Applicant:
AMERICAN GENE TECHNOLOGIES INTERNATIONAL
INC., US
(72) Inventeurs/Inventors:
LI, HAISHAN, US;
LAHUSEN, TYLER, US;
XIAO, LINGZHI, US;
PAUZA, CHARLES DAVID, US
(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : IMMUNOTHERAPIE DU VIH SANS ETAPE DE PRE-IMMUNISATION
(54) Title: HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP




Figure 17

(57) **Abrégé/Abstract:**

The present invention relates generally to immunotherapy for the treatment or prevention of HIV. In particular, the disclosure provides lentiviral vectors and associated methods that are optimized to treat HIV without a pre-immunization step.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 July 2018 (12.07.2018)



(10) International Publication Number
WO 2018/129540 A1

(51) International Patent Classification:

A61K 31/7088 (2006.01) A61K 35/76 (2015.01)
A61K 35/17 (2015.01) A61P 31/18 (2006.01)

(21) International Application Number:

PCT/US2018/012998

(22) International Filing Date:

09 January 2018 (09.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/444,147 09 January 2017 (09.01.2017) US

(71) Applicant: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC. [US/US]; 9640 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: LI, Haishan; 9640 Medical Center Drive, Rockville, MD 20850 (US). LAHUSEN, Tyler; 9640 Medical Center Drive, Rockville, MD 20850 (US). XIAO, Lingzhi; 9640 Medical Center Drive, Rockville, MD 20850 (US). PAUZA, Charles, David; 9640 Medical Center Drive, Rockville, MD 20850 (US).

(74) Agent: MULHOLLAND, William, F.; Snell & Wilmer LLP, One Arizona Center, 400 E. Van Buren, Phoenix, AZ 85004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP




Figure 17

(57) Abstract: The present invention relates generally to immunotherapy for the treatment or prevention of HIV. In particular, the disclosure provides lentiviral vectors and associated methods that are optimized to treat HIV without a pre-immunization step.

WO 2018/129540 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP

CROSS-REFERENCE TO RELATED APPLICATION

This Application claims priority to U.S. Patent Application No. 62/444,147 filed on
5 January 9, 2017, entitled “HIV Immunotherapy With No Pre-Immunization Step,” the disclosure of which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to the field of immunotherapy for the treatment
10 and prevention of HIV. In particular, the disclosed methods of treatment and prevention relate to the administration of viral vectors and systems for the delivery of genes and other therapeutic, diagnostic, or research uses without a pre-immunization step.

BACKGROUND OF THE INVENTION

15 Combination antiretroviral therapy (cART) (also known as Highly Active Antiretroviral Therapy or HAART) limits HIV-1 replication and retards disease progression, but drug toxicities and the emergence of drug-resistant viruses are challenges for long-term control in HIV-infected persons. Additionally, traditional anti-retroviral therapy, while successful at delaying the onset of AIDS or death, has yet to provide a functional cure.
20 Alternative treatment strategies are needed.

Intense interest in immunotherapy for HIV infection has been precipitated by emerging data indicating that the immune system has a major, albeit usually insufficient, role in limiting HIV replication. Virus-specific T-helper cells, which are critical to maintenance of cytolytic T cell (CTL) function, likely play a role. Viremia is also influenced by neutralizing antibodies,
25 but they are generally low in magnitude in HIV infection and do not keep up with evolving viral variants *in vivo*.

Together these data indicate that increasing the strength and breadth of HIV-specific cellular immune responses might have a clinical benefit through so-called HIV immunotherapy. Some studies have tested vaccines against HIV, but success has been limited
30 to date. Additionally, there has been interest in augmenting HIV immunotherapy by utilizing gene therapy techniques, but as with other immunotherapy approaches, success has been limited.

Viral vectors can be used to transduce genes into target cells owing to specific virus envelope-host cell receptor interactions and viral mechanisms for gene expression. As a result, viral vectors have been used as vehicles for the transfer of genes into many different cell types including whole T cells or other immune cells as well as embryos, fertilized eggs, isolated
5 tissue samples, tissue targets *in situ* and cultured cells. The ability to introduce and express foreign or altered genes in a cell is useful for therapeutic interventions such as gene therapy, somatic cell reprogramming of induced pluripotent stem cells, and various types of immunotherapy.

Gene therapy is one of the ripest areas of biomedical research with the potential to
10 create new therapeutics that may involve the use of viral vectors. In view of the wide variety of potential genes available for therapy, an efficient means of delivering these genes is needed to fulfill the promise of gene therapy as a means of treating infectious and non-infectious diseases. Several viral systems including murine retrovirus, adenovirus, parvovirus (adeno-associated virus), vaccinia virus, and herpes virus have been developed as therapeutic gene
15 transfer vectors.

There are many factors that must be considered when developing viral vectors, including tissue tropism, stability of virus preparations, stability and control of expression, genome packaging capacity, and construct-dependent vector stability. In addition, *in vivo* application of viral vectors is often limited by host immune responses against viral structural
20 proteins and/or transduced gene products.

Thus, toxicity and safety are key hurdles that must be overcome for viral vectors to be used *in vivo* for the treatment of subjects. There are numerous historical examples of gene therapy applications in humans that have met with problems associated with the host immune responses against the gene delivery vehicles or the therapeutic gene products. Viral vectors
25 (*e.g.*, adenovirus) which co-transduce several viral genes together with one or more therapeutic gene(s) are particularly problematic.

Although lentiviral vectors do not generally induce cytotoxicity and do not elicit strong host immune responses, some lentiviral vectors such as HIV-1, which carry several immunostimulatory gene products, have the potential to cause cytotoxicity and induce strong
30 immune responses *in vivo*. However, this may not be a concern for lentiviral derived transducing vectors that do not encode multiple viral genes after transduction. Of course, this may not always be the case, as sometimes the purpose of the vector is to encode a protein that will provoke a clinically useful immune response.

Another important issue related to the use of lentiviral vectors is that of possible cytopathogenicity upon exposure to some cytotoxic viral proteins. Exposure to certain HIV-1 proteins may induce cell death or functional unresponsiveness in T cells. Likewise, the possibility of generating replication-competent, virulent virus by recombination is often a concern. Accordingly, there remains a need for improved treatments of HIV.

SUMMARY OF THE INVENTION

In one aspect of the disclosure, a method of treating HIV infection in a subject is disclosed. The method includes removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC). The method further includes contacting the PBMC *ex vivo* with a therapeutically effective amount of a stimulatory agent; transducing the PBMC *ex vivo* with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for at least 1 day. The transduced PBMC may be cultured from about 1 to about 35 days. The method may further involve infusing the transduced PBMC into a subject. The subject may be a human. The stimulatory agent may include a peptide or mixture of peptides. In a preferred embodiment, the stimulatory agents include a gag peptide. The stimulatory agent may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In one embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one genetic element may include a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least
5 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
ACCA (SEQ ID NO: 2); or at least 80%, or at least 85%, or at least 90%, or at least 95%
percent identity with

10 GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG
TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC
GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
15 ACCA (SEQ ID NO: 2); or
GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC
CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA
ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, or at
20 least 85%, or at least 90%, or at least 95% percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCT
GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG
25 TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC
GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT
CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the
microRNA cluster includes:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
30 ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC
GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATG
TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG
ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA

GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC
GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a method of treating cells infected with HIV is provided. The method includes contacting peripheral blood mononuclear cells (PBMC) isolated from a subject
5 infected with HIV with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out *ex vivo*; transducing the PBMC *ex vivo* with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for at least 1 day. The transduced PBMC may be cultured from about 1 to about 35 days. The method may further involve infusing the transduced PBMC into a subject. The subject may be a human. The
10 stimulatory agent may include a peptide or mixture of peptides, and in a preferred embodiment includes a gag peptide. The stimulatory agent may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In one embodiment, the at least one genetic element may include a small RNA
15 capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at
20 least one genetic element may include a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
25 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
30 GGGGCTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA

ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
ACCA (SEQ ID NO: 2); or at least 80%, or at least 85%, or at least 90%, or at least 95%
percent identity with

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG

5 TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC

GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes

CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA

ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG

ACCA (SEQ ID NO: 2); or

10 GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC

CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA

ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, or at
least 85%, or at least 90%, or at least 95% percent identity with

15 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG

CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA

GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCT

GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG

TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC

20 GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT

CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the

microRNA cluster includes:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT

ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC

25 GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATG

TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG

ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA

GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC

GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

30 In another aspect, a lentiviral vector is disclosed. The lentiviral vector includes at least
one encoded genetic element, wherein the at least one encoded genetic element comprises a
small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small
RNA capable of targeting an HIV RNA sequence. In another aspect, the at least one encoded

genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one encoded genetic element may include a microRNA or a shRNA. The
 5 at least one encoded genetic element may include a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
 10 GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
 GGGGCTT (SEQ ID NO: 1).

15 In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
 CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
 ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
 ACCA (SEQ ID NO: 2); or at least 80%, or at least 85%, or at least 90%, or at least 95%
 20 percent identity with

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG
 TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC
 GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes
 CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
 25 ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
 ACCA (SEQ ID NO: 2); or
 GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC
 CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA
 ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

30 In another aspect, the microRNA cluster includes a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA

GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGGATGTGTACTTCT
 GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG
 TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC
 GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT
 5 CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the
 microRNA cluster includes:
 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
 ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC
 GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGGATG
 10 TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG
 ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA
 GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC
 GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector system for expressing a lentiviral particle is
 15 disclosed. The system includes a lentiviral vector as described herein; an envelope plasmid for
 expressing an envelope protein optimized for infecting a cell; and at least one helper plasmid
 for expressing gag, pol, and rev genes, wherein when the lentiviral vector, the envelope
 plasmid, and the at least one helper plasmid are transfected into a packaging cell line, a
 lentiviral particle is produced by the packaging cell line, wherein the lentiviral particle is
 20 capable of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA
 sequence. The system may further include a first helper plasmid for expressing the gag and pol
 genes, and a second plasmid for expressing the rev gene.

In another aspect, a lentiviral particle capable of infecting a cell is disclosed. The
 lentiviral particle includes an envelope protein optimized for infecting a cell, and a lentiviral
 25 vector as described herein. The envelope protein may be optimized for infecting a T cell. In a
 preferred embodiment, the envelope protein is optimized for infecting a CD4⁺ T cell.

In another aspect, a modified cell is disclosed. The modified cell includes a CD4⁺ T
 cell, wherein the CD4⁺ T cell has been infected with a lentiviral particle as described herein. In
 a preferred embodiment, the CD4⁺ T cell also recognizes an HIV antigen. In a further
 30 preferred embodiment, the HIV antigen includes a gag antigen. In a further preferred
 embodiment, the CD4⁺ T cell expresses a decreased level of CCR5 following infection with
 the lentiviral particle.

In another aspect, a method of selecting a subject for a therapeutic treatment regimen is disclosed. The method includes removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC) and determining a first quantifiable measurement associated with at least one factor associated with the PBMC; contacting the PBMC *ex vivo* with a therapeutically effective amount of a second stimulatory agent, and determining a second measurement associated with the at least one factor associated with the PBMC, whereby when the second quantifiable measurement is higher than the first quantifiable measurement, the subject is selected for the treatment regimen. The at least one factor may be T cell proliferation or IFN gamma production.

In another aspect, the methods disclosed herein include depleting at least one subset of cells from the PBMC. The method includes depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the depleting occurs after removing the leukocytes. In embodiments, the depleting occurs at the same time as removing the leukocytes.

The foregoing general description and following brief description of the drawings and detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following brief description of the drawings and detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a flow chart diagram of a particular clinical therapy strategy.

Figure 2 depicts diagrammatically how CD4⁺ T cells may be altered using gene therapy to prevent other cells from becoming infected and/or to prevent viral replication.

Figure 3 depicts an exemplary lentiviral vector system comprised of a therapeutic vector, a helper plasmid, and an envelope plasmid. The therapeutic vector shown here is a preferred therapeutic vector, which is also referred to herein as AGT103, and contains miR30CCR5-miR21Vif-miR185-Tat.

Figure 4 depicts an exemplary 3-vector lentiviral vector system in a circularized form.

Figure 5 depicts an exemplary 4-vector lentiviral vector system in a circularized form.

Figure 6 depicts exemplary vector sequences. Positive (genomic) strand sequence of the promoter and miR cluster were developed for inhibiting the spread of CCR5-tropic HIV

strains. Sequences that are not underlined comprise the EF-1alpha promoter of transcription that was selected as best for this miR cluster. Sequences that are underlined show the miR cluster consisting of miR30 CCR5 (a modification of the natural human miR30 that redirects to CCR5 mRNA), miR21 Vif (redirects to Vif RNA sequence) and miR185 Tat (redirects to Tat RNA sequence) (as shown collectively in SEQ ID NO: 33).

Figure 7 depicts exemplary lentiviral vector constructs according to aspects of the disclosure.

Figure 8 shows that knockdown of CCR5 by an experimental vector prevents R5-tropic HIV infection in AGTc120 cells. **(A)** shows CCR5 expression in AGTc120 cells with or without AGT103 lentivirus vector. **(B)** shows the sensitivity of transduced AGTc120 cells to infection with a HIV BaL virus stock that was expressing green fluorescent protein (GFP) fused to the Nef gene of HIV.

Figure 9 depicts data demonstrating regulation of CCR5 expression by shRNA inhibitor sequences in a lentiviral vector. **(A)** Screening data for potential candidates is shown. **(B)** CCR5 knock-down data following transduction with CCR5 shRNA-1 (SEQ ID NO: 16) is shown.

Figure 10 depicts data demonstrating regulation of HIV components by shRNA inhibitor sequences in a lentiviral vector. **(A)** Knock-down data for the Rev/Tat target gene is shown. **(B)** Knock-down data for the Gag target gene is shown.

Figure 11 depicts data demonstrating that AGT103 reduces expression of Tat protein expression in cells transfected with an HIV expression plasmid, as described herein.

Figure 12 depicts data demonstrating regulation of HIV components by synthetic microRNA sequences in a lentiviral vector. **(A)** Tat knock-down data is shown. **(B)** Vif knock-down data is shown.

Figure 13 depicts data demonstrating regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector.

Figure 14 depicts data demonstrating regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector containing either a long or short WPRE sequence.

Figure 15 depicts data demonstrating regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector with or without a WPRE sequence.

Figure 16 depicts data demonstrating regulation of CCR5 expression by a CD4 promoter regulating synthetic microRNA sequences in a lentiviral vector.

Figure 17 depicts data demonstrating detection of HIV Gag-specific CD4 T cells.

Figure 18 depicts data demonstrating HIV-specific CD4 T cell expansion and lentivirus transduction. **(A)** A schedule of treatment is shown. **(B)** IFN-gamma production in CD4-gated T cells is shown, as described herein. **(C)** IFN-gamma production and GFP expression in CD4-gated T cells is shown, as described herein. **(D)** Frequency of HIV-specific CD4⁺ T cells is shown, as described herein, and importantly, pre- and post-vaccination. **(E)** IFN-gamma production from PBMCs post-vaccination is shown, as described herein.

Figure 19 depicts data demonstrating a functional assay for a dose response of increasing AGT103-GFP and inhibition of CCR5 expression. **(A)** Dose response data for increasing amounts of AGT103-GFP is shown. **(B)** Normal distribution populations in terms of CCR5 expression are shown. **(C)** Percentage inhibition of CCR5 expression with increasing doses of AGT103-GFP is shown.

Figure 20 depicts data demonstrating that AGT103 efficiently transduces primary human CD4⁺ T cells. **(A)** Frequency of transduced cells (GFP-positive) is shown by FACS, as described herein. **(B)** Number of vector copies per cell is shown, as described herein.

Figure 21 depicts data demonstrating that AGT103 inhibits HIV replication in primary CD4⁺ T cells, as described herein.

Figure 22 depicts data demonstrating that AGT103 protects primary human CD4⁺ T cells from HIV-induced depletion.

Figure 23 depicts data demonstrating generation of a CD4⁺ T cell population that is highly enriched for HIV-specific, AGT103-transduced CD4 T cells. **(A)** shows CD4 and CD8 expression profiles for cell populations, as described herein. **(B)** shows CD4 and CD8 expression profiles for cell populations, as described herein. **(C)** shows IFN-gamma and CD4 expression profiles for cell populations, as described herein. **(D)** shows IFN-gamma and GFP expression profiles for cell populations, as described herein.

Figure 24 depicts a schematic of a CD8 depletion protocol.

Figure 25 depicts expansion of Gag-specific T cells by peptide stimulation, CD8 depletion and IL-7/IL-15 incubation. **(A)**, **(B)**, and **(C)** depict flow cytometry data that shows significantly improved CD4⁺ T cell expansion after depletion of CD8⁺ cells. In addition to improved CD4⁺ T cell expansion, there was also **(A)** overgrowth of Vδ1 T cells and **(C)** overgrowth of NK cells.

Figure 26 depicts a schematic of a CD8/CD56/CD19/γδ depletion protocol.

Figure 27 depicts expansion of Gag-specific T cells by peptide stimulation, CD8/γδ/NK/B cell depletion and IL-7/IL-15 incubation. **(A)-(B)** depict flow cytometry data

that shows that overgrowth of CD8⁺, $\gamma\delta$, or NK cells either inhibits CD4⁺ T cell growth or kills lentivirus-transduced antigen-specific CD4⁺ T cells. After depletion of CD8⁺, $\gamma\delta$, or NK cells, CD4⁺ T cells were expanded.

Figure 28 depicts expansion and transduction of Gag-specific T cells by peptide stimulation, CD8/ $\gamma\delta$ /NK/B cell depletion and IL-7/IL-15 incubation. IFN- γ positive, antigen-specific CD4⁺ T cells resulted in better transduction efficiency compared to other subsets in culture.

Figure 29 depicts a relationship between the percentage of transduced cells and the vector copy number. **(A)** depicts a table that shows that as the percentage of transduced cells increase, the vector copy number also increases (n=4). **(B)** shows regression analysis of the same samples depicted in the table, which shows a positive correlation between the percentage of transduced cells and the vector copy number (n=4).

DETAILED DESCRIPTION

15 Overview

Disclosed herein are methods and compositions for treating and/or preventing human immunodeficiency virus (HIV) disease to achieve a functional cure. A functional cure is defined as a condition resulting from the disclosed treatments and methods that reduces or eliminates the need for cART and may or may not require supporting adjuvant therapy. The methods of the invention include gene delivery by integrating lentivirus, non-integrating lentivirus, and related viral vector technology as described below.

Disclosed herein are therapeutic viral vectors (e.g., lentiviral vectors), immunotherapies, and methods for their use in a strategy to achieve a functional cure for HIV infection. As depicted in Figure 1 herein, a strategy for treating HIV includes a first therapeutic immunization with vaccines intended to produce strong immune responses against HIV in HIV-infected patients with stable suppression of viremia due to daily administration of HAART, for the purpose of enriching the fraction of HIV-specific CD4 T cells. However, as detailed herein, the first therapeutic immunization may not be necessary. This is then followed by (1) isolating peripheral leukocytes by leukapheresis or purifying PBMC from venous blood, (2) re-stimulating CD4 T cells *ex vivo* with HIV vaccine proteins, (3) performing therapeutic lentivirus transduction, *ex vivo* T cell culture, and (4) re-infusion back into the original donor.

In respect of the foregoing, and in reference to Figure 2 herein, the methods can be used to prevent new cells, such as CD4⁺ T cells, from becoming infected with HIV. To prevent new

cells from becoming infected, CCR5 expression can be targeted to prevent virus attachment. Further, destruction of any residual infecting viral RNA can also be targeted. In respect of the foregoing, and in reference to Figure 2 herein, the methods can also be used to stop the HIV viral cycle in cells that have already become infected with HIV. To stop the HIV viral cycle, viral RNA produced by latently-infected cells, such as latently-infected CD4⁺ T cells, can be targeted.

By providing highly effective therapeutic lentiviruses capable of inhibiting HIV, a new strategy for achieving a functional cure of HIV has been developed.

10 **Definitions and Interpretation**

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclature used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, *e.g.*: Sambrook J. & Russell D. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2000); Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, John & Sons, Inc. (2002); Harlow and Lane Using Antibodies: A Laboratory Manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1998); and Coligan et al., Short Protocols in Protein Science, Wiley, John & Sons, Inc. (2003). Any enzymatic reactions or purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art.

As used herein, the term "about" will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are

uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term.

As used herein, the terms “administration of” or “administering” an active agent means providing an active agent of the invention to the subject in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically effective amount.

As used herein, the term “AGT103” refers to a particular embodiment of a lentiviral vector that contains a miR30-CCR5/miR21-Vif/miR185-Tat microRNA cluster sequence, as detailed herein.

As used herein, the term “AGT103T” refers to a cell that has been transduced with a lentivirus or lentiviral particle that contains the AGT103 lentiviral vector.

Throughout this specification and claims, the word “comprise,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Further, as used herein, the term “includes” means includes without limitation.

The term “engraftment” refers to the ability for one skilled in the art to determine a quantitative level of sustained engraftment in a subject following infusion of a cellular source (see for *e.g.*: Rosenberg et al., *N. Engl. J. Med.* 323:570-578 (1990); Dudley et al., *J. Immunother.* 24:363-373 (2001); Yee et al., *Curr. Opin. Immunol.* 13:141-146 (2001); Rooney et al., *Blood* 92:1549-1555 (1998)).

The terms, “expression,” “expressed,” or “encodes” refer to the process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. Expression may include splicing of the mRNA in a eukaryotic cell or other forms of post-transcriptional modification or post-translational modification.

The term “functional cure” refers to a state or condition wherein HIV+ individuals who previously required cART or HAART, may survive with low or undetectable virus replication using lower doses, intermittent doses, or discontinued dosing of cART or HAART. An individual may be said to have been “functionally cured” while still requiring adjunct therapy to maintain low level virus replication and slow or eliminate disease progression. A possible outcome of a functional cure is the eventual eradication of HIV to prevent all possibility of recurrence.

The term “HIV vaccine” encompasses immunogens plus vehicle plus adjuvant intended to elicit HIV-specific immune responses. A “HIV vaccine” may include purified or whole inactivated virus particles that may be HIV or a recombinant virus vectors capable of expressing HIV proteins, protein fragments or peptides, glycoprotein fragments or glycopeptides, in addition to recombinant bacterial vectors, plasmid DNA or RNA capable of directing cells to producing HIV proteins, glycoproteins or protein fragments able to elicit specific immunity. Alternately, specific methods for immune stimulation including anti-CD3/CD28 beads, T cell receptor-specific antibodies, mitogens, superantigens and other chemical or biological stimuli may be used to activate dendritic, T or B cells for the purposes of enriching HIV-specific CD4 T cells prior to transduction or for *in vitro* assay of lentivirus-transduced CD4 T cells. Activating substances may be soluble, polymeric assemblies, liposome or endosome-based or linked to beads. Cytokines including interleukin-2, 6, 7, 12, 15, 23 or others may be added to improve cellular responses to stimuli and/or improve the survival of CD4 T cells throughout the culture and transduction intervals. Alternately, and without limiting any of the foregoing, the term “HIV vaccine” encompasses the MVA/HIV62B vaccine and variants thereof. The MVA/HIV62B vaccine is a known highly attenuated double recombinant MVA vaccine. The MVA/HIV62B vaccine was constructed through the insertion of HIV-1 gag-pol and env sequences into the known MVA vector (see: for *e.g.*: Goepfert et al. (2014) J. Infect. Dis. 210(1): 99-110, and see WO2006026667, both of which are incorporated herein by reference). The term “HIV vaccine” also includes any one or more vaccines provided in Table 1, below.

Table 1

IAVI Clinical Trial ID*	Prime**
HVTN 704 AMP	VRC-HIVMAB060-00-AB
VAC89220HPX2004	Ad26.Mos.HIV Trivalent
01-I-0079	VRC4302
04/400-003-04	APL 400-003 GENEVAX-HIV
10-1074	10-1074
87 I-114	gp160 Vaccine (Immuno-AG)

96-I-0050	APL 400-003 GENEVAX-HIV
ACTG 326; PACTG 326	ALVAC vCP1452
Ad26.ENVA.01	Ad26.EnvA-01
Ad26.ENVA.01 Mucosal/IPCAVD003	Ad26.EnvA-01
Ad5HVR48.ENVA.01	Ad5HVR48.ENVA.01
ANRS VAC 01	ALVAC vCP125
ANRS VAC 02	rgp 160 + peptide V3 ANRS VAC 02
ANRS VAC 03	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 04	LIPO-6
ANRS VAC 04 bis	LIPO-6
ANRS VAC 05	ALVAC vCP125
ANRS VAC 06	ALVAC vCP125
ANRS VAC 07	ALVAC vCP300
ANRS VAC 08	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 09	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 09 bis	LIPO-6
ANRS VAC 10	ALVAC vCP1452
ANRS VAC 12	LPHIV1
ANRS VAC 14	gp160 MN/LAI
ANRS VAC 16	LPHIV1
ANRS VAC 17	LIPO-6
ANRS VAC 18	LIPO-5
APL 400-003RX101	APL 400-003 GENEVAX-HIV
AVEG 002	HIVAC-1e

AVEG 002A	HIVAC-1e
AVEG 002B	HIVAC-1e
AVEG 003	VaxSyn gp160 Vaccine (MicroGeneSys)
AVEG 003A	VaxSyn gp160 Vaccine (MicroGeneSys)
AVEG 003B	VaxSyn gp160 Vaccine (MicroGeneSys)
AVEG 004	gp160 Vaccine (Immuno-AG)
AVEG 004A	gp160 Vaccine (Immuno-AG)
AVEG 004B	gp160 Vaccine (Immuno-AG)
AVEG 005A/B	Env 2-3
AVEG 005C	Env 2-3
AVEG 006X; VEU 006	MN rgp120
AVEG 007A/B	rgp120/HIV-1 SF-2
AVEG 007C	rgp120/HIV-1 SF-2
AVEG 008	HIVAC-1e
AVEG 009	MN rgp120
AVEG 010	HIVAC-1e
AVEG 011	UBI HIV-1 Peptide Immunogen, Multivalent
AVEG 012A/B	ALVAC vCP125
AVEG 013A	gp160 Vaccine (Immuno-AG)
AVEG 013B	gp160 Vaccine (Immuno-AG)
AVEG 014A/B	TBC-3B
AVEG 014C	TBC-3B
AVEG 015	rgp120/HIV-1 SF-2
AVEG 016	MN rgp120

AVEG 016A	MN rgp120
AVEG 016B	MN rgp120
AVEG 017	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent
AVEG 018	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent
AVEG 019	p17/p24:Ty- VLP
AVEG 020	gp120 C4-V3
AVEG 021	P3C541b Lipopeptide
AVEG 022	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 022A	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 023	UBI HIV-1 Peptide Immunogen, Multivalent
AVEG 024	rgp120/HIV-1 SF-2
AVEG 026	ALVAC vCP300
AVEG 027	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 028	Salmonella typhi CVD 908-HIV-1 LAI gp 120
AVEG 029	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 031	APL 400-047
AVEG 032	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 033	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 034/034A	ALVAC vCP1433
AVEG 036	MN rgp120
AVEG 038	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 201	rgp120/HIV-1 SF-2
AVEG 202/HIVNET 014	ALVAC-HIV MN120TMG strain (vCP205)

C060301	GTU-MultiHIV
C86P1	HIV gp140 ZM96
Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine (TL01)	CN54gp140
CM235 and SF2gp120	CM235 (ThaiE) gp120 plus SF2(B) gp120
CM235gp120 and SF2gp120	CM235 (ThaiE) gp120 plus SF2(B) gp120
CombiHIVvac (KombiVICHvak)	CombiHIVvac
CRC282	P2G12
CRO2049/ CUT*HIVAC001	GTU-MultiHIV
CUTHIVAC002	DNA-C CN54ENV
DCVax-001	DCVax-001
DNA-4	DNA-4
DP6?001	DP6?001 DNA
DVP-1	EnvDNA
EN41-UGR7C	EN41-UGR7C
EnvDNA	EnvDNA
EnvPro	EnvPro
EuroNeut41	EN41-FPA2
EV01	NYVAC-C
EV02 (EuroVacc 02)	DNA-C
EV03/ANRSVAC20	DNA-C
Extention HVTN 073E/SAAVI 102	Sub C gp140
F4/AS01	F4/AS01
FIT Biotech	GTU-Nef
Guangxi CDC DNA vaccine	Chinese DNA

HGP-30 memory responses	HGP-30
HIV-CORE002	ChAdV63.HIVconsv
HIV-POL-001	MVA-mBN32
HIVIS 01	HIVIS-DNA
HIVIS 02	MVA-CMDR
HIVIS 03	HIVIS-DNA
HIVIS 05	HIVIS-DNA
HIVIS06	HIVIS-DNA
HIVIS07	HIVIS-DNA
HIVNET 007	ALVAC-HIV MN120TMG strain (vCP205)
HIVNET 026	ALVAC vCP1452
HPTN 027	ALVAC-HIV vCP1521
HVRF-380-131004	Vichrepol
HVTN 039	ALVAC vCP1452
HVTN 040	AVX101
HVTN 041	rgp120w61d
HVTN 042 / ANRS VAC 19	ALVAC vCP1452
HVTN 044	VRC-HIVDNA009-00-VP
HVTN 045	pGA2/JS7 DNA
HVTN 048	EP HIV-1090
HVTN 049	Gag and Env DNA/PLG microparticles
HVTN 050/Merck 018	MRKAd5 HIV-1 gag
HVTN 052	VRC-HIVDNA009-00-VP
HVTN 054	VRC-HIVADV014-00-VP

HVTN 055	TBC-M335
HVTN 056	MEP
HVTN 057	VRC-HIVDNA009-00-VP
HVTN 059	AVX101
HVTN 060	HIV-1 gag DNA
HVTN 063	HIV-1 gag DNA
HVTN 064	EP HIV-1043
HVTN 065	pGA2/JS7 DNA
HVTN 067	EP-1233
HVTN 068	VRC-HIVADV014-00-VP
HVTN 069	VRC-HIVDNA009-00-VP
HVTN 070	PENNVAX-B
HVTN 071	MRKAd5 HIV-1 gag
HVTN 072	VRC-HIVDNA044-00-VP
HVTN 073	SAAVI DNA-C2
HVTN 076	VRC-HIVDNA016-00-VP
HVTN 077	VRC-HIVADV027-00-VP
HVTN 078	NYVAC-B
HVTN 080	PENNVAX-B
HVTN 082	VRC-HIVDNA016-00-VP
HVTN 083	VRC-HIVADV038-00-VP
HVTN 084	VRC-HIVADV054-00-VP
HVTN 085	VRC-HIVADV014-00-VP
HVTN 086, SAAVI 103	SAAVI MVA-C

HVTN 087	HIV-MAG
HVTN 088	Oligomeric gp140/MF59
HVTN 090	VSV-Indiana HIV gag vaccine
HVTN 092	DNA-HIV-PT123
HVTN 094	GEO-D03
HVTN 096	DNA-HIV-PT123
HVTN 097	ALVAC-HIV vCP1521
HVTN 098	PENNVAX-GP
HVTN 100	ALVAC-HIV-C (vCP2438)
HVTN 101	DNA-HIV-PT123
HVTN 102	DNA-HIV-PT123
HVTN 104	VRC-HIVMAB060-00-AB
HVTN 105	AIDSVAX B/E
HVTN 106	DNA Nat-B env
HVTN 110	Ad4-mgag
HVTN 112	HIV-1 nef/tat/vif, env pDNA vaccine
HVTN 114; GOVX-B11	AIDSVAX B/E
HVTN 116	VRC-HIVMAB060-00-AB
HVTN 203	ALVAC vCP1452
HVTN 204	VRC-HIVDNA016-00-VP
HVTN 205	pGA2/JS7 DNA
HVTN 502/Merck 023 (Step Study)	MRKAd5 HIV-1 gag/pol/nef
HVTN 503 (Phambili)	MRKAd5 HIV-1 gag/pol/nef
HVTN 505	VRC-HIVDNA016-00-VP

HVTN 702	ALVAC-HIV-C (vCP2438)
HVTN 703 AMP	VRC-HIVMAB060-00-AB
HVTN 908	pGA2/JS7 DNA
IAVI 001	DNA.HIVA
IAVI 002	DNA.HIVA
IAVI 003	MVA.HIVA
IAVI 004	MVA.HIVA
IAVI 005	DNA.HIVA
IAVI 006	DNA.HIVA
IAVI 008	MVA.HIVA
IAVI 009	DNA.HIVA
IAVI 010	DNA.HIVA
IAVI 011	MVA.HIVA
IAVI 016	MVA.HIVA
IAVI A001	tgAAC09
IAVI A002	tgAAC09
IAVI A003	AAV1-PG9
IAVI B001	Ad35-GRIN/ENV
IAVI B002	Adjuvanted GSK investigational HIV vaccine formulation 1
IAVI B003	Ad26.EnvA-01
IAVI B004	HIV-MAG
IAVI C001	ADVAX
IAVI C002	ADMVA
IAVI C003	ADMVA

IAVI C004/DHO-614	ADVAX
IAVI D001	TBC-M4
IAVI N004 HIV-CORE 004	Ad35-GRIN
IAVI P001	ADVAX
IAVI P002	ADVAX
IAVI R001	rcAd26.MOS1.HIVEnv
IAVI S001	SeV-G
IAVI V001	VRC-HIVDNA016-00-VP
IAVI V002	VRC-HIVDNA016-00-VP
IDEA EV06	DNA-HIV-PT123
IHV01	Full-Length Single Chain (FLSC)
IMPAACT P1112	VRC-HIVMAB060-00-AB
IPCAVD006	MVA mosaic
IPCAVD008	Trimeric gp140
IPCAVD009	Ad26.Mos.HIV Trivalent
IPCAVD010	Ad26.Mos.HIV Trivalent
ISS P-001	Tat vaccine
ISS P-002	Tat vaccine
LFn-p24 vaccine	LFn-p24
MCA-0835	3BNC117
Merck V520-007	Ad-5 HIV-1 gag (Merck)
MRC V001	rgp120w61d
MRK Ad5	Ad-5 HIV-1 gag (Merck)
MRKAd5 + ALVAC	MRKAd5 HIV-1 gag

Mucovac2	CN54gp140
MV1-F4	Measles Vector - GSK
MYM-V101	Virosome-Gp41
NCHECR-AE1	pHIS-HIV-AE
PACTG 230	AIDSVAX B/E
PAVE100	VRC-HIVDNA016-00-VP
PEACHI-04	ChAdV63.HIVconsV
PedVacc001 & PedVacc002	MVA.HIVA
PolyEnv1	PolyEnv1
PXVX-HIV-100-001	Ad4-mgag
RISVAC02	MVA-B
RisVac02 boost	MVA-B
RV 124	ALVAC-HIV MN120TMG strain (vCP205)
RV 132	ALVAC-HIV vCP1521
RV 135	ALVAC-HIV vCP1521
RV 138; B011	ALVAC-HIV MN120TMG strain (vCP205)
RV 144	ALVAC-HIV vCP1521
RV 151 / WRAIR 984	LFn-p24
RV 156	VRC-HIVDNA009-00-VP
RV 156A	VRC-HIVDNA009-00-VP
RV 158	MVA-CMDR
RV 172	VRC-HIVDNA016-00-VP
RV 305	ALVAC-HIV vCP1521
RV 306	ALVAC-HIV vCP1521

RV 328	AIDSVAX B/E
RV 365	MVA-CMDR
RV262	Pennvax-G
SG06RS02	HIV gp140 ZM96
TAB9	TAB9
TaMoVac II	HIVIS-DNA
TAMOVAC-01-MZ	HIVIS-DNA
Tiantan vaccinia HIV Vaccine	Chinese DNA
Tiantan vaccinia HIV Vaccine and DNA	Chinese DNA
TMB-108	Ibalizumab
UBI HIV-1 MN China	UBI HIV-1 Peptide Immunogen, Multivalent
UBI HIV-1MN octameric - Australia study	UBI HIV-1 Peptide Immunogen, Multivalent
UBI V106	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent
UCLA MIG-001	TBC-3B
UCLA MIG-003	ALVAC-HIV MN120TMG strain (vCP205)
UKHVCSpoke003	DNA - CN54ENV and ZM96GPN
V24P1	HIV p24/MF59 Vaccine
V3-MAPS	V3-MAPS
V520-016	MRKAd5 HIV-1 gag/pol/nef
V520-027	MRKAd5 HIV-1 gag/pol/nef
V526-001 MRKAd5 and MRKAd6 HIV-1 Trigene Vaccines	MRKAd5 HIV-1 gag/pol/nef
VAX 002	AIDSVAX B/B
VAX 003	AIDSVAX B/E

VAX 004	AIDSVAX B/B
VRC 004 (03-I-0022)	VRC-HIVDNA009-00-VP
VRC 006 (04-I-0172)	VRC-HIVADV014-00-VP
VRC 007 (04-I-0254)	VRC-HIVDNA016-00-VP
VRC 008 (05-I-0148)	VRC-HIVDNA016-00-VP
VRC 009 (05-I-0081)	VRC-HIVDNA009-00-VP
VRC 010 (05-I-0140)	VRC-HIVADV014-00-VP
VRC 011(06-I-0149)	VRC-HIVDNA016-00-VP
VRC 012 (07-I-0167)	VRC-HIVADV027-00-VP
VRC 015 (08-I-0171)	VRC-HIVADV014-00-VP
VRC 016	VRC-HIVDNA016-00-VP
VRC 602	VRC-HIVMAB060-00-AB
VRC 607	VRCHIVMAB080-00-AB
VRC01LS	VRCHIVMAB080-00-AB
VRI01	MVA-B
X001	CN54gp140

*IAVI is the International AIDS Vaccine Initiative, whose clinical trials database is publicly available at <http://www.iavi.org/trials-database/trials>.

** As used herein, the term “Prime” refers to the composition initially used as an immunological inoculant in a given clinical trial as referenced in Table 1 herein.

5 The term “*in vivo*” refers to processes that occur in a living organism. The term “*ex vivo*” refers to processes that occur outside of a living organism.

 The term “miRNA” refers to a microRNA and also maybe referred to as “miR”.

 The term “packaging cell line” refers to any cell line that can be used to express a lentiviral particle.

10 The term “percent identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of

nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (*e.g.*, BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the “percent identity” can exist over a region of the sequence being compared, *e.g.*, over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared. For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel *et al.*, *infra*).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website.

The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62

matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

The nucleic acid and protein sequences of the present disclosure can further be used as a “query sequence” to perform a search against public databases to, for example, identify
5 related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST
10 protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

15 As used herein, “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

20 As used herein, a “pharmaceutically acceptable carrier” refers to, and includes, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The compositions can include a pharmaceutically acceptable salt, *e.g.*, an acid addition salt or a base addition salt (see, *e.g.*, Berge *et al.* (1977) *J Pharm Sci* 66:1-19).

25 As used herein, the term “SEQ ID NO” is synonymous with the term “Sequence ID No.”

As used herein, “small RNA” refers to non-coding RNA that are generally less than about 200 nucleotides or less in length and possess a silencing or interference function. In other embodiments, the small RNA is about 175 nucleotides or less, about 150 nucleotides or
30 less, about 125 nucleotides or less, about 100 nucleotides or less, or about 75 nucleotides or less in length. Such RNAs include microRNA (miRNA), small interfering RNA (siRNA), double stranded RNA (dsRNA), and short hairpin RNA (shRNA). “Small RNA” of the

disclosure should be capable of inhibiting or knocking-down gene expression of a target gene, generally through pathways that result in the destruction of the target gene mRNA.

As used herein, the term “stimulatory agent” refers to any exogenous agent that can stimulate a leukocyte.

5 As used herein, the term “subject” includes a human patient but also includes other mammals. The terms “subject,” “individual,” “host,” and “patient” may be used interchangeably herein.

As used herein, the term “target cell” generally refers to a CD4⁺ T cell that responds to stimulation with protein or peptide fragments representing HIV gene sequences, and includes a
10 CD4⁺ T cell that has been transduced with the lentivirus vectors detailed herein rendering it less sensitive to HIV.

The term “therapeutically effective amount” refers to a sufficient quantity of the active agents of the present invention, in a suitable composition, and in a suitable dosage form to treat or prevent the symptoms, progression, or onset of the complications seen in patients suffering
15 from a given ailment, injury, disease, or condition. The therapeutically effective amount will vary depending on the state of the patient’s condition or its severity, and the age, weight, *etc.*, of the subject to be treated. A therapeutically effective amount can vary, depending on any of a number of factors, including, *e.g.*, the route of administration, the condition of the subject, as well as other factors understood by those in the art.

20 As used herein, the term “therapeutic vector” is synonymous with a lentiviral vector such as the AGT103 vector.

The term “treatment” or “treating” generally refers to an intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include, but are not
25 limited to, preventing occurrence or recurrence of disease, alleviating symptoms, suppressing, diminishing or inhibiting any direct or indirect pathological consequences of the disease, ameliorating or palliating the disease state, and causing remission or improved prognosis.

Description of Aspects of the Disclosure

30 As detailed herein, in one aspect, a method of treating HIV infection in a subject is disclosed. The method includes removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC). The method further includes contacting the PBMC *ex vivo* with a therapeutically effective amount of a stimulatory agent; transducing the PBMC *ex vivo*

with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for at least 1 day. The method may further include further enrichment of the PBMC, for example, by preferably enriching the PBMC for CD4⁺ T cells. The transduced PBMC may be cultured from about 1 to about 35 days. The method may further involve infusing the transduced PBMC into a subject. The subject may be a human. The stimulatory agent may include a peptide or mixture of peptides. In a preferred embodiment, the stimulatory agent includes a gag peptide. The stimulatory agent may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In one embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one genetic element may include a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA GGGGCTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG ACCA (SEQ ID NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%,

at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%,
at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG
TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC

5 GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
ACCA (SEQ ID NO: 2); or

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC

10 CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA
ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, at
least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at
least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at

15 least 95% or more percent identity with

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCT
GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG

20 TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC
GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT
CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the
microRNA cluster includes:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT

25 ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC
GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATG
TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG
ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA
GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC
30 GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a method of treating cells infected with HIV is provided. The method
includes contacting peripheral blood mononuclear cells (PBMC) isolated from a subject
infected with HIV with a therapeutically effective amount of a stimulatory agent, wherein the

contacting is carried out *ex vivo*; transducing the PBMC *ex vivo* with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for at least 1 day. The transduced PBMC may be cultured from about 1 to about 35 days. The method may further involve infusing the transduced PBMC into a subject. The subject may be a human. The
5 stimulatory agent may include a peptide or mixture of peptides, and in a preferred embodiment includes a gag peptide. The stimulatory agent may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In one embodiment, the at least one genetic element may include a small RNA
10 capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another embodiment, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at
15 least one genetic element may include a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least
20 94%, at least 95% or more percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

25 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least
30 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG

ACCA (SEQ ID NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG

5 TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC
GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG
ACCA (SEQ ID NO: 2); or
10 GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC
CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA
ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at
15 least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCT
20 GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG
TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC
GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT
CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the
microRNA cluster includes:

25 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC
GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATG
TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG
ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA
30 GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC
GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector is disclosed. The lentiviral vector includes at least one encoded genetic element, wherein the at least one encoded genetic element comprises a

small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another aspect a lentiviral vector is disclosed in the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one encoded genetic element may include a microRNA or a shRNA. The at least one encoded genetic element may include a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA GGGGCTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA GGGGCTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG ACCA (SEQ ID NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGG TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTC GTCG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTG

ACCA (SEQ ID NO: 2); or
 GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC
 CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCA
 ATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

5 In another aspect, the microRNA cluster includes a sequence having at least 80%, at
 least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at
 least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at
 least 95% or more percent identity with
 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
 10 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
 GGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGGATGTGTACTTCT
 GAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGG
 TATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCC
 GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTT
 15 CCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the
 microRNA cluster includes:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
 ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTC
 GGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGGATG
 20 TGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTG
 ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGA
 GGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC
 GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector system for expressing a lentiviral particle is
 25 disclosed. The system includes a lentiviral vector as described herein; an envelope plasmid for
 expressing an envelope protein optimized for infecting a cell; and at least one helper plasmid
 for expressing gag, pol, and rev genes, wherein when the lentiviral vector, the envelope
 plasmid, and the at least one helper plasmid are transfected into a packaging cell line, a
 lentiviral particle is produced by the packaging cell line, wherein the lentiviral particle is
 30 capable of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA
 sequence.

In another aspect, a lentiviral particle capable of infecting a cell is disclosed. The
 lentiviral particle includes an envelope protein optimized for infecting a cell, and a lentiviral

vector as described herein. The envelope protein may be optimized for infecting a T cell. In a preferred embodiment, the envelope protein is optimized for infecting a CD4⁺ T cell.

In another aspect, a modified cell is disclosed. The modified cell includes a CD4⁺ T cell, wherein the CD4⁺ T cell has been infected with a lentiviral particle as described herein. In
 5 a preferred embodiment, the CD4⁺ T cell also recognizes an HIV antigen. In a further preferred embodiment, the HIV antigen includes a gag antigen. In a further preferred embodiment, the CD4⁺ T cell expresses a decreased level of CCR5 following infection with the lentiviral particle.

In another aspect, a method of selecting a subject for a therapeutic treatment regimen is
 10 disclosed. The method includes removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC) and determining a first quantifiable measurement associated with at least one factor associated with the PBMC; contacting the PBMC *ex vivo* with a therapeutically effective amount of a second stimulatory agent, and determining a second measurement associated with the at least one factor associated with the PBMC, whereby when
 15 the second quantifiable measurement is higher than the first quantifiable measurement, the subject is selected for the treatment regimen. The at least one factor may be T cell proliferation or IFN gamma production.

In another aspect, any of the methods comprising treating cells infected with HIV described herein further comprise depleting at least one subset of cells from the PBMC. In
 20 embodiments, the method includes depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the depleting occurs after removing the leukocytes. In embodiments, the depleting occurs at the same time as removing the leukocytes.

In other aspect, any of the methods comprising treating HIV in a subject described herein further comprise depleting at least one subset of cells from the PBMC. In embodiments, the method includes depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes. In
 25
 30 embodiments, the depleting occurs after removing the leukocytes. In embodiments, the depleting occurs at the same time as removing the leukocytes.

In another aspect, any of the methods comprising selected a subject for a therapeutic regimen described herein further comprise depleting at least one subset of cells from the

PBMC. In embodiments, the method includes depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the depleting occurs after removing the leukocytes. In
 5 embodiments, the depleting occurs at the same time as removing the leukocytes.

In another aspect, any of the methods described herein further comprise depleting at least one subset of immune cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells
 10 depleted from the PBMC are CD8⁺ T cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells. In embodiments, the cells depleted from the PBMC are NK cells. In embodiments, the cells depleted from the PBMC are B cells. In embodiments, the cells depleted from the PBMC are T regulatory cells. In embodiments, the cells depleted from the PBMC are NKT cells. In embodiments, the cells depleted from the PBMC are erythrocytes.
 15 In embodiments, the cells depleted from the PBMC are CD8⁺ T cells and $\gamma\delta$ cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, $\gamma\delta$ cells, and NK cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, $\gamma\delta$ cells, NK cells, and B cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, and T regulatory cells. In embodiments, the cells depleted from the PBMC are CD8⁺
 20 T cells, $\gamma\delta$ cells, NK cells, B cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, $\gamma\delta$ cells, NK cells, B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells and NK cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells, NK cells, and B cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells, NK cells, B cells, and T
 25 regulatory cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells, NK cells, B cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ cells, NK cells, B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are NK cells and B cells. In embodiments, the cells depleted from the PBMC are NK cells, B cells, and T regulatory cells. In embodiments,
 30 the cells depleted from the PBMC are NK cells, B cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are NK cells, B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are B cells and T regulatory cells. In embodiments, the cells depleted from the PBMC are B cells, T regulatory

cells, and NKT cells. In embodiments, the cells depleted from the PBMC are B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are T regulatory cells and NKT cells. In embodiments, the cells depleted from the PBMC are T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are NKT cells and erythrocytes. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells and NK cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, NK cells, and B cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, NK Cells, B cells, and T regulatory cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, NK Cells, B cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are CD8⁺ T cells, NK Cells, B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are $\gamma\delta$ and B cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$, B cells, and T regulatory cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$, B cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are $\gamma\delta$, B cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are NK cells and T regulatory cells. In embodiments, the cells depleted from the PBMC are NK cells, T regulatory cells, and NKT cells. In embodiments, the cells depleted from the PBMC are NK cells, T regulatory cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are B cells and NKT cells. In embodiments, the cells depleted from the PBMC are B cells, NKT cells, and erythrocytes. In embodiments, the cells depleted from the PBMC are T regulatory cells and erythrocytes. In embodiments, the cells depleted from the PBMC, as described herein, include any one or any combination of neutrophils, basophils, and eosinophils.

In another aspect, CD8⁺ T cells are depleted at the beginning of cell expansion to improve CD4⁺ T cell expansion. In embodiments, the cell depletion is performed after peptide stimulation and before lentivirus transduction, when cells are better able to withstand mechanical stress. In embodiments, after CD8⁺ T cell depletion, the cells are placed in culture medium for approximately 24 hours. In embodiments, after CD8⁺ cell depletion, the cells are placed in culture for less than 24 hours, for example, less than 20 hours, less than 16 hours, less than 8 hours, or less than 4 hours. In embodiments, after CD8⁺ T cell depletion, the cells are placed in culture for greater than 24 hours, for example, greater than 30 hours, greater than 36 hours, greater than 42 hours, or greater than 48 hours. In embodiments, the culture medium comprises IL-7. In embodiments, the culture medium comprises IL-15. In

embodiments, the culture medium comprises IL-7 and IL-15. In embodiments, the cell depletion is performed before peptide stimulation. In embodiments, a gag protein is used to cause peptide stimulation. In embodiments, a HIV vaccine is used to cause peptide stimulation. In embodiments, the vaccine is a MVA/HIV62B vaccine, which is used to cause peptide stimulation. In embodiments, CD8⁺ T cells are depleted with a PE anti-human CD8 antibody and anti-PE microbeads. In embodiments, the CD8 antibody is an anti-rat antibody. In embodiments, the CD8 antibody is an anti-mouse antibody. In embodiments, the CD8 antibody is an anti-rabbit antibody. In embodiments, the CD8 antibody is an anti-goat antibody. In embodiments, after cell depletion and peptide stimulation, the cells are transduced. In embodiments, the cells are transduced with a lentivirus. In embodiments, the lentivirus carries GFP. In embodiments, the lentivirus carries RFP. In embodiments, the lentivirus carries EGFP. In embodiments, the cells are placed in culture after transduction. In embodiments, the culture medium comprises IL-7. In embodiments, the culture medium comprises IL-15. In embodiments, the culture medium comprises IL-7 and IL-15. In embodiments, the cells are cultured for approximately 2 days to allow for CD4⁺ T cell expansion. In embodiments, the cells are cultured approximately 3 days to allow for CD4⁺ T cell expansion. In embodiments, the cells are cultured for less than 2 days, for example, less than 42 hours, less than 36 hours, less than 30 hours, less than 24 hours, less than 18 hours, less than 12 hours, or less than 6 hours. In embodiments, the cells are cultured for greater than 3 days, for example, greater than 4 days, greater than 5 days, greater than 6 days, greater than 7 days, greater than 8 days, greater than 9 days, or greater than 10 days. In embodiments, the cells are cultured between 2 and 3 days, for example, approximately 30 hours, approximately 36 hours, or approximately 42 hours.

In another aspect, CD8⁺, $\gamma\delta$, NK, or B cells are depleted to improve CD4⁺ T cell expansion. In embodiments, any two or more of CD8⁺, $\gamma\delta$, NK, and B cells are depleted to improve CD4⁺ T cell expansion. In embodiments, CD8⁺, $\gamma\delta$, NK, B, T regulatory, NKT, or erythrocyte cells are depleted to improve CD4⁺ T cell expansion. In embodiments any two or more of CD8⁺, $\gamma\delta$, NK, B, T regulatory, NKT, and erythrocyte cells are depleted to improve CD4⁺ T cell expansion. In embodiments, cell depletion is performed after peptide stimulation and before lentivirus transduction. In embodiments, after cell depletion, the cells are placed in culture medium for ~24 hours. In embodiments, after cell depletion, the cells are placed in culture for less than 24 hours, for example, less than 20 hours, less than 16 hours, less than 8 hours, or less than 4 hours. In embodiments, after CD8⁺ T cell depletion, the cells are placed

in culture for greater than 24 hours, for example, greater than 30 hours, greater than 36 hours, greater than 42 hours, or greater than 48 hours. In embodiments, the culture medium comprises IL-7. In embodiments, the culture medium comprises IL-15. In embodiments, the culture medium comprises IL-7 and IL-15. In embodiments, cell depletion is performed before peptide stimulation. In embodiments, a gag protein is used to cause peptide stimulation. In
5 embodiments, a HIV vaccine is used to cause peptide stimulation. In embodiments, the MVA/HIV62B vaccine is used to cause peptide stimulation. In embodiments, CD8⁺ T, $\gamma\delta$, NK, and/or B cells are depleted with PE labeled specific antibodies and anti-PE microbeads. In embodiments, the antibody used is an anti-human antibody. In embodiments, the antibody
10 used was an anti-rat antibody. In embodiments, the antibody used is an anti-mouse antibody. In embodiments, the antibody used is an anti-goat antibody. In embodiments, after cell depletion and peptide stimulation, the cells are transduced. In embodiments, the cells are transduced with a lentivirus. In embodiments, the lentivirus carries GFP. In embodiments, the lentivirus carries RFP. In embodiments, the lentivirus carries EGFP. In embodiments, the cells
15 are placed in culture after transduction. In embodiments, the culture medium comprises IL-7. In embodiments, the culture medium comprises IL-15. In embodiments, the culture medium comprises IL-7 and IL-15. In embodiments, the cells are cultured for approximately 2 days to allow for CD4⁺ T cell expansion. In embodiments, the cells are cultured ~3 days to allow for CD4⁺ T cell expansion. In embodiments, the cells are cultured for less than 2 days, for
20 example, less than 42 hours, less than 36 hours, less than 30 hours, less than 24 hours, less than 18 hours, less than 12 hours, or less than 6 hours. In embodiments, the cells are cultured for greater than 3 days, for example, greater than 4 days, greater than 5 days, greater than 6 days, greater than 7 days, greater than 8 days, greater than 9 days, or greater than 10 days. In
25 embodiments, the cells are cultured between 2 and 3 days, for example, ~30 hours, ~36 hours, or ~42 hours.

In another aspect, a lentivirus includes GFP, which is used to measure transduction efficiency. In embodiments, the lentivirus includes RFP. In embodiments, the lentivirus is carrying EGFP. In embodiments, a cytokine capture system is used to identify antigen-specific CD4⁺ T cells with GFP positive cells. In embodiments, GFP is used to identify the transduced
30 cell subsets. In embodiments, RFP is used to identify the transduced cell subsets. In embodiments, EGFP is used to identify the transduced cell subsets. In embodiments, any of the transduction methods described herein can be used to measure transduction efficiency. In embodiments, prior to lentiviral transduction, any of the depletion methods described herein

can be used to deplete any one or more of CD8⁺ T, $\gamma\delta$, NK, B, neutrophils, basophils, eosinophils, T regulatory, NKT, and erythrocyte cells.

In other aspect, transduction efficiency is measured by detecting vector copy number (VCN) by qPCR. In embodiments, the percentage of transduced cells based on VCN in the
 5 final cell product can be estimated by establishing the relationship between transduced cells and VCN. In embodiments, a lentivirus carrying GFP is used to determine the percentage of the cells transduced. In embodiments, a lentivirus carrying RFP is used to determine the percentage of cells transduced. In embodiments, a lentivirus carrying EGFP is used to determine the percentage of cells transduced. In embodiments, any of the transduction
 10 methods described herein can be used to measure transduction efficiency. In embodiments, prior to lentiviral transduction, any of the depletion methods described herein can be used to deplete any one or more of CD8⁺ T, $\gamma\delta$, NK, B cells.

Human Immunodeficiency Virus (HIV)

15 Human Immunodeficiency Virus, which is also commonly referred to as “HIV”, is a retrovirus that causes acquired immunodeficiency syndrome (AIDS) in humans. AIDS is a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending upon the HIV subtype. Infection
 20 with HIV occurs by the transfer of bodily fluids, including but not limited to blood, semen, vaginal fluid, pre-ejaculate, saliva, tears, lymph or cerebro-spinal fluid, or breast milk. HIV may be present in an infected individual as both free virus particles and within infected immune cells.

HIV infects vital cells in the human immune system such as helper T cells, although
 25 tropism can vary among HIV subtypes. Immune cells that may be specifically susceptible to HIV infection include but are not limited to CD4⁺ T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4⁺ T cells through a number of mechanisms, including but not limited to apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4⁺ T cells by CD8 cytotoxic lymphocytes that recognize infected
 30 cells. When CD4⁺ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections and cancer.

Structurally, HIV is distinct from many other retroviruses. The RNA genome consists of at least seven structural landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and INS), and at least nine genes (gag, pol, env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, which is a fusion of tat, env and rev), encoding 19 proteins. Three of these genes, gag, pol, and env, contain information needed to make the structural proteins for new virus particles.

HIV replicates primarily in CD4 T cells, and causes cellular destruction or dysregulation to reduce host immunity. Because HIV establishes infection as an integrated provirus and may enter a state of latency wherein virus expression in a particular cell decreases below the level for cytopathology affecting that cell or detection by the host immune system, HIV is difficult to treat and has not been eradicated even after prolonged intervals of highly active antiretroviral therapy (HAART). In the vast majority of cases, HIV infection causes fatal disease although survival may be prolonged by HAART.

A major goal in the fight against HIV is to develop strategies for curing disease. Prolonged HAART has not accomplished this goal, so investigators have turned to alternative procedures. Early efforts to improve host immunity by therapeutic immunization (using a vaccine after infection has occurred) had marginal or no impact. Likewise, treatment intensification had moderate or no impact.

Some progress has been made using genetic therapy, but positive results are sporadic and found only among rare human beings carrying defects in one or both alleles of the gene encoding CCR5 (chemokine receptor), which plays a critical role in viral penetration of host cells. However, many investigators are optimistic that genetic therapy holds the best promise for eventually achieving an HIV cure.

As disclosed herein, the methods and compositions of the invention are able to achieve a functional cure that may or may not include complete eradication of all HIV from the body. As mentioned above, a functional cure is defined as a state or condition wherein HIV+ individuals who previously required HAART, may survive with low or undetectable virus replication and using lower or intermittent doses of HAART, or are potentially able to discontinue HAART altogether. As used herein, a functional cure may still possibly require adjunct therapy to maintain low level virus replication and slow or eliminate disease progression. A possible outcome of a functional cure is the eventual eradication of HIV to prevent all possibility of recurrence.

The primary obstacles to achieving a functional cure lie in the basic biology of HIV itself. Virus infection deletes CD4 T cells that are critical for nearly all immune functions.

Most importantly, HIV infection and depletion of CD4 T cells requires activation of individual cells. Activation is a specific mechanism for individual CD4 T cell clones that recognize pathogens or other molecules, using a rearranged T cell receptor.

In the case of HIV, infection activates a population of HIV-specific T cells that become infected and are consequently depleted before other T cells that are less specific for the virus, which effectively cripples the immune system's defense against the virus. The capacity for HIV-specific T cell responses is rebuilt during prolonged HAART; however, when HAART is interrupted the rebounding virus infection repeats the process and again deletes the virus-specific cells, resetting the clock on disease progression.

Clearly, a functional cure is only possible if enough HIV-specific CD4 T cells are protected to allow for a host's native immunity to confront and control HIV once HAART is interrupted. In one embodiment, aspects of the disclosure provide methods and compositions for enhancing host immunity against HIV to provide a functional cure without the need for prior immunization.

Gene Therapy

Viral vectors are used to deliver genetic constructs to host cells for the purposes of disease therapy or prevention.

Genetic constructs can include, but are not limited to, functional genes or portions of genes to correct or complement existing defects, DNA sequences encoding regulatory proteins, DNA sequences encoding regulatory RNA molecules including antisense, short homology RNA, long non-coding RNA, small interfering RNA or others, and decoy sequences encoding either RNA or proteins designed to compete for critical cellular factors to alter a disease state. Gene therapy involves delivering these therapeutic genetic constructs to target cells to provide treatment or alleviation of a particular disease.

There are multiple ongoing efforts to utilize genetic therapy in the treatment of HIV disease, but thus far, the results have been poor. A small number of treatment successes were obtained in rare HIV patients carrying a spontaneous deletion of the CCR5 gene (an allele known as CCR5delta32).

Lentivirus-delivered nucleases or other mechanisms for gene deletion/modification may be used to lower the overall expression of CCR5 and/or help to lower HIV replication. At least one study has reported having success in treating the disease when lentivirus was administered

in patients with a genetic background of CCR5delta32. However, this was only one example of success, and many other patients without the CCR5delta32 genotype have not been treated as successfully. Consequently, there is a substantial need to improve the performance of viral genetic therapy against HIV, both in terms of performance for the individual viral vector
5 construct and for improved use of the vector through a strategy for achieving functional HIV cure.

For example, some existing therapies rely on zinc finger nucleases to delete a portion of CCR5 in an attempt to render cells resistant to HIV infection. However, even after optimal treatment, only 30% of T cells had been modified by the nuclease at all, and of those that were
10 modified, only 10% of the total CD4 T cell population had been modified in a way that would prevent HIV infection. In contrast, the disclosed methods result in virtually every cell carrying a lentivirus transgene having a reduction in CCR5 expression below the level needed to allow HIV infection. This can result in successful treatment of HIV even without a prior immunization step to increase the number of the initial CD4+ T cell pool.

For the purposes of the disclosed methods, gene therapy can include, but is not limited to, affinity-enhanced T cell receptors, chimeric antigen receptors on CD4 T cells (or alternatively on CD8 T cells), modification of signal transduction pathways to avoid cell death cause by viral proteins, increased expression of HIV restriction elements including TREX, SAMHD1, MxA or MxB proteins, APOBEC complexes, TRIM5-alpha complexes, tetherin
15 (BST2), and similar proteins identified as being capable of reducing HIV replication in mammalian cells.
20

Immunotherapy

Historically, vaccines have been a go-to weapon against deadly infectious diseases, including smallpox, polio, measles, and yellow fever. Unfortunately, there is no currently
25 approved vaccine for HIV. The HIV virus has unique ways of evading the immune system, and the human body seems incapable of mounting an effective immune response against it. As a result, scientists do not have a clear picture of what is needed to provide protection against HIV.

However, immunotherapy may provide a solution that was previously unaddressed by conventional vaccine approaches. Immunotherapy, also called biologic therapy, is a type of treatment designed to boost the body's natural defenses to fight infections or cancer. It uses
30

materials either made by the body or in a laboratory to improve, target, or restore immune system function.

In certain aspects of the present disclosure, immunotherapeutic approaches may be used to enrich a population of HIV-specific CD4 T cells for the purpose of increasing the host's anti-HIV immunity. In other aspects of the disclosed invention, integrating or non-integrating lentivirus vectors may be used to transduce a host's immune cells for the purposes of increasing the host's anti-HIV immunity. In other aspects of the disclosure, a vaccine comprising HIV proteins including but not limited to a killed particle, a virus-like particle, HIV peptides or peptide fragments, a recombinant viral vector, a recombinant bacterial vector, a purified subunit or plasmid DNA combined with a suitable vehicle and/or biological or chemical adjuvants to increase a host's immune responses may be used to enrich the population of virus-specific T cells or antibodies, and these methods may be further enhanced through the use of HIV-targeted genetic therapy using lentivirus or other viral vector.

15 **Methods**

In one aspect, the disclosure provides methods for using viral vectors to achieve a functional cure for HIV disease. The methods may include immunotherapy to enrich the proportion of HIV-specific CD4 T cells, followed by lentivirus transduction to deliver inhibitors of HIV and CCR5 and CXCR4 as required. Importantly, enrichment for HIV-specific CD4 T cells and lentiviral transduction can be effective even without a prior immunization step.

In embodiments, the methods include therapeutic immunization as a method for enriching the proportion of HIV-specific CD4 T cells, wherein the immunization occurs simultaneously with or after infusion of stimulated cells into a subject. Therapeutic immunization can include purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, virus-like particles (VLPs), biological or chemical adjuvants including cytokines and/or chemokines, vehicles, and methods for immunization.

Therapeutic vaccines can include one or more HIV protein with protein sequences representing the predominant viral types of the geographic region where treatment is occurring. Therapeutic vaccines will include purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, virus-like particles (VLPs), biological or chemical adjuvants including cytokines and/or chemokines, vehicles, and

methods for immunization. Vaccinations may be administered according to standard methods known in the art and HIV patients may continue antiretroviral therapy during the interval of immunization and subsequent *ex vivo* lymphocyte culture including lentivirus transduction.

In certain embodiments, HIV+ patients can be immunized with an HIV vaccine, increasing the frequency of HIV-specific CD4 T cells by about 2, about 25, about 250, about 500, about 750, about 1000, about 1250, or about 1500-fold (or any amount in between these values). The vaccine may be any clinically utilized or experimental HIV vaccine, including the disclosed lentiviral, other viral vectors or other bacterial vectors used as vaccine delivery systems. In another embodiment, the vectors can encode virus-like particles (VLPs) to induce higher titers of neutralizing antibodies and stronger HIV-specific T cell responses. In another embodiment, the vectors can encode peptides or peptide fragments associated with HIV including but not limited to gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and tev, as well as LTR, TAR, RRE, PE, SLIP, CRS, and INS. Alternatively, the HIV vaccine used in the disclosed methods may comprise purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, virus-like particles (VLPs), or biological or chemical adjuvants including cytokines and/or chemokines.

For example, peripheral blood mononuclear cells (PBMCs) can be obtained by leukapheresis and treated *ex vivo* to obtain about 1×10^{10} CD4 T cells of which about 0.1%, about 1%, about 5% or about 10% or about 30% are both HIV-specific in terms of antigen responses, and HIV-resistant by virtue of carrying the therapeutic transgene delivered by the disclosed lentivirus vector. Alternatively, about 1×10^7 , about 1×10^8 , about 1×10^9 , about 1×10^{10} , about 1×10^{11} , or about 1×10^{12} CD4 T cells may be isolated for re-stimulation. Importantly, any suitable amount of CD4 T cells can be isolated for *ex vivo* re-stimulation.

The isolated CD4 T cells can be cultured in appropriate medium throughout re-stimulation with HIV vaccine antigens, which may or may not include antigens present in the prior therapeutic vaccination. Antiretroviral therapeutic drugs including inhibitors of reverse transcriptase, protease or integrase may be added to prevent virus re-emergence during prolonged *ex vivo* culture. CD4 T cell re-stimulation can be used to enrich the proportion of HIV-specific CD4 T cells in culture. The same procedure may also be used for analytical objectives wherein smaller blood volumes with peripheral blood mononuclear cells obtained by purification, are used to identify HIV-specific T cells and measure the frequency of this sub-population.

The PBMC fraction may be enriched for HIV-specific CD4 T cells by contacting the cells with HIV proteins matching or complementary to the components of the vaccine previously used for *in vivo* immunization. *Ex vivo* re-stimulation can increase the relative frequency of HIV-specific CD4 T cells by about 5, about 10, about 25, about 50, about 75,
5 about 100, about 125, about 150, about 175, or about 200-fold. *Ex vivo* re-stimulation can increase the relative frequency of HIV-specific CD4 T cells regardless of whether there has been a pre-immunization step.

The methods detailed herein can include *ex vivo* re-stimulation of CD4 T cells with *ex vivo* lentiviral transduction and culturing. The methods detailed herein can also include *ex vivo*
10 re-stimulation of CD4 T cells with *ex vivo* lentiviral transduction and culturing without a pre-immunization step.

Thus, in one embodiment, the re-stimulated PBMC fraction that has been enriched for HIV-specific CD4 T cells can be transduced with therapeutic anti-HIV lentivirus or other vectors and maintained in culture about 1 to about 21 days or up to about 35 days.
15 Alternatively, the cells may be cultured for about 1- about 18 days, about 1- about 15 days, about 1- about 12 days, about 1- about 9 days, or about 3- about 7 days. Thus, the transduced cells may be cultured for about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27,
20 about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 days.

Once the transduced cells have been sufficiently cultured, transduced CD4 T cells are infused back into the original patient. Infusion can be performed using various machines and methods known in the art. In some embodiments, infusion may be accompanied by pre-treatment with cyclophosphamide or similar compounds to increase the efficiency of re-
25 engraftment.

In some embodiments, a CCR5-targeted therapy may be added to a subject's antiretroviral therapy regimen, which was continued throughout the treatment process. Examples of CCR5-targeted therapies include but are not limited to Maraviroc (a CCR5 antagonist) or Rapamycin (immunosuppressive agent that lowers CCR5). In some
30 embodiments, the antiretroviral therapy may be ceased and the subject can be tested for virus rebound. If no rebound occurs, adjuvant therapy can also be removed and the subject can be tested again for virus rebound.

Continued virus suppression with reduced or no antiretroviral therapy including cART or HAART, and reduced or no adjuvant therapy for about 26 weeks can be considered a functional cure for HIV. Other definitions of a functional cure are described herein.

The lentiviral and other vectors used in the disclosed methods may encode at least one, at least two, at least three, at least four, or at least five genes, or at least six genes, or at least seven genes, or at least eight genes, or at least nine genes, or at least ten genes, or at least eleven genes, or at least twelve genes of interest. Given the versatility and therapeutic potential of HIV-targeted gene therapy, a viral vector of the invention may encode genes or nucleic acid sequences that include but are not limited to (i) an antibody directed to an antigen associated with an infectious disease or a toxin produced by the infectious pathogen, (ii) cytokines including interleukins that are required for immune cell growth or function and may be therapeutic for immune dysregulation encountered in HIV and other chronic or acute human viral or bacterial pathogens, (iii) factors that suppress the growth of HIV in vivo including CD8 suppressor factors, (iv) mutations or deletions of chemokine receptor CCR5, mutations or deletions of chemokine receptor CXCR4, or mutations or deletions of chemokine receptor CXCR5, (v) antisense DNA or RNA against specific receptors or peptides associated with HIV or host protein associated with HIV, (vi) small interfering RNA against specific receptors or peptides associated with HIV or host protein associated with HIV, or (vii) a variety of other therapeutically useful sequences that may be used to treat HIV or AIDS.

Additional examples of HIV-targeted gene therapy that can be used in the disclosed methods include, but are not limited to, affinity-enhanced T cell receptors, chimeric antigen receptors on CD4 T cells (or alternatively on CD8 T cells), modification of signal transduction pathways to avoid cell death cause by viral proteins, increased expression of HIV restriction elements including TREX, SAMHD1, MxA or MxB proteins, APOBEC complexes, TRIM5-alpha complexes, tetherin (BST2), and similar proteins identified as being capable of reducing HIV replication in mammalian cells.

In some embodiments, a patient may be undergoing cART or HAART concurrently while being treated according to the methods of the invention. In other embodiments, a patient may undergo cART or HAART before or after being treated according to the methods of the invention. In some embodiments, cART or HAART is maintained throughout treatment according to the methods of the invention and the patient may be monitored for HIV viral burden in blood and frequency of lentivirus-transduced CD4 T cells in blood. Preferably, a patient receiving cART or HAART prior to being treated according to the methods of the

invention is able to discontinue or reduce cART or HAART following treatment according to the methods of the invention.

For the purpose of assessing efficacy, the frequency of transduced, HIV-specific CD4 T cells, which is a novel surrogate marker for gene therapy effects, may be determined, as
5 discussed in more detail herein.

Compositions

In one aspect, the disclosed invention provides lentiviral vectors capable of delivering genetic constructs to inhibit HIV penetration of susceptible cells. For instance, one mechanism
10 of action is to reduce mRNA levels for CCR5 and/or CXCR4 chemokine receptors and thus reduce the rates for viral entry into susceptible cells.

Alternatively, the disclosed lentiviral vectors may be capable of inhibiting the formation of HIV-infected cells by reducing the stability of incoming HIV genomic RNA. And in yet another embodiment, the disclosed lentivirus vectors are capable of preventing HIV
15 production from a latently infected cell, wherein the mechanism of action is to cause instability of viral RNA sequences through the action of inhibitory RNA including short-homology, small-interfering or other regulatory RNA species.

The therapeutic lentiviruses disclosed in this application generally comprise at least one of two types of genetic cargo. First, the lentiviruses may encode genetic elements that direct
20 expression of small RNA capable of inhibiting the production of chemokine receptors CCR5 and/or CXCR4 that are important for HIV penetration of susceptible cells. The second type of genetic cargo includes constructs capable of expressing small RNA molecules targeting HIV RNA sequences for the purpose of preventing reverse transcription, RNA splicing, RNA translation to produce proteins, or packaging of viral genomic RNA for particle production and
25 spreading infection. An exemplary structure is diagrammed in Figure 3.

As shown in Figure 3 (top panel), an exemplary construct may comprise numerous sections or components. For example, in one embodiment, an exemplary LV construct may comprise the following sections or components:

- RSV - a Rous Sarcoma virus long terminal repeat;
- 30 • 5'LTR - a portion of an HIV long terminal repeat that can be truncated to prevent replication of the vector after chromosomal integration;

- Psi - a packaging signal that allows for incorporation of the vector RNA genome into viral particles during packaging;
- RRE - a Rev Responsive element can be added to improve expression from the transgene by mobilizing RNA out of the nucleus and into the cytoplasm of cells;
- 5 • c PPT - a Poly purine tract that facilitates second strand DNA synthesis prior to integration of the transgene into the host cell chromosome;
- Promoter - a promoter initiates RNA transcription from the integrated transgene to express micro-RNA clusters (or other genetic elements of the construct), and in some embodiments, the vectors may use an EF-1 promoter;
- 10 • Anti-CCR5 - a micro RNA targeting messenger RNA for the host cell factor CCR5 to reduce its expression on the cell surface;
- Anti-Rev/Tat - a micro RNA targeting HIV genomic or messenger RNA at the junction between HIV Rev and Tat coding regions, which is sometimes designated miRNA Tat or given a similar description in this application;
- 15 • Anti-Vif - a micro RNA targeting HIV genomic or messenger RNA within the Vif coding region;
- WPRE - a woodchuck hepatitis virus post-transcriptional regulatory element is an additional vector component that can be used to facilitate RNA transport of the nucleus; and
- 20 • deltaU3 3'LTR - a modified version of a HIV 3' long terminal repeat where a portion of the U3 region has been deleted to improve safety of the vector.

One of skill in the art will recognize that the above components are merely examples, and that such components may be reorganized, substituted with other elements, or otherwise changed, including but not limited to making nucleotide substitutions, deletions, additions, or mutations, so long as the construct is able to prevent expression of HIV genes and decrease the spread of infection.

Vectors of the invention may include either or both of the types of genetic cargo discussed above (*i.e.*, genetic elements that direct expression of a gene or small RNAs, such as siRNA, shRNA, or miRNA that can prevent translation or transcription), and the vectors of the invention may also encode additionally useful products for the purpose of treatment or diagnosis of HIV. For instance, in some embodiments, these vectors may also encode green

fluorescent protein (GFP) for the purpose of tracking the vectors or antibiotic resistance genes for the purposes of selectively maintaining genetically-modified cells *in vivo*.

The combination of genetic elements incorporated into the disclosed vectors is not particularly limited. For example, a vector may encode a single small RNA, two small RNAs, 5 three small RNA, four small RNAs, five small RNAs, six small RNAs, seven small RNAs, eight small RNAs, nine small RNAs, or ten small RNAs, or eleven small RNAs, or twelve small RNAs. Such vectors may additionally encode other genetic elements to function in concert with the small RNAs to prevent expression and infection of HIV.

Those of skill in the art will understand that the therapeutic lentivirus may substitute 10 alternate sequences for the promoter region, targeting of regulatory RNA, and types of regulatory RNA. Further, the therapeutic lentivirus of the disclosure may comprise changes in the plasmids used for packaging the lentivirus particles; these changes are required to increase levels of production *in vitro*.

15 **Lentiviral Vector System**

A lentiviral virion (particle) is expressed by a vector system encoding the necessary viral proteins to produce a virion (viral particle). There is at least one vector containing a nucleic acid sequence encoding the lentiviral pol proteins necessary for reverse transcription and integration, operably linked to a promoter. In another embodiment, the pol proteins are 20 expressed by multiple vectors. There is also a vector containing a nucleic acid sequence encoding the lentiviral gag proteins necessary for forming a viral capsid operably linked to a promoter. In an embodiment, this gag nucleic acid sequence is on a separate vector than at least some of the pol nucleic acid sequence. In another embodiment, the gag nucleic acid is on a separate vector from all the pol nucleic acid sequences that encode pol proteins.

25 Numerous modifications can be made to the vectors, which are used to create the particles to further minimize the chance of obtaining wild type revertants. These include, but are not limited to deletions of the U3 region of the LTR, tat deletions and matrix (MA) deletions.

The gag, pol and env vector(s) do not contain nucleotides from the lentiviral genome 30 that package lentiviral RNA, referred to as the lentiviral packaging sequence.

The vector(s) forming the particle preferably do not contain a nucleic acid sequence from the lentiviral genome that expresses an envelope protein. Preferably, a separate vector that contains a nucleic acid sequence encoding an envelope protein operably linked to a

promoter is used. This env vector also does not contain a lentiviral packaging sequence. In one embodiment the env nucleic acid sequence encodes a lentiviral envelope protein.

In another embodiment the envelope protein is not from the lentivirus, but from a different virus. The resultant particle is referred to as a pseudotyped particle. By appropriate selection of envelopes one can "infect" virtually any cell. For example, one can use an env gene that encodes an envelope protein that targets an endocytic compartment such as that of the influenza virus, VSV-G, alpha viruses (Semliki forest virus, Sindbis virus), arenaviruses (lymphocytic choriomeningitis virus), flaviviruses (tick-borne encephalitis virus, Dengue virus, hepatitis C virus, GB virus), rhabdoviruses (vesicular stomatitis virus, rabies virus), paramyxoviruses (mumps or measles) and orthomyxoviruses (influenza virus). Other envelopes that can preferably be used include those from Moloney Leukemia Virus such as MLV-E, MLV-A and GALV. These latter envelopes are particularly preferred where the host cell is a primary cell. Other envelope proteins can be selected depending upon the desired host cell. For example, targeting specific receptors such as a dopamine receptor can be used for brain delivery. Another target can be vascular endothelium. These cells can be targeted using a filovirus envelope. For example, the GP of Ebola, which by post-transcriptional modification become the GP₁ and GP₂ glycoproteins. In another embodiment, one can use different lentiviral capsids with a pseudotyped envelope. For example, FIV or SHIV [U.S. Patent No. 5,654,195]. A SHIV pseudotyped vector can readily be used in animal models such as monkeys.

As detailed herein, a lentiviral vector system typically includes at least one helper plasmid comprising at least one of a gag, pol, or rev gene. Each of the gag, pol and rev genes may be provided on individual plasmids, or one or more genes may be provided together on the same plasmid. In one embodiment, the gag, pol, and rev genes are provided on the same plasmid (*e.g.*, Figure 4). In another embodiment, the gag and pol genes are provided on a first plasmid and the rev gene is provided on a second plasmid (*e.g.*, Figure 5). Accordingly, both 3-vector and 4-vector systems can be used to produce a lentivirus as described in the Examples section and elsewhere herein. The therapeutic vector, the envelope plasmid and at least one helper plasmid are transfected into a packaging cell line. A non-limiting example of a packaging cell line is the 293T/17 HEK cell line. When the therapeutic vector, the envelope plasmid, and at least one helper plasmid are transfected into the packaging cell line, a lentiviral particle is ultimately produced.

In another aspect, a lentiviral vector system for expressing a lentiviral particle is disclosed. The system includes a lentiviral vector as described herein; an envelope plasmid for

expressing an envelope protein optimized for infecting a cell; and at least one helper plasmid for expressing gag, pol, and rev genes, wherein when the lentiviral vector, the envelope plasmid, and the at least one helper plasmid are transfected into a packaging cell line, a lentiviral particle is produced by the packaging cell line, wherein the lentiviral particle is
 5 capable of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA sequence.

In another aspect, and as detailed herein, the lentiviral vector, which is also referred to herein as a therapeutic vector, can include the following elements: hybrid 5' long terminal repeat (RSV/5' LTR) (SEQ ID NOS: 34-35), Psi sequence (RNA packaging site) (SEQ ID NO:
 10 36), RRE (Rev-response element) (SEQ ID NO: 37), cPPT (polypurine tract) (SEQ ID NO: 38), EF-1 α promoter (SEQ ID NO: 4), miR30CCR5 (SEQ ID NO: 1), miR21Vif (SEQ ID NO: 2), miR185Tat (SEQ ID NO: 3), Woodchuck Post-Transcriptional Regulatory Element (WPRE) (SEQ ID NOS: 32 or 80), and Δ U3 3' LTR (SEQ ID NO: 39). In another aspect, sequence variation, by way of substitution, deletion, or addition can be used to modify the
 15 above-referenced sequences.

In another aspect, and as detailed herein, a helper plasmid has been designed to include the following elements: CAG promoter (SEQ ID NO: 41); HIV component gag (SEQ ID NO: 43); HIV component pol (SEQ ID NO: 44); HIV Int (SEQ ID NO: 45); HIV RRE (SEQ ID NO: 46); and HIV Rev (SEQ ID NO: 47). In another aspect, the helper plasmid may be
 20 modified to include a first helper plasmid for expressing the gag and pol genes, and a second and separate plasmid for expressing the rev gene. In another aspect, sequence variation, by way of substitution, deletion, or addition can be used to modify the above-referenced sequences.

In another aspect, and as detailed herein, an envelope plasmid has been designed to include the following elements being from left to right: RNA polymerase II promoter (CMV)
 25 (SEQ ID NO: 60) and vesicular stomatitis virus G glycoprotein (VSV-G) (SEQ ID NO: 62). In another aspect, sequence variation, by way of substitution, deletion, or addition can be used to modify the above-referenced sequences.

In another aspect, the plasmids used for lentiviral packaging can be modified with similar elements and the intron sequences could potentially be removed without loss of vector
 30 function. For example, the following elements can replace similar elements in the plasmids that comprise the packaging system: Elongation Factor-1 (EF-1), phosphoglycerate kinase (PGK), and ubiquitin C (UbC) promoters can replace the CMV or CAG promoter. SV40 poly A and bGH poly A can replace the rabbit beta globin poly A. The HIV sequences in the helper

plasmid can be constructed from different HIV strains or clades. The VSV-G glycoprotein can be substituted with membrane glycoproteins from feline endogenous virus (RD114), gibbon ape leukemia virus (GALV), Rabies (FUG), lymphocytic choriomeningitis virus (LCMV), influenza A fowl plague virus (FPV), Ross River alphavirus (RRV), murine leukemia virus
5 10A1 (MLV), or Ebola virus (EboV).

Of note, lentiviral packaging systems can be acquired commercially (*e.g.*, Lenti-vpak packaging kit from OriGene Technologies, Inc., Rockville, MD), and can also be designed as described herein. Moreover, it is within the skill of a person skilled in the art to substitute or modify aspects of a lentiviral packaging system to improve any number of relevant factors,
10 including the production efficiency of a lentiviral particle.

Bioassays

In one aspect, the present invention includes bioassays for determining the success of HIV treatment for achieving a functional cure. These assays will provide a method for
15 measuring the efficacy of the disclosed methods by measuring the frequency of transduced, HIV specific CD4 T cells in a patient. HIV-specific CD4 T cells are recognizable because they proliferate, change the composition of cell surface markers, induce signaling pathways including phosphorylation, or express specific marker proteins that may be cytokines, chemokines, caspases, phosphorylated signaling molecules or other cytoplasmic and/or nuclear
20 components. Specific responding CD4 T cells are recognized for example, using labeled monoclonal antibodies or specific in situ amplification of mRNA sequences, that allow sorting of HIV-specific cells using flow cytometry sorting, magnetic bead separation or other recognized methods for antigen-specific CD4 T cell isolation. The isolated CD4 T cells are tested to determine the frequency of cells carrying integrated therapeutic lentivirus. Single cell
25 testing methods may also be used including microfluidic separation of individual cells that are coupled with mass spectrometry, PCR, ELISA or antibody staining to confirm responsiveness to HIV and presence of integrated therapeutic lentivirus.

Thus, in certain embodiments, following application of a treatment according to the invention (*e.g.*, (a) no immunization, (b) *ex vivo* lymphocyte culture; (c) re-stimulation with
30 purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, biological or chemical adjuvants including cytokines and/or chemokines, vehicles; and (d) infusion of the enriched, transduced T cells), a patient may be subsequently assayed to

determine the efficacy of the treatment. A threshold value of target T cells in the cell product for infusion may be established to measure a functional cure at, for instance, about 1×10^8 HIV-specific CD4 T cells bearing genetic modification from therapeutic lentivirus. Alternatively, the threshold value may be about 1×10^5 , about 1×10^6 , about 1×10^7 , about 1×10^8 , about 1×10^9 ,
 5 or about 1×10^{10} CD4 T cells in the body of the patient.

HIV-specific CD4 T cells bearing genetic modification from therapeutic lentivirus can be determined using any suitable method, such as but not limited to flow cytometry, cell sorting, FACS analysis, DNA cloning, PCR, RT-PCR or Q-PCR, ELISA, FISH, western blotting, southern blotting, high throughput sequencing, RNA sequencing, oligonucleotide
 10 primer extension, or other methods known in the art.

Methods for defining antigen specific T cells with genetic modifications are known in the art. However, utilizing such methods to combine identifying HIV-specific T cells with integrated or non-integrated gene therapy constructs as a standard measure for efficacy is a new concept in the field of HIV treatment.

Doses and Dosage Forms

The disclosed methods and compositions can be used for treating HIV+ patients during various stages of their disease. Accordingly, dosing regimens may vary based upon the condition of the patient and the method of administration.

In one aspect, HIV-specific vaccines may be administered simultaneously with infusion or after infusion of stimulated cells into a subject. In one embodiment, HIV-specific vaccines may be administered to a subject in need in varying doses. In general, vaccines delivered by intramuscular injection include about 10 μ g to about 300 μ g, about 25 μ g to about 275 μ g, about 50 μ g to about 250 μ g, about 75 μ g to about 225, or about 100 μ g to about 200 μ g of
 20 HIV protein, either total virus protein prepared from inactivated virus particles, virus-like particles or purified virus protein from recombinant systems or purified from virus preparations. Recombinant viral or bacterial vectors may be administered by any and all of the routes described. Intramuscular vaccines will include about 1 μ g to about 100 μ g, about 10 μ g to about 90 μ g, about 20 μ g to about 80 μ g, about 30 μ g to about 70 μ g, about 40 μ g to about
 25 60 μ g, or about 50 μ g of suitable adjuvant molecules and be suspended in oil, saline, buffer or water in volumes of 0.1 to 5 ml per injection dose, and may be soluble or emulsion preparations. Vaccines delivered orally, rectally, buccally, at genital mucosal or intranasally,
 30

including some virally-vectored or bacterially-vectored vaccines, fusion proteins, liposome formulations or similar preparations, may contain higher amounts of virus protein and adjuvant. Dermal, sub-dermal or subcutaneous vaccines utilize protein and adjuvant amounts more similar to oral, rectal or intranasal-delivered vaccines. Depending on responses to the initial immunization, vaccination may be repeated 1-5 times using the same or alternate routes for delivery. Intervals may be of 2-24 weeks between immunizations. Immune responses to vaccination are measured by testing HIV-specific antibodies in serum, plasma, vaginal secretions, rectal secretions, saliva or bronchoalveolar lavage fluids, using ELISA or similar methodology. Cellular immune responses are tested by in vitro stimulation with vaccine antigens followed by staining for intracellular cytokine accumulation followed by flow cytometry or similar methods including lymphoproliferation, expression of phosphorylated signaling proteins or changes in cell surface activation markers. Upper limits of dosing may be determined based on the individual patient and will depend on toxicity/safety profiles for each individual product or product lot.

Immunization may occur once, twice, three times, or repeatedly. For instance, an agent for HIV immunization may be administered to a subject in need once a week, once every other week, once every three weeks, once a month, every other month, every three months, every six months, every nine months, once a year, every eighteen months, every two years, every 36 months, or every three years.

After *ex vivo* expansion and enrichment of CD4 T cells, immunization may occur once, twice, three times, or more after *ex vivo* lymphocyte culture/re-stimulation and infusion.

In one embodiment, HIV-vaccines for immunization are administered as a pharmaceutical composition. In one embodiment, the pharmaceutical composition comprising an HIV vaccine can be formulated in a wide variety of nasal, pulmonary, oral, topical, or parenteral dosage forms for clinical application. Each of the dosage forms can comprise various disintegrating agents, surfactants, fillers, thickeners, binders, diluents such as wetting agents or other pharmaceutically acceptable excipients. The pharmaceutical composition comprising an HIV vaccine can also be formulated for injection.

HIV vaccine compositions for the purpose of immunization can be administered using any pharmaceutically acceptable method, such as intranasal, buccal, sublingual, oral, rectal, ocular, parenteral (intravenously, intradermally, intramuscularly, subcutaneously, intracisternally, intraperitoneally), pulmonary, intravaginal, locally administered, topically

administered, topically administered after scarification, mucosally administered, via an aerosol, or via a buccal or nasal spray formulation.

Further, the HIV vaccine compositions can be formulated into any pharmaceutically acceptable dosage form, such as a solid dosage form, tablet, pill, lozenge, capsule, liquid
5 dispersion, gel, aerosol, pulmonary aerosol, nasal aerosol, ointment, cream, semi-solid dosage form, and a suspension. Further, the composition may be a controlled release formulation, sustained release formulation, immediate release formulation, or any combination thereof. Further, the composition may be a transdermal delivery system.

In another embodiment, the pharmaceutical composition comprising an HIV vaccine
10 can be formulated in a solid dosage form for oral administration, and the solid dosage form can be powders, granules, capsules, tablets or pills. In yet another embodiment, the solid dosage form can include one or more excipients such as calcium carbonate, starch, sucrose, lactose, microcrystalline cellulose or gelatin. In addition, the solid dosage form can include, in addition to the excipients, a lubricant such as talc or magnesium stearate. In some
15 embodiments, the oral dosage form can be immediate release or a modified release form. Modified release dosage forms include controlled or extended release, enteric release, and the like. The excipients used in the modified release dosage forms are commonly known to a person of ordinary skill in the art.

In a further embodiment, the pharmaceutical composition comprising a HIV vaccine
20 can be formulated as a sublingual or buccal dosage form. Such dosage forms comprise sublingual tablets or solution compositions that are administered under the tongue and buccal tablets that are placed between the cheek and gum.

In yet a further embodiment, the pharmaceutical composition comprising an HIV vaccine can be formulated as a nasal dosage form. Such dosage forms of the present invention
25 comprise solution, suspension, and gel compositions for nasal delivery.

In one embodiment, the pharmaceutical composition can be formulated in a liquid dosage form for oral administration, such as suspensions, emulsions or syrups. In other embodiments, the liquid dosage form can include, in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as humectants, sweeteners,
30 aromatics or preservatives. In particular embodiments, the composition comprising HIV vaccine or a pharmaceutically acceptable salt thereof can be formulated to be suitable for administration to a pediatric patient.

In one embodiment, the pharmaceutical composition can be formulated in a dosage form for parenteral administration, such as sterile aqueous solutions, suspensions, emulsions, non-aqueous solutions or suppositories. In other embodiments, the non-aqueous solutions or suspensions can include propyleneglycol, polyethyleneglycol, vegetable oils such as olive oil
5 or injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao oil, laurin oil or glycerinated gelatin can be used.

The dosage of the pharmaceutical composition can vary depending on the patient's weight, age, gender, administration time and mode, excretion rate, and the severity of disease.

For the purposes of re-stimulation, lymphocytes, PBMC, and/or CD4 T cells are
10 removed from a patient and isolated for stimulation and culturing. The isolated cells may be contacted with the same HIV vaccine or activating agent used for immunization or a different HIV vaccine or activating agent. In one embodiment, the isolated cells are contacted with about 10 ng to 5 µg of an HIV vaccine or activating agent per about 10^6 cells in culture (or any other suitable amount). More specifically, the isolated cells may be contacted with about 50 ng,
15 about 100 ng, about 200 ng, about 300 ng, about 400 ng, about 500 ng, about 600 ng, about 700 ng, about 800 ng, about 900 ng, about 1 µg, about 1.5 µg, about 2 µg, about 2.5 µg, about 3 µg, about 3.5 µg, about 4 µg, about 4.5 µg, or about 5 µg of an HIV vaccine or activating agent per about 10^6 cells in culture.

Activating agents or vaccines are generally used once for each in vitro cell culture but
20 may be repeated after intervals of about 15 to about 35 days. For example, a repeat dosing could occur at about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 days.

For transduction of the enriched, re-stimulated cells, the cells may be transduced with
25 lentiviral vectors or with other known vector systems as disclosed herein. The cells being transduced may be contacted with about 1-1,000 viral genomes (measured by RT-PCR assay of culture fluids containing lentivirus vector) per target cell in culture (or any other suitable amount). Lentivirus transduction may be repeated 1-5 times using the same range of 1-1,000 viral genomes per target cell in culture.

Cellular Enrichment

In one approach, cells such as T cells may be obtained from an HIV infected patient and cultured in multi-well plates in a culture medium comprising conditioned media (“CM”).

5 The levels of supernatant p24^{gag} (“p24”) and viral RNA levels may be assessed by standard means. Those patients whose CM-cultured cells have peak p24 supernatant levels of less than 1 ng/ml may be suitable patients for large-scale T-cell expansion in CM with or without the use of additional anti-viral agents. Additionally, different drugs or drug combinations of interest may be added to different wells and the impact on virus levels in the sample may be assessed
10 by standard means. Those drug combinations providing adequate viral suppression are therapeutically useful combinations. It is within the capacity of a competent technician to determine what constitutes adequate viral suppression in relation to a particular subject. In order to test the effectiveness of drugs of interest in limiting viral expansion, additional factors such as anti-CD3 antibodies may be added to the culture to stimulate viral production. Unlike
15 culture methods for HIV infected cell samples known in the art, CM allows the culture of T cells for periods of over two months, thereby providing an effective system in which to assay long term drug effectiveness.

This approach allows the inhibition of gene expression driven by the HIV LTR promoter region in a cell population by the culture of cells in a medium comprising the CM.
20 Culture in CM4 likely inhibits HIV LTR driven gene expression by altering one or more interactions between transcription mediating proteins and HIV gene expression regulatory elements. Transcription-mediating proteins of interest include host cell encoded proteins such as AP-1, NFkappaB, NF-AT, IRF, LEF-1 and Sp1, and the HIV encoded protein Tat. HIV gene expression regulatory elements of interest include binding sites for AP-1, NFkappaB, NF-
25 AT, IRF, LEF-1 and Sp1, as well as the transacting responsive element (“TAR”) which interacts with Tat.

In a preferred embodiment, the HIV infected cells are obtained from a subject with susceptible transcription mediating protein sequences and susceptible HIV regulatory element sequences. In a more preferred embodiment, the HIV infected cells are obtained from a subject
30 having wild-type transcription-mediating protein sequences and wild-type HIV regulatory sequences.

Another method of enriching T cells utilizes immunoaffinity-based selection. This approach may involve the simultaneous enrichment or selection of a first and second population of cells, such as a CD4⁺ and CD8⁺ cell population. Cells containing primary human T cells are contacted with a first immunoaffinity reagent that specifically binds to CD4 and a second immunoaffinity reagent that specifically binds to CD8 in an incubation composition, under conditions whereby the immunoaffinity reagents specifically bind to CD4 and CD8 molecules, respectively, on the surface of cells in the sample. Cells bound to the first and/or the second immunoaffinity reagent are recovered, thereby generating an enriched composition comprising CD4⁺ cells and CD8⁺ cells. This approach may include incubation of the composition with a concentration of the first and/or second immunoaffinity reagent that is at a sub-optimal yield concentration. Notably, in some embodiments, transduced cells are a mixed T cell population, and in other embodiments transduced cells are not a mixed T cell population.

In some embodiments, immunoaffinity-based selection is used where the solid support is a sphere, such as a bead, such as a microbead or nanobead. In other embodiments, the bead can be a magnetic bead. In another embodiment, the antibody contains one or more binding partners capable of forming a reversible bond with a binding reagent immobilized on the solid surface, such as a sphere or chromatography matrix, wherein the antibody is reversibly mobilized to the solid surface. In some embodiments, cells expressing a cell surface marker bound by the antibody on said solid surface are capable of being recovered from the matrix by disruption of the reversible binding between the binding reagent and binding partner. In some embodiments, the binding reagent is streptavidin or is a streptavidin analog or mutant.

Stable transduction of primary cells of the hematopoietic system and/or hematopoietic stem cells may be obtained by contacting, *in vitro* or *ex vivo*, the surface of the cells with both a lentiviral vector and at least one molecule which binds the cell surface. The cells may be cultured in a ventilated vessel comprising two or more layers under conditions conducive to growth and/or proliferation. In some embodiments, this approach may be used in conjunction with non-CD4⁺ T cell depletion and/or broad polyclonal expansion.

In another approach to T cell enrichment, PBMC are stimulated with a peptide and enriched for cells secreting a cytokine, such as interferon-gamma. This approach generally involves stimulating a mixture of cells containing T cells with antigen, and effecting a separation of antigen-stimulated cells according to the degree to which they are labeled with the product. Antigen stimulation is achieved by exposing the cells to at least one antigen under

conditions effective to elicit antigen-specific stimulation of at least one T cell. Labeling with the product is achieved by modifying the surface of the cells to contain at least one capture moiety, culturing the cells under conditions in which the product is secreted, released and specifically bound (“captured” or “entrapped”) to said capture moiety; and labeling the
 5 captured product with a label moiety, where the labeled cells are not lysed as part of the labeling procedure or as part of the separation procedure. The capture moiety may incorporate detection of cell surface glycoproteins CD3 or CD4 to refine the enrichment step and increase the proportion of antigen-specific T cells in general, of CD4+ T cells in specific.

The following examples are given to illustrate aspects of the present invention. It
 10 should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. All printed publications referenced herein are specifically incorporated by reference.

Examples

15 Example 1: Development of a Lentiviral Vector System

A lentiviral vector system was developed as summarized in Figure 3 (linear form) and Figure 4 (circularized form). Referring first to the top portion of Figure 3, a representative therapeutic vector has been designed and produced with the following elements being from left to right: hybrid 5’ long terminal repeat (RSV/5’ LTR) (SEQ ID NOS: 34-35), Psi sequence
 20 (RNA packaging site) (SEQ ID NO: 36), RRE (Rev-response element) (SEQ ID NO: 37), cPPT (polypurine tract) (SEQ ID NO: 38), EF-1 α promoter (SEQ ID NO: 4), miR30CCR5 (SEQ ID NO: 1), miR21Vif (SEQ ID NO: 2), miR185Tat (SEQ ID NO: 3), Woodchuck Post-Transcriptional Regulatory Element (WPRE) (SEQ ID NOS: 32 or 80), and Δ U3 3’ LTR (SEQ ID NO: 39). The therapeutic vector detailed in Figure 3 is also referred to herein as AGT103.

25 Referring next to the middle portion of Figure 3, a helper plasmid has been designed and produced with the following elements being from left to right: CAG promoter (SEQ ID NO: 41); HIV component gag (SEQ ID NO: 43); HIV component pol (SEQ ID NO: 44); HIV Int (SEQ ID NO: 45); HIV RRE (SEQ ID NO: 46); and HIV Rev (SEQ ID NO: 47).

Referring next to the lower portion of Figure 3, an envelope plasmid has been designed
 30 and produced with the following elements being from left to right: RNA polymerase II promoter (CMV) (SEQ ID NO: 60) and vesicular stomatitis virus G glycoprotein (VSV-G) (SEQ ID NO: 62).

Lentiviral particles were produced in 293T/17 HEK cells (purchased from American Type Culture Collection, Manassas, VA) following transfection with the therapeutic vector, the envelope plasmid, and the helper plasmid (as shown in Figure 3). The transfection of 293T/17 HEK cells, which produced functional viral particles, employed the reagent Poly (ethylenimine) (PEI) to increase the efficiency of plasmid DNA uptake. The plasmids and DNA were initially added separately in culture medium without serum in a ratio of 3:1 (mass ratio of PEI to DNA). After 2-3 days, cell medium was collected and lentiviral particles were purified by high-speed centrifugation and/or filtration followed by anion-exchange chromatography. The concentration of lentiviral particles can be expressed in terms of transducing units/ml (TU/ml). The determination of TU was accomplished by measuring HIV p24 levels in culture fluids (p24 protein is incorporated into lentiviral particles), measuring the number of viral DNA copies per cell by quantitative PCR, or by infecting cells and using light (if the vectors encode luciferase or fluorescent protein markers).

As mentioned above, a 3-vector system (*i.e.*, a 2-vector lentiviral packaging system) was designed for the production of lentiviral particles. A schematic of the 3-vector system is shown in Figure 4. The schematic of Figure 4 is a circularized version of the linear system previously described in Figure 3. Briefly, and with reference to Figure 4, the top-most vector is a helper plasmid, which, in this case, includes Rev. The vector appearing in the middle of Figure 4 is the envelope plasmid. The bottom-most vector is the previously described therapeutic vector.

Referring more specifically to Figure 4, the Helper plus Rev plasmid includes a CAG enhancer (SEQ ID NO: 40); a CAG promoter (SEQ ID NO: 41); a chicken beta actin intron (SEQ ID NO: 42); a HIV gag (SEQ ID NO: 43); a HIV Pol (SEQ ID NO: 44); a HIV Int (SEQ ID NO: 45); a HIV RRE (SEQ ID NO: 46); a HIV Rev (SEQ ID NO: 47); and a rabbit beta globin poly A (SEQ ID NO: 48).

The Envelope plasmid includes a CMV promoter (SEQ ID NO: 60); a beta globin intron (SEQ ID NO: 61); a VSV-G (SEQ ID NO: 62); and a rabbit beta globin poly A (SEQ ID NO: 63).

Synthesis of a 2-vector lentiviral packaging system including Helper (plus Rev) and Envelope plasmids.

Materials and Methods:

Construction of the helper plasmid: The helper plasmid was constructed by initial PCR amplification of a DNA fragment from the pNL4-3 HIV plasmid (NIH Aids Reagent Program) containing Gag, Pol, and Integrase genes. Primers were designed to amplify the fragment with EcoRI and NotI restriction sites which could be used to insert at the same sites in the pCDNA3

5 plasmid (Invitrogen). The forward primer was (5'-TAAGCAGAATTC ATGAATTTGCCAGGAAGAT-3') (SEQ ID NO: 81) and reverse primer was (5'-CCATACAATGAATGGACACTAGGCGGCCGCACGAAT-3') (SEQ ID NO: 82). The sequence for the Gag, Pol, Integrase fragment was as follows:

GAATTCATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGA

10 GGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGCGGACATA
AAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAA
TCTGTTGACTCAGATTGGCTGCACTTTAAATTTTCCCATTAGTCCTATTGAGACTGT
ACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCATTG
ACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAA

15 GGAAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCAT
AAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTTCAGAGAACTTAAT
AAGAGAACTCAAGATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGT
TAAACAGAAAAAATCAGTAACAGTACTGGATGTGGGCGATGCATATTTTTCAGT
TCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACA

20 ATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGG
ATCACCAGCAATATTCCAGTGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAA
CAAAATCCAGACATAGTCATCTATCAATACATGGATGATTTGTATGTAGGATCTGA
CTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAACTGAGACAACATCTGTTG
AGGTGGGGATTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTT

25 GGATGGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCC
AGAAAAGGACAGCTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAAT
TGGGCAAGTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAACTTCTTA
GGGGAACCAAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGCTAG
AACTGGCAGAAAACAGGGAGATTCTAAAAGAACCGGTACATGGAGTGTATTATGA

30 CCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGAC
ATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAGTATGCAAGA
ATGAAGGGTGCCCACTAATGATGTGAAACAATTAACAGAGGCAGTACAAAAA
ATAGCCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAATTACCCA

TACAAAAGGAAACATGGGAAGCATGGTGGACAGAGTATTGGCAAGCCACCTGGA
 TTCCTGAGTGGGAGTTTGTCAATACCCCTCCCTTAGTGAAGTTATGGTACCAGTTA
 GAGAAAGAACCCATAATAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCCAATA
 GGGAAACTAAATTAGGAAAAGCAGGATATGTAACTGACAGAGGAAGACAAAAAG
 5 TTGTCCCCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCT
 AGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAATATGCA
 TTGGGAATCATTCAAGCACAAACCAGATAAGAGTGAATCAGAGTTAGTCAGTCAA
 TAATAGAGCAGTTAATAAAAAAGGAAAAAGTCTACCTGGCATGGGTACCAGCACA
 CAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTGGTCAGTGCTGGAATCAG
 10 GAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGAAGAACATGAGAAATAT
 CACAGTAATTGGAGAGCAATGGCTAGTGATTTTAACCTACCACCTGTAGTAGCAA
 AAGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGGGAAGCCATGCATGG
 ACAAGTAGACTGTAGCCCAGGAATATGGCAGCTAGATTGTACACATTTAGAAGGA
 AAAGTTATCTTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTAA
 15 TTCCAGCAGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGAAG
 ATGGCCAGTAAAAACAGTACATACAGACAATGGCAGCAATTTCCACCAGTACTACA
 GTTAAGGCCGCCTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCCCTACA
 ATCCCCAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAATTAAAGAAAATTAT
 AGGACAGGTAAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGT
 20 ATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGGTACAGTGCAGGGGAA
 AGAATAGTAGACATAATAGCAACAGACATACAACTAAAGAATTACAAAAACAA
 ATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTTG
 GAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGA
 TAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTAT
 25 GGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAA
 (SEQ ID NO: 83).

Next, a DNA fragment containing the Rev, RRE, and rabbit beta globin poly A
 sequence with XbaI and XmaI flanking restriction sites was synthesized by MWG Operon.
 The DNA fragment was then inserted into the plasmid at the XbaI and XmaI restriction sites

30 The DNA sequence was as follows:

TCTAGAATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTC
 AGACTCATCAAGCTTCTCTATCAAAGCAACCCACCTCCCAATCCCGAGGGGACCC
 GACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATC

CATTCGATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGT
 GCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTG
 GAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTAC
 AATATTGGAGTCAGGAGCTAAAGAATAGAGGAGCTTTGTTCCCTTGGGTTCTTGGG
 5 AGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAG
 ACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAG
 GCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA
 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTAGATCTTTTTTCCC
 TCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTA
 10 ATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTTGTGTCTCTCACT
 CGGAAGGACATATGGGAGGGCAAATCATTAAAACATCAGAATGAGTATTTGGTT
 TAGAGTTTGGCAACATATGCCATATGCTGGCTGCCATGAACAAAGGTGGCTATAA
 AGAGGTCATCAGTATATGAAACAGCCCCCTGCTGTCCATTCCCTTATTCCATAGAAA
 AGCCTTGACTTGAGGTTAGATTTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTA
 15 ACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGA
 CTACTCCCAGTCATAGCTGTCCCTCTTCTCTTATGAAGATCCCTCGACCTGCAGCCC
 AAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCA
 CAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTA
 ATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGG
 20 GAAACCTGTCGTGCCAGCGGATCCGCATCTCAATTAGTCAGCAACCATAGTCCCGC
 CCTAACTCCGCCCATCCCGCCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCC
 ATGGCTGACTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAG
 CTATTCCAGAAGTAGTGAGGAGGCTTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCT
 AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTT
 25 CACAAATAAAGCATTTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAA
 TGTATCTTATCAGCGGCCGCCCCGGG (SEQ ID NO: 84)

Finally, the CMV promoter of pCDNA3.1 was replaced with the CAG
 enhancer/promoter plus a chicken beta actin intron sequence. A DNA fragment containing the
 CAG enhancer/promoter/intron sequence with MluI and EcoRI flanking restriction sites was
 30 synthesized by MWG Operon. The DNA fragment was then inserted into the plasmid at the
 MluI and EcoRI restriction sites. The DNA sequence was as follows:

ACGCGTTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATA
 TGGAGTTCCGCGTTACATAAATTACGGTAAATGGCCCGCCTGGCTGACCGCCCAAC

GACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGG
 GACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAG
 TACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAA
 TGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCA
 5 GTACATCTACGTATTAGTCATCGCTATTACCATGGGTTCGAGGTGAGCCCCACGTTC
 TGCTTCACTCTCCCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTT
 TTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCG
 GGGCGGGGGCGGGGGCGAGGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGGCGGCA
 GCCAATCAGAGCGGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGGCGGGCGGC
 10 GGCGGGCCCTATAAAAAGCGAAGCGCGCGGGCGGGAGTCGCTGCGTTGCCTTC
 GCCCCGTGCCCCGCTCCGCGCCGCTCGCGCCGCCCCGCCCCGGCTCTGACTGACCG
 CGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGGCTGTAATTAG
 CGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTAAAGG
 GCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTG
 15 TGTGTGCGTGGGGAGCGCCGCGTGCGGGCCCGCGCTGCCCGGCGGGCTGTGAGCGCT
 GCGGGCGCGGGCGCGGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGGCC
 GGGGGCGGTGCCCCGCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGC
 GGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGGTGTGGGCGCGGCGGTTCGGGCTGT
 AACCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGC
 20 GGGGCTCCGTGCGGGGGCGTGGCGCGGGGGCTCGCCGTGCCGGGCGGGGGGTGGCG
 GCAGGTGGGGGTGCCGGGCGGGGGCGGGGGCCGCCTCGGGCCGGGGAGGGCTCGGG
 GGAGGGGGCGCGGGCGGCCCCGGAGCGCCGGCGGGCTGTCGAGGCGCGGGCGAGCCGC
 AGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCA
 AATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCG
 25 GGCGAAGCGGTGCGGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGC
 GTCGCCGCGCCGCGCGTCCCCTTCTCCATCTCCAGCCTCGGGGGCTGCCGCAGGGGGA
 CGGCTGCCTTCGGGGGGGGACGGGGCAGGGCGGGGGTTCGGCTTCTGGCGTGTGACC
 GGCGGGGAATTC (SEQ ID NO: 85)

Construction of the VSV-G Envelope plasmid:

30 The vesicular stomatitis Indiana virus glycoprotein (VSV-G) sequence was synthesized
 by MWG Operon with flanking EcoRI restriction sites. The DNA fragment was then inserted
 into the pCDNA3.1 plasmid (Invitrogen) at the EcoRI restriction site and the correct

orientation was determined by sequencing using a CMV specific primer. The DNA sequence was as follows:

```

GAATTCATGAAGTGCCTTTTGTACTTAGCCTTTTATTTCATTGGGGTGAATTGCAAG
TTCACCATAGTTTTTCCACACAACCAAAAAGGAAACTGGAAAAATG TTCCTTCTAA
5 TTACCATTATTGCCCGTCAAGCTCAGATTTAAATTGGCATAATGACTTAATAGGCA
CAGCCTTACAAGTCAAAATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTG
GATGTGTCATGCTTCCAAATGGGTCACTACTTGTGATTTCCGCTGGTATGGACCGA
AGTATATAACACATTCCATCCGATCCTTCACTCCATCTGTAGAACAATGCAAGGAA
AGCATTGAACAAACGAAACAAGGAACTTGGCTGAATCCAGGCTTCCCTCCTCAAA
10 GTTGTGGATATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCCAGGTGACTCCT
CACCATGTGCTGGTTGATGAATACACAGGAGAATGGGTTGATTCACAGTTCATCA
ACGGAAAATGCAGCAATTACATATGCCCCACTGTCCATAACTCTACAACCTGGCAT
TCTGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTTCCATGGACATCAC
CTTCTTCTCAGAGGACGGAGAGCTATCATCCCTGGGAAAGGAGGGGCACAGGGTTC
15 AGAAGTAACTACTTTGCTTATGAAACTGGAGGCAAGGCCTGCAAAATGCAATACT
GCAAGCATTGGGGAGTCAGACTCCCATCAGGTGTCTGGTTCGAGATGGCTGATAA
GGATCTCTTTGCTGCAGCCAGATTCCCTGAATGCCCAGAAGGGTCAAGTATCTCTG
CTCCATCTCAGACCTCAGTGGATGTAAGTCTAATTCAGGACGTTGAGAGGATCTTG
GATTATTCCCTCTGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCTTCCAATCTC
20 TCCAGTGGATCTCAGCTATCTTGCTCCTAAAAACCCAGGAACCGGTCCTGCTTTCA
CCATAATCAATGGTACCCTAAAATACTTTGAGACCAGATACATCAGAGTCGATATT
GCTGCTCCAATCCTCTCAAGAATGGTCGGAATGATCAGTGGAACCTACCACAGAAA
GGGAACTGTGGGATGACTGGGCACCATATGAAGACGTGGAAATTGGACCCAATGG
AGTTCTGAGGACCAGTTCAGGATATAAGTTTCCTTTATACATGATTGGACATGGTA
25 TGTTGGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTGTTCGAACATCCTCAC
ATTCAAGACGCTGCTTCGCAACTTCCTGATGATGAGAGTTTATTTTTTGGTGATACT
GGGCTATCCAAAAATCCAATCGAGCTTGTAGAAGGTTGGTTCAGTAGTTGGAAAA
GCTCTATTGCCTCTTTTTTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTCT
CCGAGTTGGTATCCATCTTTGCATTAAATTAAAGCACACCAAGAAAAGACAGATTT
30 ATACAGACATAGAGATGAGAATTC (SEQ ID NO: 86)

```

A 4-vector system (*i.e.*, a 3-vector lentiviral packaging system) has also been designed and produced using the methods and materials described herein. A schematic of the 4-vector system is shown in Figure 5. Briefly, and with reference to Figure 5, the top-most vector is a

helper plasmid, which, in this case, does not include Rev. The vector second from the top is a separate Rev plasmid. The vector second from the bottom is the envelope plasmid. The bottom-most vector is the previously described therapeutic vector.

Referring, in part, to Figure 5, the Helper plasmid includes a CAG enhancer (SEQ ID NO: 49); a CAG promoter (SEQ ID NO: 50); a chicken beta actin intron (SEQ ID NO: 51); a HIV gag (SEQ ID NO: 52); a HIV Pol (SEQ ID NO: 53); a HIV Int (SEQ ID NO: 54); a HIV RRE (SEQ ID NO: 55); and a rabbit beta globin poly A (SEQ ID NO: 56).

The Rev plasmid includes a RSV promoter (SEQ ID NO: 57); a HIV Rev (SEQ ID NO: 58); and a rabbit beta globin poly A (SEQ ID NO: 59).

The Envelope plasmid includes a CMV promoter (SEQ ID NO: 60); a beta globin intron (SEQ ID NO: 61); a VSV-G (SEQ ID NO: 62); and a rabbit beta globin poly A (SEQ ID NO: 63).

Synthesis of a 3-vector lentiviral packaging system including Helper, Rev, and Envelope plasmids.

Materials and Methods:

Construction of the Helper plasmid without Rev:

The Helper plasmid without Rev was constructed by inserting a DNA fragment containing the RRE and rabbit beta globin poly A sequence. This sequence was synthesized by MWG Operon with flanking XbaI and XmaI restriction sites. The RRE/rabbit poly A beta globin sequence was then inserted into the Helper plasmid at the XbaI and XmaI restriction sites. The DNA sequence is as follows:

TCTAGAAGGAGCTTTGTTCCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC
GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGC
25 AGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACT
CACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATAC
CTAAAGGATCAACAGCTCCTAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT
CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTG
CAATAGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCA
30 AATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCAT
ATGCTGGCTGCCATGAACAAAGGTGGCTATAAAGAGGTCATCAGTATATGAAACA
GCCCCCTGCTGTCCATTCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTT
TTTTATATTTTGTGTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACAT

GTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCT
 CTTCTCTTATGAAGATCCCTCGACCTGCAGCCCAAGCTTGGCGTAATCATGGTCAT
 AGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCC
 GGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAA
 5 TTGCGTTGCGCTCACTGCCCCGCTTTCAGTCGGGAAACCTGTCGTGCCAGCGGATC
 CGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCCATCCCGCCC
 CTA ACTCCGCCCAGTTCCGCCCCATTCTCCGCCCCCATGGCTGACTAATTTTTTTTATT
 TATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
 GCTTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTAACTTGTTTATTGCAGCTTATA
 10 ATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTTCA
 CTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCACCCGGG (SEQ
 ID NO: 87)

Construction of the Rev plasmid:

The RSV promoter and HIV Rev sequence was synthesized as a single DNA fragment
 15 by MWG Operon with flanking MfeI and XbaI restriction sites. The DNA fragment was then
 inserted into the pCDNA3.1 plasmid (Invitrogen) at the MfeI and XbaI restriction sites in
 which the CMV promoter is replaced with the RSV promoter. The DNA sequence was as
 follows:

CAATTGCGATGTACGGGCCAGATATACGCGTATCTGAGGGGACTAGGGTGTGTTT
 20 AGGCGAAAAGCGGGGCTTCGGTTGTACGCGGTTAGGAGTCCCCTCAGGATATAGT
 AGTTTCGCTTTTGCATAGGGAGGGGGAAATGTAGTCTTATGCAATACACTTGTAGT
 CTTGCAACATGGTAACGATGAGTTAGCAACATGCCTTACAAGGAGAGAAAAAGCA
 CCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTGCCTTATTAGGAAGG
 CAACAGACAGGTCTGACATGGATTGGACGAACCACTGAATTCCGCATTGCAGAGA
 25 TAATTGTATTTAAGTGCCTAGCTCGATACAATAAACGCCATTTGACCATTACACCAC
 ATTGGTGTGCACCTCCAAGCTCGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAG
 ACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCC
 CCTCGAAGCTAGCGATTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGAC
 GAAGAACTCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAACCCAC
 30 CTCCCAATCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGA
 GAGAGAGACAGAGACAGATCCATTTCGATTAGTGAACGGATCCTTAGCACTTATCT
 GGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTC
 TTGATTGTAACGAGGATTGTGGAACCTTCTGGGACGCAGGGGGTGGGAAGCCCTCA

AATATTGGTGGGAATCTCCTACAATATTGGAGTCAGGAGCTAAAGAATAGTCTAGA
(SEQ ID NO: 88)

The plasmids for the 2-vector and 3-vector packaging systems could be modified with similar elements and the intron sequences could potentially be removed without loss of vector
5 function. For example, the following elements could replace similar elements in the 2-vector and 3-vector packaging system:

Promoters: Elongation Factor-1 (EF-1) (SEQ ID NO: 64), phosphoglycerate kinase (PGK) (SEQ ID NO: 65), and ubiquitin C (UbC) (SEQ ID NO: 66) can replace the CMV (SEQ ID NO: 60) or CAG promoter (SEQ ID NO: 100).

10 Poly A sequences: SV40 poly A (SEQ ID NO: 67) and bGH poly A (SEQ ID NO: 68) can replace the rabbit beta globin poly A (SEQ ID NO: 48).

HIV Gag, Pol, and Integrase sequences: The HIV sequences in the Helper plasmid can be constructed from different HIV strains or clades. For example, HIV Gag (SEQ ID NO: 69); HIV Pol (SEQ ID NO: 70); and HIV Int (SEQ ID NO: 71) from the Bal strain can be
15 interchanged with the gag, pol, and int sequences contained in the helper/helper plus Rev plasmids as outlined herein.

Envelope: The VSV-G glycoprotein can be substituted with membrane glycoproteins from feline endogenous virus (RD114) (SEQ ID NO: 72), gibbon ape leukemia virus (GALV) (SEQ ID NO: 73), Rabies (FUG) (SEQ ID NO: 74), lymphocytic choriomeningitis virus
20 (LCMV) (SEQ ID NO: 75), influenza A fowl plague virus (FPV) (SEQ ID NO: 76), Ross River alphavirus (RRV) (SEQ ID NO: 77), murine leukemia virus 10A1 (MLV) (SEQ ID NO: 78), or Ebola virus (EboV) (SEQ ID NO: 79). Sequences for these envelopes are identified in the sequence portion herein.

In summary, the 3-vector versus 4-vector systems can be compared and contrasted as
25 follows. The 3-vector lentiviral vector system contains: 1. Helper plasmid: HIV Gag, Pol, Integrase, and Rev/Tat; 2. Envelope plasmid: VSV-G/FUG envelope; and 3. Therapeutic vector: RSV 5'LTR, Psi Packaging Signal, Gag fragment, RRE, Env fragment, cPPT, WPRE, and 3'delta LTR. The 4-vector lentiviral vector system contains: 1. Helper plasmid: HIV Gag, Pol, and Integrase; 2. Rev plasmid: Rev; 3. Envelope plasmid: VSV-G/FUG envelope; and 4.
30 Therapeutic vector: RSV 5'LTR, Psi Packaging Signal, Gag fragment, RRE, Env fragment, cPPT, WPRE, and 3'delta LTR. Sequences corresponding with the above elements are identified in the sequence listings portion herein.

Example 2: Development of an Anti-HIV Lentivirus Vector

The purpose of this example was to develop an anti-HIV lentivirus vector.

Inhibitory RNA Designs. The sequence of Homo sapiens chemokine C-C motif receptor 5 (CCR5) (GC03P046377) mRNA was used to search for potential siRNA or shRNA candidates to knockdown CCR5 levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Broad Institute or the BLOCK-iT RNAi Designer from Thermo Scientific. Individual selected shRNA sequences were inserted into lentiviral vectors immediately 3' to a RNA polymerase III promoter such as H1, U6, or 7SK to regulate shRNA expression. These lentivirus-shRNA constructs were used to transduce cells and measure the change in specific mRNA levels. The shRNA most potent for reducing mRNA levels were embedded individually within a microRNA backbone to allow for expression by either the CMV or EF-1alpha RNA polymerase II promoters. The microRNA backbone was selected from mirbase.org. RNA sequences were also synthesized as synthetic siRNA oligonucleotides and introduced directly into cells without using a lentiviral vector.

The genomic sequence of Bal strain of human immunodeficiency virus type 1 (HIV-1 85US_BaL, accession number AY713409) was used to search for potential siRNA or shRNA candidates to knockdown HIV replication levels in human cells. Based on sequence homology and experience, the search focused on regions of the Tat and Vif genes of HIV although an individual of skill in the art will understand that use of these regions is non-limiting and other potential targets might be selected. Importantly, highly conserved regions of Gag or Polymerase genes could not be targeted by shRNA because these same sequences were present in the packaging system complementation plasmids needed for vector manufacturing. As with the CCR5 (NM 000579.3, NM 001100168.1-specific) RNAs, potential HIV-specific RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Gene-E Software Suite hosted by the Broad Institute (broadinstitute.org/mai/public) or the BLOCK-iT RNAi Designer from Thermo Scientific (rnadesigner.thermofisher.com/rnaiexpress/setOption.do?designOption=shrna&pid=6712627360706061801). Individual selected shRNA sequences were inserted into lentiviral vectors immediately 3' to a RNA polymerase III promoter such as H1, U6, or 7SK to regulate shRNA expression. These lentivirus-shRNA constructs were used to transduce cells and measure the change in specific mRNA levels. The shRNA most potent for reducing mRNA levels were

embedded individually within a microRNA backbone to allow for expression by either the CMV or EF-1alpha RNA polymerase II promoters.

Vector Constructions. For CCR5, Tat or Vif shRNA, oligonucleotide sequences
 5 containing BamHI and EcoRI restriction sites were synthesized by Eurofins MWG Operon, LLC. Overlapping sense and antisense oligonucleotide sequences were mixed and annealed during cooling from 70 degrees Celsius to room temperature. The lentiviral vector was digested with the restriction enzymes BamHI and EcoRI for one hour at 37 degrees Celsius. The digested lentiviral vector was purified by agarose gel electrophoresis and extracted from
 10 the gel using a DNA gel extraction kit from Invitrogen. The DNA concentrations were determined and vector to oligo (3:1 ratio) were mixed, allowed to anneal, and ligated. The ligation reaction was performed with T4 DNA ligase for 30 minutes at room temperature. 2.5 microliters of the ligation mix were added to 25 microliters of STBL3 competent bacterial cells. Transformation was achieved after heat-shock at 42 degrees Celsius. Bacterial cells were
 15 spread on agar plates containing ampicillin and drug-resistant colonies (indicating the presence of ampicillin-resistance plasmids) were recovered, purified and expanded in LB broth. To check for insertion of the oligo sequences, plasmid DNA were extracted from harvested bacteria cultures with the Invitrogen DNA mini prep kit. Insertion of the shRNA sequence in the lentiviral vector was verified by DNA sequencing using a specific primer for the promoter
 20 used to regulate shRNA expression. Exemplary vector sequences that were determined to restrict HIV replication can be found in Figure 6. For example, the shRNA sequences with the highest activity against CCR5, Tat or Vif gene expression were then assembled into a microRNA (miR) cluster under control of the EF-1alpha promoter. The promoter and miR sequences are depicted in Figure 6.

25 Further, and using standard molecular biology techniques (*e.g.*, Sambrook; Molecular Cloning: A Laboratory Manual, 4th Ed.) as well as the techniques described herein, a series of lentiviral vectors have been developed as depicted in Figure 7 herein.

Vector 1 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18,
 30 20, 22, or 24); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 2 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 element (SEQ ID NO: 101); a shRev/Tat (SEQ ID NO: 10); a

H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 3 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 element (SEQ ID NO: 101); a shGag (SEQ ID NO: 12); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 4 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a 7SK element (SEQ ID NO: 103); a shRev/Tat (SEQ ID NO: 10); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 5 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 6 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR155Tat (SEQ ID NO: 104); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 7 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 8 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 9 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a CD4 element (SEQ ID NO: 30); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Development of Vectors

It should be noted that not all vectors developed for these experiments necessarily worked as planned. More specifically, a lentivirus vector against HIV might include three main components: 1) inhibitory RNA to reduce the level of HIV binding proteins (receptors) on the target cell surface to block initial virus attachment and penetration; 2) overexpression of the HIV TAR sequence that will sequester viral Tat protein and decrease its ability to transactivate viral gene expression; and 3) inhibitory RNA that attack important and conserved sequences within the HIV genome.

With respect to the first point above, a key cell surface HIV binding protein is the chemokine receptor CCR5. HIV particles attach to susceptible T cells by binding to the CD4 and CCR5 cell surface proteins. Because CD4 is an essential glycoprotein on the cell surface that is important for the immunological function of T cells, this was not chosen as a target to manipulate its expression levels. However, people born homozygous for null mutations in the CCR5 gene and completely lacking receptor expression, live normal lives save for enhanced susceptibility to a few infectious diseases and the possibility of developing rare autoimmunity. Safety is enhanced in this example, because relatively few of total body CD4⁺ T cells are genetically modified to reduce CCR5 expression, and CD4⁺ T cells needed for pathogen immunity or control of autoimmunity are unlikely to be among the modified cells. Thus, modulating CCR5 was determined to be a relatively safe approach and was a primary target in the development of anti-HIV lentivirus vectors.

With respect to the second point above, the viral TAR sequence is a highly structured region of HIV genomic RNA that binds tightly to viral Tat protein. The Tat:TAR complex is important for efficient generation of viral RNA. Over-expression of the TAR region was envisioned as a decoy molecule that would sequester Tat protein and decrease the levels of viral RNA. However, TAR proved toxic to most mammalian cells including cells used for manufacturing lentivirus particles. Further, TAR was inefficient for inhibiting viral gene

expression in other laboratories and has been discarded as a viable component in HIV gene therapy.

With respect to the third point above, viral gene sequences have been identified that meet 3 criteria: i) Sequences are reasonably conserved across a range of HIV isolates
5 representative of the epidemic in a geographic region of interest; ii) reduction in RNA levels due to the activity of an inhibitory RNA in a viral vector will reduce the corresponding protein levels by an amount sufficient to meaningfully reduce HIV replication; and iii) the viral gene sequence(s) targeted by inhibitory RNA are not present in the genes required for packaging and assembling viral vector particles during manufacturing. The lattermost point is important as it
10 would be completely disadvantageous to have an inhibitory RNA that targets genes necessary for effective functioning of the viral particles themselves. In the present embodiment, a sequence at the junction of HIV Tat and Rev genes and a second sequence within the HIV Vif gene have been targeted by inhibitory RNA. The Tat/Rev targeting has an additional benefit of reducing HIV envelope glycoprotein expression because this region overlaps with the envelope
15 gene in the HIV genome.

The strategy for vector development and testing relies first on identifying suitable targets (as described herein) followed by constructing plasmid DNAs expressing individual or multiple inhibitory RNA species for testing in cell models, and finally constructing lentivirus vectors containing inhibitory RNA with proven anti-HIV function. The lentivirus vectors are
20 tested for toxicity, yield during *in vitro* production, and effectiveness against HIV in terms of reducing CCR5 expression levels or lowering viral gene products to inhibit virus replication.

Table 2 below demonstrates progression through multiple versions of inhibitory constructs until arriving at a clinical candidate. Initially, shRNA (short homology RNA) molecules were designed and expressed from plasmid DNA constructs.

25 Plasmids 1-4, as detailed in Table 2 below, tested shRNA sequences against Gag, Pol and RT genes of HIV. While each shRNA was active for suppressing viral protein expression in a cell model, there were two important problems that prevented further development. First, the sequences were targeted to a laboratory isolate of HIV that was not representative of Clade B HIV strains currently circulating in North America and Europe. Second, these shRNA
30 targeted critical components in the lentivirus vector packaging system and would severely reduce vector yield during manufacturing. Plasmid 5, as detailed in Table 2, was selected to target CCR5 and provided a lead candidate sequence. Plasmids 6, 7, 8, 9, 10, and 11, as detailed in Table 2, incorporated the TAR sequence and it was found they produced

unacceptable toxicity for mammalian cells including cells used for lentivirus vector manufacturing. Plasmid 2, as detailed in Table 2, identified a lead shRNA sequence capable of reducing Tat RNA expression. Plasmid 12, as detailed in Table 2, demonstrated the effectiveness of shCCR5 expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final product. Plasmid 13, as detailed in Table 2, demonstrated the effectiveness of a shVif expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final product. Plasmid 14, as detailed in Table 2, demonstrated the effectiveness of shTat expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final product. Plasmid 15, as detailed in Table 2, contained the miR CCR5, miR Tat and miR Vif in the form of a miR cluster expressed from a single promoter. These miR do not target critical components in the lentivirus vector packaging system and proved to have negligible toxicity for mammalian cells. The miR within the cluster was equally effective to individual miR that were tested previously, and the overall impact was a substantial reduction in replication of a CCR5-tropic HIV BaL strain.

Table 2: Development of HIV Vectors

	Internal Code	Material	Description	Remarks	Decision
1	SIH-H1-shRT-1,3	Lentiviral vector	shRNA construct for RT of LAI strain	Wrong target, lab virus, no virus test	Abandon
2	SIH-H1-shRT43 (Tat/Rev NL4-3)	Lentiviral vector	H1 promoter shRNA Tat/Rev overlap	Tat protein knock-down >90%	Lead
<i>Vector Construction:</i> For Rev/Tat (RT) shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. Two different Rev/Tat target sequences were tested for their ability to decrease Tat mRNA expression. The RT1,3 target sequence is (5'-ATGGCAGGAAGAAGCGGAG-3') (SEQ ID NO: 89) and shRNA sequence is (5'-ATGGCAGGAAGAAGCGGAGTTCAAGAGACTCCGCTTCTTCCTGCCATTTTTT-3') (SEQ ID NO: 90). The RT43 sequence is (5'-GCGGAGACAGCGACGAAGAGC-3')					

(SEQ ID NO: 9) and shRNA sequence is (5'-GCGGAGACAGCGACGAAGAGCTTCAAGAGAGCTCTTCGTCGCTGTCTCCGCTTTTT-3') (SEQ ID NO: 10). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences).

Functional test for shRNA against Rev/Tat: The ability of the vector to reduce Tat expression was tested using a luciferase reporter plasmid which contained the Rev/Tat target sequences inserted into the 3'-UTR (untranslated region of the mRNA). Either the shRT1,3 or shRT43 plasmid was co-transfected with the plasmid containing luciferase and the Rev/Tar target sequence. There was a 90% reduction in light emission indicating strong function of the shRT43 shRNA sequence but less than 10% with the shRT1,3 plasmid.

Conclusion: The SIH-H1-shRT43 was superior to SIH-H1-shRT-1,3 in terms of reducing mRNA levels in the Luciferase assay system. This indicates potent inhibitory activity of the shRT43 sequence and it was selected as a lead candidate for further development.

3	SIH-H1-shGag-1	Lentiviral vector	shRNA construct for LAI Gag	Inhibits Gag expression but will inhibit packaging	Abandon
---	----------------	-------------------	-----------------------------	--	---------

Vector Construction: For Gag shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. A Gag target sequence was tested for their ability to decrease Gag mRNA expression. The Gag target sequence is (5'-GAAGAAATGATGACAGCAT-3') (SEQ ID NO: 11) and shRNA sequence is (5'-GAAGAAATGATGACAGCATTTC AAGAGAATGCTGTCATCATTCTTTCTTTT-3') (SEQ ID NO: 12). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences).

Functional test for shRNA against Gag: The ability of the vector to reduce Gag expression was tested using a luciferase reporter plasmid which contained the Gag target sequences inserted into the 3'-UTR (untranslated region of the mRNA). The Gag plasmid was co-transfected with the plasmid containing luciferase and the Gag target sequence. There was nearly a 90% reduction in light emission indicating a strong effect of the shGag shRNA sequence.

Conclusion: This shRNA sequence is potent against HIV Gag expression but was abandoned. The lentivirus packaging system requires production of Gag from the helper plasmid and

shRNA inhibition of Gag will reduce lentivirus vector yield. This shRNA sequence could be used as an oligonucleotide inhibitor of HIV or incorporated into an alternate viral vector packaging system that uses a different vector genome or is modified to resist inhibition by this shRNA.					
4	SIH-H1-shPol-1	Lentiviral vector	shRNA construct for Pol	Inhibits Pol expression but will inhibit packaging	Abandon
<i>Vector Construction:</i> A Pol shRNA was constructed with oligonucleotide sequences containing BamHI and EcoRI restriction sites that were synthesized by MWG Operon. A Pol target sequence was tested for its ability to decrease Pol mRNA expression. The Pol target sequence is (5'- CAGGAGCAGATGATACAG -3') (SEQ ID NO: 13) and shRNA sequence is (5'- CAGGAGATGATACAGTTCAAGAGACTGTATCATCTGCTCCTGTTTTT-3') (SEQ ID NO: 14). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences). <i>Functional tests for shRNA against HIV Pol:</i> The ability of the vector to reduce Pol expression was tested using a luciferase reporter plasmid which contained the Pol target sequences inserted into the 3'-UTR (untranslated region of the mRNA). The Pol plasmid was co-transfected with the plasmid containing luciferase and the Pol target sequence. There was a 60% reduction in light emission indicating a strong effect of the shPol shRNA sequence. <i>Conclusion:</i> This shRNA sequence is potent against HIV Pol expression but was abandoned. The lentivirus packaging system requires production of Pol from the helper plasmid and shRNA inhibition of Pol will reduce lentivirus vector yield. This shRNA sequence could be used as an oligonucleotide inhibitor of HIV or incorporated into an alternate viral vector packaging system that uses a different vector genome or is modified to resist inhibition by this shRNA.					
5	SIH-H1-shCCR5-1	Lentiviral vector	shRNA construct for CCR5	Best of 5 candidates, Extracellular CCR5 protein reduction >90%	Lead

Vector Construction: A CCR5 shRNA was constructed with oligonucleotide sequences containing BamHI and EcoRI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences). The CCR5 target sequence #1, which focuses on CCR5 gene sequence 1 (SEQ ID NO: 25), is (5'-GTGTCAAGTCCAATCTATG-3') (SEQ ID NO: 15) and the shRNA sequence is (5'-GTGTCAAGTCCAATCTATGTTCAAGAGACATAGATTGGACTTGACACTTTTT-3') (SEQ ID NO: 16). The CCR5 target sequence #2, which focuses on CCR5 gene sequence 2 (SEQ ID NO: 26), is (5'-GAGCATGACTGACATCTAC-3') (SEQ ID NO: 17) and the shRNA sequence is (5'-GAGCATGACTGACATCTACTTCAAGAGAGTAGATGTCAGTCATGCTCTTTTT-3') (SEQ ID NO: 18). The CCR5 target sequence #3, which focuses on CCR5 gene sequence 3 (SEQ ID NO: 27), is (5'-GTAGCTCTAACAGGTTGGA-3') (SEQ ID NO: 19) and the shRNA sequence is (5'-GTAGCTCTAACAGGTTGGATTCAAGAGATCCAACCTGTTAGAGCTACTTTTT-3') (SEQ ID NO: 20). The CCR5 target sequence #4, which focuses on CCR5 gene sequence 4 (SEQ ID NO: 28), is (5'-GTTTCAGAACTACCTCTTA-3') (SEQ ID NO: 21) and the shRNA sequence is (5'-GTTTCAGAACTACCTCTTATTCAAGAGATAAGAGGTAGTTTCTGAACTTTTT-3') (SEQ ID NO: 22). The CCR5 target sequence #5, which focuses on CCR5 gene sequence 5 (SEQ ID NO: 29), is (5'-GAGCAAGCTCAGTTTACACC-3') (SEQ ID NO: 23) and the shRNA sequence is (5'-GAGCAAGCTCAGTTTACACCTTCAAGAGAGGTGTAAACTGAGCTTGCTCTTTTT-3') (SEQ ID NO: 24).

Functional test for shRNA against CCR5: The ability of a CCR5 shRNA sequence to knock-down CCR5 RNA expression was initially tested by co-transfecting each of the lentiviral plasmids, in separate experiments for each plasmid, containing one of the five CCR5 target sequences with a plasmid expressing the human CCR5 gene. CCR5 mRNA expression was then assessed by qPCR analysis using CCR5-specific primers.

Conclusion: Based on the reduction in CCR5 mRNA levels the shRNACCR5-1 was most potent for reducing CCR5 gene expression. This shRNA was selected as a lead candidate.

6	SIH-U6-	Lentiviral	U6 promoter-	Toxic to cells	Abandon
---	---------	------------	--------------	----------------	---------

	TAR	vector	TAR		
7	SIH-U6-TAR-H1-shCCR5	Lentiviral vector	U6 promoter-TAR-H1-shCCR5	Toxic to cells	Abandon
8	U6-TAR-H1-shRT	Lentiviral vector	U6 promoter-TAR-H1-RT	Suppress HIV, toxic to cells, poor packaging	Abandon
9	U6-TAR-7SK-shRT	Lentiviral vector	Change shRNA promoter to 7SK	Toxic, poor packaging	Abandon
10	U6-TAR-H1-shRT-H1-shCCR5	Lentiviral vector	U6 promoter-TAR-H1-RT-H1-shCCR5	Toxic, poor packaging, H1 repeats	Abandon
11	U6-TAR-7SK-shRT-H1-CCR5	Lentiviral vector	Change shRNA promoter to 7SK	Toxic, poor packaging	Abandon

Vector Construction: A TAR decoy sequence containing flanking KpnI restriction sites was synthesized by MWG operon and inserted into the pSIH lentiviral vector (System Biosciences) at the KpnI site. In this vector, TAR expression is regulated by the U6 promoter. The TAR decoy sequence is (5'-CTTGCAATGATGTCGTAATTTGCGTCTTACCTCGTTCTCGACAGCGACCAGATCTGAGCCTGGGAGCTCTCTGGCTGTCAGTAAGCTGGTACAGAAGGTTGACGAAAATTC TTAGTGAGCAAGAAA-3') (SEQ ID NO: 8). Expression of the TAR decoy sequence was determined by qPCR analysis using specific primers for the TAR sequence. Additional vectors were constructed also containing the TAR sequence. The H1 promoter and shRT sequence was inserted in this vector in the XhoI site. The H1 shRT sequence is (5'-GAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCCTAGGC GGGAACACCCAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGG GAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAA CGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTTGGAT CCGCGGAGACAGCGACGAAGAGCTTCAAGAGAGCTCTTCGTCGCTGTCTCCGCTTT TT-3') (SEQ ID NO: 91). This vector could express TAR and knockdown RT. The 7SK

promoter was also substituted for the H1 promoter to regulate shRT expression. Another vector was constructed containing U6 TAR, H1 shRT, and H1 shCCR5. The H1 shCCR5 sequence was inserted into the SpeI site of the plasmid containing U6 TAR and H1 shRT. The H1 CCR5 sequence is (5'-GAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGC GGGAACACCCAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGG GAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAA CGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTTGGAT CCGTGTCAAGTCCAATCTATGTTCAAGAGACATAGATTGGACTTGACACTTTTT-3') (SEQ ID NO: 92). The 7SK promoter was also substituted for the H1 promoter to regulate shRT expression.

Functional test for TAR decoy activity: We tested the effect of SIH-U6-TAR on packaging efficiency. When TAR sequence was included, the yield of vector in the SIH packaging system was reduced substantially.

Conclusion: Lentivirus vectors expressing the TAR decoy sequence are unsuitable for commercial development due to low vector yields. These constructs were abandoned.

12	shCCR5	Lentiviral vector	microRNA sequence	Extracellular CCR5 protein reduction >90%	Lead
----	--------	-------------------	-------------------	---	------

Vector Construction: A CCR5 microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the pCDH lentiviral vector (System Biosciences). The EF-1 promoter was substituted for a CMV promoter that was used in the plasmid construct Test Material 5. The EF-1 promoter was synthesized by MWG Operon containing flanking ClaI and BsrGI restriction sites and inserted into the pCDH vector containing shCCR5-1. The EF-1 promoter sequence is (5'-CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTG GCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC GTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTG TGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTA

CTTCCACGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAG
 TGGGTGGGAGAGTTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAG
 TTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCG
 CGCCTGTCTCGCTGCTTTTCGATAAGTCTCTAGCCATTATAAAATTTTGTGATGACCTGC
 TGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAATGCGGGCCAAGATCTGCACA
 CTGGTATTTTCGGTTTTTTGGGGCCGCCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGC
 ACATGTTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGG
 TAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGC
 CCCGCCCTGGGCGGCAAGGCTGGCCCGGTGCGCACCAAGTTGCGTGAGCGGAAAGA
 TGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGG
 GAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGC
 CGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGT
 TCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATG
 GAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGA
 TGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGC
 CTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA-3') (SEQ ID
 NO: 4).

Functional test for lentivirus CDH-shCCR5-1: The ability of the miR CCR5 sequences to knock-down CCR5 expression was determined by transducing CEM-CCR5 T cells and measuring cell surface CCR5 expression after staining with a fluorescently-labeled monoclonal antibody against CCR5 and measuring the intensity of staining, that is directly proportional to the number of cell surface CCR5 molecules, by analytical flow cytometry. The most effective shRNA sequence for targeting CCR5 was CCR5 shRNA sequence #1. However, the most effective CCR5 targeting sequence for constructing the synthetic microRNA sequence was overlapping with CCR5 sequence #5; this conclusion was based on sequence alignments and experience with miRNA construction. Finally, the miR30 hairpin sequence was used to construct the synthetic miR30 CCR5 sequence which is (5'-
 AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAG
 CCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAA
 GGGG CTT-3') (SEQ ID NO: 1). The miR CCR5 target sequence is (5'-
 GAGCAAGCTCAGTTTACA-3') (SEQ ID NO: 5). At multiplicity of infection equal to 5,
 generating on average 1.25 genome copies of integrated lentivirus per cell, CCR5 expression

levels were reduced by $\geq 90\%$ indicating potent inhibition of CCR5 mRNA by the miR30CCR5 micro RNA construct in a lentivirus vector.

Conclusion: The miR30CCR5 construct is potent for reducing CCR5 cell surface expression and is a lead candidate for a therapeutic lentivirus for HIV.

13	shVif	Lentiviral vector	microRNA sequence	Vif protein reduction > 80%	Lead
----	-------	-------------------	-------------------	-----------------------------	------

Vector Construction: A Vif microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the pCDH lentiviral vector (System Biosciences) containing an EF-1 promoter. Based on sequence alignments and experience with constructing synthetic miRNA, the miR21 hairpin sequence was used to construct the synthetic miR21 Vif sequence which is (5'-CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTGACCA-3') (SEQ ID NO: 2). The miR Vif target sequence is (5'-GGGATGTGTACTTCTGAACTT-3') (SEQ ID NO: 6).

Functional test for potency of miR21Vif: The ability of the miR Vif sequence to knock-down Vif expression was determined by measuring Vif protein expression by immunoblot analysis using an anti-Vif monoclonal antibody to identify the Vif protein.

Conclusion: the miR21Vif reduced Vif protein expression by ≥ 10 -fold as determined by quantitative image analysis of immunoblot data. This was sufficient to justify miR21Vif as a lead candidate for our therapeutic lentivirus.

14	shTat	Lentiviral vector	microRNA sequence	Tat RNA reduction > 80%	Lead
----	-------	-------------------	-------------------	-------------------------	------

Vector Construction: A Tat microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI restriction sites that were synthesized by MWG Operon. The microRNA cluster was inserted into the pCDH lentiviral vector (System Biosciences) containing an EF-1 promoter. Based on sequence alignments and experience in the construction of synthetic miRNA, the miR185 hairpin sequence was selected for constructing a

synthetic miR185 Tat sequence which is (5'-GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTCG-3') (SEQ ID NO: 3). The miR Tat target sequence is (5'-TCCGCTTCTTCCTGCCATAG-3') (SEQ ID NO: 7). <i>Functional test for potency of miR185Tat:</i> The ability of miR Tat to knock-down Tat expression was determined by measuring Tat mRNA expression by RT-PCR analysis using Tat specific primers. We compared the miR185Tat with a similar miR155Tat on the basis of reducing the relative levels of Tat mRNA. <i>Conclusion:</i> The miR185Tat was approximately twice as potent for reducing Tat mRNA compare to miR155Tat, and was selected as the lead candidate for our therapeutic lentivirus.					
15	shCCR5-shVif-shTat	Lentiviral vector	microRNA cluster sequence	CCR5 reduction>90%, Vif protein reduction>80%, Tat RNA reduction>80%, >95% inhibition of HIV replication	Candidate
<i>Vector Construction:</i> A miR30CCR5 miR21Vif miR185Tat microRNA cluster sequence was constructed with a synthetic DNA fragment containing BsrGI and NotI restriction sites that was synthesized by MWG Operon. The DNA fragment was inserted into the pCDH lentiviral vector (System Biosciences) containing the EF-1 promoter. The miR cluster sequence is (5'-AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC-3') (SEQ ID NO: 31) and incorporates Test Material					

12, Test Material 13 and Test Material 14 into a single cluster that can be expressed under control of the EF-1 promoter.

Functional test for potency of the Lentivirus Vector AGT103 containing the microRNA cluster of miR30CCR5, miR21Vif and miR185Tat: The AGT103 vector was tested for potency against CCR5 using the assay for reduction in cell surface CCR5 expression (Test Material 12). The AGT103 vector was tested for potency against Vif using the assay for reduction in cell surface Vif expression (Test Material 13). The AGT103 vector was tested for potency against Tat using the assay for reduction in cell surface Tat expression (Test Material 14).

Conclusion: Potency for reducing CCR5 expression by the miRNA cluster was similar to potency observed for the miR30CCR5 alone. Potency for reducing Vif expression by the miRNA cluster was similar to potency observed for the miR21Vif alone. Potency for reducing Tat expression by the miRNA cluster was similar to potency observed for the miR185Tat alone. The miRNA cluster is potent for reducing cell surface CCR5 levels and for inhibiting two HIV genes. Thus, AGT103 containing this miRNA cluster was selected as the therapeutic vector construct for our HIV functional cure program.

Functional Assays. Individual lentivirus vectors containing CCR5, Tat or Vif shRNA sequences and, for experimental purposes, expressing green fluorescent protein (GFP) under control of the CMV Immediate Early Promoter, and designated AGT103/CMV-GFP were tested for their ability to knockdown CCR5, Tat or Vif expression. Mammalian cells were transduced with lentiviral particles either in the presence or absence of Polybrene. Cells were collected after 2-4 days; protein and RNA were analyzed for CCR5, Tat or Vif expression. Protein levels were tested by Western blot assay or by labeling cells with specific fluorescent antibodies (CCR5 assay), followed by analytical flow cytometry comparing modified and unmodified cell fluorescence using either the CCR5-specific or isotype control antibodies.

Starting Testing of Lentivirus. T cell culture medium was made using RPMI 1640 supplemented with 10% FBS and 1% penicillin–streptomycin. Cytokine stocks of IL2 10,000 units/ml, IL-12 1µg/ml, IL-7 1µg/ml, IL-15 1µg/ml were also prepared in advance.

Prior to transduction with the lentivirus, an infectious viral titer was determined and used to calculate the amount of virus to add for the proper multiplicity of infection (MOI).

Day 0-12: Antigen-specific enrichment. On day 0, cryopreserved PBMC were thawed, washed with 10 ml 37°C medium at 1200 rpm for 10 minutes and resuspended at a concentration of 2×10^6 /ml in 37°C medium. The cells were cultured at 0.5 ml/well in a 24-well plate at 37°C in 5% CO₂. To define the optimal stimulation conditions, cells were stimulated with combinations of reagents as listed in Table 3 below:

Table 3

1	2	3	4	5	6
IL-2+IL-12	IL-7+IL-15	Peptides+ IL-2+IL-12	Peptides+ IL-7+IL-15	MVA+ IL- 2+IL-12	MVA+ IL- 7+IL-15

Final concentrations: IL-2=20 units/ml, IL-12=10 ng/ml, IL-7=10 ng/ml, IL-15=10 ng/ml, peptides=5 µg/ml individual peptide, MVA MOI=1.

On days 4 and 8, 0.5 ml fresh medium and cytokine at listed concentrations (all concentrations indicate the final concentration in the culture) were added to the stimulated cells.

Day 12-24: non-specific expansion and lentivirus transduction. On day 12, the stimulated cells were removed from the plate by pipetting and resuspended in fresh T cell culture medium at a concentration of 1×10^6 /ml. The resuspended cells were transferred to T25 culture flasks and stimulated with DYNABEADS® Human T-Activator CD3/CD28 following the manufacturer's instruction plus cytokine as listed above; flasks were incubated in the vertical position.

On day 14, AGT103/CMV-GFP was added at MOI 20 and cultures were returned to the incubator for 2 days. At this time, cells were recovered by pipetting, collected by centrifugation at 1300 rpm for 10 minutes, resuspended in the same volume of fresh medium, and centrifuged again to form a loose cell pellet. That cell pellet was resuspended in fresh medium with the same cytokines used in previous steps, with cells at 0.5×10^6 viable cells per ml.

From days 14 to 23, the number of the cells was evaluated every 2 days and the cells were diluted to 0.5×10^6 /ml with fresh media. Cytokines were added every time.

On day 24, the cells were collected and the beads were removed from the cells. To remove the beads, cells were transferred to a suitable tube that was placed in the sorting magnet for 2 minutes. Supernatant containing the cells was transferred to a new tube. Cells

were then cultured for 1 day in fresh medium at 1×10^6 /ml. Assays were performed to determine the frequencies of antigen-specific T cells and lentivirus transduced cells.

To prevent possible viral outgrowth, amprenavir (0.5 ng/ml) or saquinavir (0.5 ng/ml) or another suitable protease or integrase inhibitor was added to the cultures on the first day of stimulation and every other day during the culture.

Examine antigen-specific T cells by intracellular cytokine staining for IFN-gamma. Cultured cells after peptide stimulation or after lentivirus transduction at 1×10^6 cells/ml were stimulated with medium alone (negative control), Gag peptides (5 µg/ml individual peptide), or PHA (5 µg/ml, positive control). After 4 hours, BD GolgiPlug™ (1:1000, BD Biosciences) was added to block Golgi transport. After 8 hours, cells were washed and stained with extracellular (CD3, CD4 or CD8; BD Biosciences) and intracellular (IFN- gamma; BD Biosciences) antibodies with BD Cytofix/Cytoperm™ kit following the manufacturer's instruction. Samples were analyzed on a BD FACSCalibur™ Flow Cytometer. Control samples labeled with appropriate isotype-matched antibodies were included in each experiment. Data were analyzed using Flowjo software.

Lentivirus transduction rate was determined by the frequency of GFP+ cells. The transduced antigen-specific T cells are determined by the frequency of CD3+CD4+GFP+IFN gamma + cells; tests for CD3+CD8+GFP+IFN gamma + cells are included as a control.

These results indicate that CD4 T cells, the target T cell population, can be transduced with lentiviruses that are designed to specifically knock down the expression of HIV-specific proteins, thus producing an expandable population of T cells that are immune to the virus. This example serves as a proof of concept indicating that the disclosed lentiviral constructs can be used to produce a functional cure in HIV patients.

25 **Example 4: CCR5 Knockdown with Experimental Vectors**

AGTc120 is a HeLa cell line that stably expresses large amounts of CD4 and CCR5. AGTc120 was transduced with or without LV-CMV-mCherry (the red fluorescent protein mCherry expressed under control of the CMV Immediate Early Promoter) or AGT103/CMV-mCherry. Gene expression of the mCherry fluorescent protein was controlled by a CMV (cytomegalovirus immediate early promoter) expression cassette. The LV-CMV-mCherry vector lacked a microRNA cluster, while AGT103/CMV-mCherry expressed therapeutic miRNA against CCR5, Vif, and Tat.

As shown in Figure 8A, transduction efficiency was >90%. After 7 days, cells were collected and stained with fluorescent monoclonal antibody against CCR5 and subjected to analytical flow cytometry. Isotype controls are shown in gray on these histograms plotting Mean Fluorescence Intensity of CCR5 APC (x axis) versus cell number normalized to mode (y axis). After staining for cell surface CCR5, cells treated with no lentivirus or control lentivirus (expressing only the mCherry marker) showed no changes in CCR5 density while AGT103 (right section) reduced CCR5 staining intensity to nearly the levels of isotype control. After 7 days, cells were infected with or without R5-tropic HIV reporter virus Bal-GFP. 3 days later, cells were collected and analyzed by flow cytometry. More than 90% of cells were transduced. AGT103-CMV/CMVmCherry reduced CCR5 expression in transduced AGTc120 cells and blocked R5-tropic HIV infection compared with cells treated with the Control vector.

Figure 8B shows the relative insensitivity of transfected AGTc120 cells to infection with HIV. As above, the lentivirus vectors express mCherry protein and a transduced cell that was also infected with HIV (expressing GFP) would appear as a double positive cell in the upper right quadrant of the false color flow cytometry dot plots. In the absence of HIV (upper panels), there were no GFP+ cells under any condition. After HIV infection (lower panels), 56% of cells were infected in the absence of lentivirus transduction and 53.6% of cells became infected in AGTc120 cells transduced with the LV-CMV-mCherry. When cells were transduced with the therapeutic AGT103/CMV-mCherry vector, only 0.83% of cells appeared in the double positive quadrant indicating they were transduced and infected.

Dividing 53.62 (proportion of double positive cells with control vector) by 0.83 (the proportion of double positive cells with the therapeutic vector) shows that AGT103 provided greater than 65-fold protection against HIV in this experimental system.

Example 5: Regulation of CCR5 Expression by shRNA Inhibitor Sequences in a Lentiviral Vector

Inhibitory RNA Design. The sequence of *Homo sapiens* chemokine receptor CCR5 (CCR5, NC 000003.12) was used to search for potential siRNA or shRNA candidates to knockdown CCR5 levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Broad Institute or the BLOCK-IT RNA iDesigner from Thermo Scientific. A shRNA sequence may be inserted into a plasmid immediately after a RNA polymerase III promoter such as H1, U6,

or 7SK to regulate shRNA expression. The shRNA sequence may also be inserted into a lentiviral vector using similar promoters or embedded within a microRNA backbone to allow for expression by an RNA polymerase II promoter such as CMV or EF-1 alpha. The RNA sequence may also be synthesized as a siRNA oligonucleotide and utilized independently of a plasmid or lentiviral vector.

Plasmid Construction. For CCR5 shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. Oligonucleotide sequences were annealed by incubating at 70°C then cooled to room temperature. Annealed oligonucleotides were digested with the restriction enzymes BamHI and EcoRI for one hour at 37°C, then the enzymes were inactivated at 70°C for 20 minutes. In parallel, plasmid DNA was digested with the restriction enzymes BamHI and EcoRI for one hour at 37°C. The digested plasmid DNA was purified by agarose gel electrophoresis and extracted from the gel using a DNA gel extraction kit from Invitrogen. The DNA concentration was determined and the plasma to oligonucleotide sequence was ligated in the ratio 3:1 insert to vector. The ligation reaction was done with T4 DNA ligase for 30 minutes at room temperature. 2.5 µL of the ligation mix were added to 25 µL of STBL3 competent bacterial cells. Transformation required heat shock at 42°C. Bacterial cells were spread on agar plates containing ampicillin and colonies were expanded in L broth. To check for insertion of the oligo sequences, plasmid DNA was extracted from harvested bacterial cultures using the Invitrogen DNA Miniprep kit and tested by restriction enzyme digestion. Insertion of the shRNA sequence into the plasmid was verified by DNA sequencing using a primer specific for the promoter used to regulate shRNA expression.

Functional Assay for CCR5 mRNA Reduction: The assay for inhibition of CCR5 expression required co-transfection of two plasmids. The first plasmid contains one of five different shRNA sequences directed against CCR5 mRNA. The second plasmid contains the cDNA sequence for human CCR5 gene. Plasmids were co-transfected into 293T cells. After 48 hours, cells were lysed and RNA was extracted using the RNeasy kit from Qiagen. cDNA was synthesized from RNA using a Super Script Kit from Invitrogen. The samples were then analyzed by quantitative RT-PCR using an Applied Biosystems Step One PCR machine. CCR5 expression was detected with SYBR Green from Invitrogen using the forward primer (5'-AGGAATTGATGGCGAGAAGG-3') (SEQ ID NO: 93) and reverse primer (5'-

CCCCAAAGAAGGTCAAGGTAATCA-3') (SEQ ID NO: 94) with standard conditions for polymerase chain reaction analysis. The samples were normalized to the mRNA for beta actin gene expression using the forward primer (5'-AGCGCGGCTACAGCTTCA-3') (SEQ ID NO: 95) and reverse primer (5'-GGCGACGTAGCACAGCTTCT-3') (SEQ ID NO: 96) with
 5 standard conditions for polymerase chain reaction analysis. The relative expression of CCR5 mRNA was determined by its Ct value normalized to the level of actin messenger RNA for each sample. The results are shown in Figure 9.

As shown in Figure 9A, CCR5 knock-down was tested in 293T cells by co-transfection of the CCR5 shRNA construct and a CCR5-expressing plasmid. Control samples were
 10 transfected with a scrambled shRNA sequence that did not target any human gene and the CCR5-expressing plasmid. After 60 hours post-transfection, samples were harvested and CCR5 mRNA levels were measured by quantitative PCR. Further, as shown in Figure 9B, CCR5 knock-down after transduction with lentivirus expressing CCR5 shRNA-1 (SEQ ID NO: 16).

Example 6: Regulation of HIV Components by shRNA Inhibitor Sequences in a Lentiviral Vector

Inhibitory RNA Design.

The sequences of HIV type 1 Rev/Tat (5'-GCGGAGACAGCGACGAAGAGC-3') (SEQ ID
 20 NO: 9) and Gag (5'-GAAGAAATGATGACAGCAT-3') (SEQ ID NO: 11) were used to design:

Rev/Tat:

(5'-GCGGAGACAGCGACGAAGAGCTTCAAGAGAGCTCTTCGTCGCTGTCTCCGCTTT
 TT-3') (SEQ ID NO: 10) and

25 Gag:

(5'-GAAGAAATGATGACAGCATTTCAGAGAATGCTGTCATCATTTCTTCTTTTT-3')
 (SEQ ID NO: 12) shRNA that were synthesized and cloned into plasmids as described above.

Plasmid Construction. The Rev/Tat or Gag target sequences were inserted into the 3'UTR (untranslated region) of the firefly luciferase gene used commonly as a reporter of gene
 30 expression in cells or tissues. Additionally, one plasmid was constructed to express the Rev/Tat shRNA and a second plasmid was constructed to express the Gag shRNA. Plasmid constructions were as described above.

Functional assay for shRNA targeting of Rev/Tat or Gag mRNA: Using plasmid co-transfection we tested whether a shRNA plasmid was capable of degrading luciferase messenger RNA and decreasing the intensity of light emission in co-transfected cells. A shRNA control (scrambled sequence) was used to establish the maximum yield of light from luciferase transfected cells. When the luciferase construct containing a Rev/Tat target sequence inserted into the 3'-UTR (untranslated region of the mRNA) was co-transfected with the Rev/Tat shRNA sequence there was nearly a 90% reduction in light emission indicating strong function of the shRNA sequence. A similar result was obtained when a luciferase construct containing a Gag target sequence in the 3'-UTR was co-transfected with the Gag shRNA sequence. These results indicate potent activity of the shRNA sequences.

As shown in Figure 10A, knock-down of the Rev/Tat target gene was measured by a reduction of luciferase activity, which was fused with the target mRNA sequence in the 3'UTR, by transient transfection in 293T cells. As shown in Figure 10B, knock-down of the Gag target gene sequence fused with the luciferase gene. The results are displayed as the mean $\pm$ SD of three independent transfection experiments, each in triplicate.

Example 7: AGT103 decreases expression of Tat and Vif

Cells were transfected with exemplary vector AGT103/CMV-GFP. AGT103 and other exemplary vectors are defined in Table 3 below.

Table 3

Vector Designation	Composition
AGT103	EF1-miR30CCR5-miR21Vif-miR185-Tat-WPRE
Control-mCherry	CMV-mCherry
AGT103/CMV-mCherry	CMV-mCherry-EF1-miR30CCR5-miR21Vif-miR185-Tat-WPRE-
Control-GFP	CMV-mCherry
AGT103/CMV-GFP	CMV-GFP-EF1-miR30CCR5-miR21Vif-miR185-Tat-WPRE-
Abbreviations:	
EF-1: elongation factor 1 transcriptional promoter	
miR30CCR5 – synthetic microRNA capable of reducing CCR5 protein on cell surfaces	
miR21Vif – synthetic microRNA capable of reducing levels of HIV RNA and Vif protein	

expression

miR185Tat – synthetic micro RNA capable of reducing levels of HIV RNA and Tat protein

expression

CMV – Immediate early transcriptional promoter from human cytomegalovirus

mCherry – coding region for the mCherry red fluorescent protein

GFP – coding region for the green fluorescent protein

WPRES – Woodchuck hepatitis virus post transcriptional regulatory element

A T lymphoblastoid cell line (CEM; CCRF-CEM; American Type Culture Collection Catalogue number CCL119) was transduced with AGT103/CMV-GFP. 48 hours later the cells were transfected with an HIV expression plasmid encoding the entire viral sequence. After 24 hours, RNA was extracted from cells and tested for levels of intact Tat sequences using reverse transcriptase polymerase chain reaction. Relative expression levels for intact Tat RNA were reduced from approximately 850 in the presence of control lentivirus vector, to approximately 200 in the presence of AGT103/CMV-GFP for a total reduction of > 4 fold, as shown in Figure 11.

Example 8: Regulation of HIV Components by Synthetic MicroRNA Sequences in a Lentiviral Vector

Inhibitory RNA Design. The sequence of HIV-1 Tat and Vif genes were used to search for potential siRNA or shRNA candidates to knockdown Tat or Vif levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Broad Institute or the BLOCK-IT RNA iDesigner from Thermo Scientific. The selected shRNA sequences most potent for Tat or Vif knockdown were embedded within a microRNA backbone to allow for expression by an RNA polymerase II promoter such as CMV or EF-I alpha. The RNA sequence may also be synthesized as a siRNA oligonucleotide and used independently of a plasmid or lentiviral vector.

Plasmid Construction. The Tat target sequence (5'-TCCGCTTCTTCCTGCCATAG-3') (SEQ ID NO: 7) was incorporated into the miR185 backbone to create a Tat miRNA (5'-GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTCG-3') (SEQ ID NO: 3) that was inserted into a lentivirus vector and expressed under control

of the EF-1 alpha promoter. Similarly, the Vif target sequence (5'-GGGATGTGTACTTCTGAACTT-3') (SEQ ID NO: 6) was incorporated into the miR21 backbone to create a Vif miRNA (5'-CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGA
 5 ATCTCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTGACCA-3') (SEQ ID NO: 2) that was inserted into a lentivirus vector and expressed under control of the EF-1 alpha promoter. The resulting Vif/Tat miRNA-expressing lentivirus vectors were produced in 293T cells using a lentiviral vector packaging system. The Vif and Tat miRNA were embedded into a microRNA cluster consisting of miR CCR5, miR Vif, and miR
 10 Tat all expressed under control of the EF-1 promoter.

Functional assay for miR185Tat inhibition of Tat mRNA accumulation. A lentivirus vector expressing miR185 Tat (LV-EF1-miR-CCR5-Vif-Tat) was used at a multiplicity of infection equal to 5 for transducing 293T cells. 24 hours after transduction the cells were transfected with a plasmid expressing HIV strain NL4-3 (pNL4-3) using Lipofectamine2000
 15 under standard conditions. 24 hours later RNA was extracted and levels of Tat messenger RNA were tested by RT-PCR using Tat-specific primers and compared to actin mRNA levels for a control.

Functional assay for miR21 Vif inhibition of Vif protein accumulation. A lentivirus vector expressing miR21 Vif (LV-EF1-miR-CCR5-Vif-Tat) was used at a multiplicity of
 20 infection equal to 5 for transducing 293T cells. 24 hours after transduction, the cells were transfected with a plasmid expressing HIV strain NL4-3 (pNL4-3) using Lipofectamine2000. 24 hours later cells were lysed and total soluble protein was tested to measure the content of Vif protein. Cell lysates were separated by SDS-PAGE according to established techniques. The separated proteins were transferred to nylon membranes and probed with a Vif-specific
 25 monoclonal antibody or actin control antibody.

As shown in Figure 12A, Tat knock-down was tested in 293T cells transduced with either a control lentiviral vector or a lentiviral vector expressing either synthetic miR185 Tat or miR155 Tat microRNA. After 24 hours, the HIV vector pNL4-3 was transfected with Lipofectamine2000 for 24 hours and then RNA was extracted for qPCR analysis with primers
 30 for Tat. As shown in Figure 12B, Vif knock-down was tested in 293T cells transduced with either a control lentiviral vector or a lentiviral vector expressing a synthetic miR21 Vif

microRNA. After 24 hours, the HIV vector pNL4-3 was transfected with Lipofectamine2000 for 24 hours and then protein was extracted for immunoblot analysis with an antibody for HIV Vif.

5 Example 9: Regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector

CEM-CCR5 cells were transduced with a lentiviral vector containing a synthetic miR30 sequence for CCR5 (AGT103: TGTAAGCTGAGCTTGCTCTA (SEQ ID NO: 97), AGT103-R5-1: TGTAAGCTGAGCTTGCTCGC (SEQ ID NO: 98), or AGT103-R5-2: CATAGATTGGACTTGACAC (SEQ ID NO: 99). After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified by mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The target sequence of AGT103 and AGT103-R5-1 is in the same region as CCR5 target sequence #5. The target sequence of AGT103-R5-2 is the same as CCR5 target sequence #1. AGT103 (2% of total CCR5) is most effective at reducing CCR5 levels as compared with AGT103-R5-1 (39% of total CCR5) and AGT103-R5-2 which does not reduce CCR5 levels. The data is demonstrated in Figure 13 herein.

20 Example 10: Regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector containing either a long or short WPRE sequence.

Vector Construction. Lentivirus vectors often require an RNA regulatory element for optimal expression of therapeutic genes or genetic constructs. A common choice is to use the Woodchuck hepatitis virus post transcriptional regulatory element (WPRE). We compared AGT103 that contains a full-length WPRE:

25 (5'AATCAACCTCTGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATG
TTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTG
CTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTA
TGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTG
ACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACT
30 TTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACATCGCCGCCTGCCTTGCCCGC
TGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTCGGGGA
AATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGA

CGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCC
 TGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGG
 ATCTCCCTTTGGGCGCCTCCCCGCCT-3') (SEQ ID NO: 32)

with a modified AGT103 vector containing a shortened WPRE element
 5 (5'AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACTAT
 GTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTAATGCCTCTGTATCATGCTATT
 GCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTT
 ATGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTTGCT
 GACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGGGAC
 10 TTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCC
 GCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTGTC-3')
 (SEQ ID NO: 80).

*Functional assay for modulating cell surface CCR5 expression as a function of long
 versus short WPRE element in the vector sequence.* AGT103 containing long or short WPRE
 15 elements were used for transducing CEM-CCR5 T cells a multiplicity of infection equal to 5.
 Six days after transduction cells were collected and stained with a monoclonal antibody
 capable of detecting cell surface CCR5 protein. The antibody was conjugated to a fluorescent
 marker and the intensity of staining is directly proportional to the level of CCR5 on the cell
 surface. A control lentivirus had no effect on cell surface CCR5 levels resulting in a single
 20 population with a mean fluorescence intensity of 73.6 units. The conventional AGT103 with a
 long WPRE element reduced CCR5 expression to a mean fluorescence intensity level of 11
 units. AGT103 modified to incorporate a short WPRE element resulted in a single population
 of cells with mean fluorescence intensity of 13 units. Accordingly, substituting a short WPRE
 element had little or no effect on the capacity for AGT103 to reduce cell surface CCR5
 25 expression.

As shown in Figure 14, CEM-CCR5 cells were transduced with AGT103 containing
 either a long or short WPRE sequence. After 6 days, CCR5 expression was determined by
 FACS analysis with an APC-conjugated CCR5 antibody and quantified as mean fluorescence
 intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The
 30 reduction in CCR5 levels was similar for AGT103 with either the short (5.5% of total CCR5)
 or long (2.3% of total CCR5) WPRE sequence.

Example 11: Regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector with or without a WPRE sequence

Vector construction. In order to test whether WPRE was required for AGT103 down regulation of CCR5 expression we constructed a modified vector without WPRE element
5 sequences.

Functional assay for modulating cell surface CCR5 expression as a function of including or not including a long WPRE element in the AGT103 vector. In order to test whether WPRE was required for AGT103 modulation of CCR5 expression levels we transduced CEM-CCR5 T cells with AGT103 or a modified vector lacking WPRE using a
10 multiplicity of infection equal to 5. Six days after transduction cells were collected and stained with a monoclonal antibody capable of recognizing cell surface CCR5 protein. The monoclonal antibody was directly conjugated to a fluorescent marker and the intensity of staining is directly proportional to the number of CCR5 molecules per cell surface. A lentivirus control vector had no effect on cell surface CCR5 levels resulting in a uniform population with
15 mean fluorescence intensity of 164. The lentivirus vector (AGT103 with a long WPRE and also expressing GFP marker protein), AGT103 lacking GFP but containing a long WPRE element, or AGT103 lacking both GFP and WPRE all were similarly effective for modulating cell surface CCR5 expression. After removing GFP, AGT103 with or without WPRE elements were indistinguishable in terms of their capacity for modulating cell surface CCR5 expression.

20 CEM-CCR5 cells were transduced with AGT103 with or without GFP and WPRE. After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified as mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The reduction in CCR5 levels was similar for AGT103 with (0% of total CCR5) or without (0% of total CCR5) the WPRE
25 sequence. This data is demonstrated in Figure 15.

Example 12: Regulation of CCR5 expression by a CD4 promoter regulating synthetic microRNA sequences in a lentiviral vector.

Vector Construction. A modified version of AGT103 was constructed to test the effect
30 of substituting alternate promoters for expressing the microRNA cluster that suppresses CCR5,

Vif and Tat gene expression. In place of the normal EF-1 promoter we substituted the T cell-specific promoter for CD4 glycoprotein expression using the sequence:

(5'TGTTGGGGTTCAAATTTGAGCCCCAGCTGTTAGCCCTCTGCAAAGAAAAAAAAA
 AAAAAAAAAAGAACAAGGGCCTAGATTTCCCTTCTGAGCCCCACCCTAAGATGAA
 5 GCCTCTTCTTTCAAGGGAGTGGGGTTGGGGTGGAGGCGGATCCTGTCAGCTTTGCT
 CTCTCTGTGGCTGGCAGTTTCTCCAAAGGGTAACAGGTGTCAGCTGGCTGAGCCTA
 GGCTGAACCCTGAGACATGCTACCTCTGTCTTCTCATGGCTGGAGGCAGCCTTTGT
 AAGTCACAGAAAGTAGCTGAGGGGCTCTGGAAAAAAGACAGCCAGGGTGGAGGT
 AGATTGGTCTTTGACTCCTGATTTAAGCCTGATTCTGCTTAACCTTTTTCCCTTGACT
 10 TTGGCATTTCACCTTTGACATGTTCCCTGAGAGCCTGGGGGGTGGGGAACCCAGCT
 CCAGCTGGTGACGTTTGGGGCCGGCCCAGGCCTAGGGTGTGGAGGAGCCTTGCCA
 TCGGGCTTCCTGTCTCTCTTCATTTAAGCACGACTCTGCAGA-3') (SEQ ID NO: 30).

Functional assay comparing EF-1 and CD4 gene promoters in terms of potency for reducing cell surface CCR5 protein expression. AGT103 modified by substituting the CD4
 15 gene promoter for the normal EF-1 promoter was used for transducing CEM-CCR5 T cells. Six days after transduction cells were collected and stained with a monoclonal antibody capable of recognizing cell surface CCR5 protein. The monoclonal antibody was conjugated to a fluorescent marker and staining intensity is directly proportional to the level of cell surface CCR5 protein. A control lentivirus transduction resulted in a population of CEM-CCR5 T cells
 20 that were stained with a CCR5-specific monoclonal antibody and produced a mean fluorescence intensity of 81.7 units. The modified AGT103 using a CD4 gene promoter in place of the EF-1 promoter for expressing microRNA showed a broad distribution of staining with a mean fluorescence intensity roughly equal to 17.3 units. Based on this result, the EF-1 promoter is at least similar and likely superior to the CD4 gene promoter for microRNA
 25 expression. Depending on the desired target cell population, the EF-1 promoter is universally active in all cell types and the CD4 promoter is only active in T-lymphocytes.

CEM-CCR5 cells were transduced with a lentiviral vector containing a CD4 promoter regulating a synthetic microRNA sequence for CCR5, Vif, and Tat (AGT103). After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody
 30 and quantified as mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. In cells transduced with LV-CD4-AGT103, CCR5 levels were 11% of total CCR5. This is comparable to that observed for LV-AGT103 which contains the EF1 promoter. This data is demonstrated in Figure 16.

Example 13: Detecting HIV Gag-Specific CD4 T Cells

Cells and reagents. Viable frozen peripheral blood mononuclear cells (PBMC) were obtained from a vaccine company. Data were obtained with a representative specimen from an HIV+ individual who was enrolled into an early stage clinical trial (TRIAL REGISTRATION: clinicaltrials.gov NCT01378156) testing a candidate HIV therapeutic vaccine. Two specimens were obtained for the “Before vaccination” and “After vaccination” studies. Cell culture products, supplements and cytokines were from commercial suppliers. Cells were tested for responses to recombinant Modified Vaccinia Ankara 62B from Geovax Corporation as described in Thompson, M., S. L. Heath, B. Sweeton, K. Williams, P. Cunningham, B. F. Keele, S. Sen, B. E. Palmer, N. Chomont, Y. Xu, R. Basu, M. S. Hellerstein, S. Kwa and H. L. Robinson (2016). "DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus." PLoS One 11(10): e0163164. Synthetic peptides representing the entire HIV-1 Gag polyprotein were obtained from GeoVax or the HIV (GAG) Ultra peptide sets were obtained from JPT Peptide Technologies GmbH (www.jpt.com), Berlin, Germany. HIV (GAG) Ultra contains 150 peptides each being 15 amino acids in length and overlapping by 11 amino acids. They were chemically synthesized then purified and analyzed by liquid chromatography – mass spectrometry. Collectively these peptides represent major immunogenic regions of the HIV Gag polyprotein and are designed for average coverage of 57.8% among known HIV strains. Peptide sequences are based on the HIV sequence database from the Los Alamos National Laboratory (<http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html>). Peptides are provided as dried trifluoroacetate salts, 25 micrograms per peptide, and are dissolved in approximately 40 microliters of DMSO then diluted with PBS to final concentration. Monoclonal antibodies for detecting CD4 and cytoplasmic IFN-gamma were obtained from commercial sources and intracellular staining was done with the BD Pharmingen Intracellular Staining Kit for interferon-gamma. Peptides were resuspended in DMSO and we include a DMSO only control condition.

Functional assay for detecting HIV-specific CD4+ T cells. Frozen PBMC were thawed, washed and resuspended in RPMI medium containing 10% fetal bovine serum, supplements and cytokines. Cultured PBMC collected before or after vaccination were treated with DMSO control, MVA GeoVax (multiplicity of infection equal to 1 plaque forming unit per cell), Peptides GeoVax (1 microgram/ml) or HIV (GAG) Ultra peptide mixture (1 microgram/ml)

for 20 hours in the presence of Golgi Stop reagent. Cells were collected, washed, fixed, permeabilized and stained with monoclonal antibodies specific for cell surface CD4 or intracellular interferon-gamma. Stained cells were analyzed with a FACSCalibur analytical flow cytometer and data were gated on the CD4+ T cell subset. Cells highlighted within boxed regions are double-positive and designated HIV-specific CD4 T cells on the basis of interferon-gamma expression after MVA or peptide stimulation. Numbers within the boxed regions show the percentage of total CD4 that were identified as HIV-specific. We did not detect strong responses to DMSO or MVA. Peptides from GeoVax elicited fewer responding cells compared to HIV (GAG) Ultra peptide mixture from JPT but differences were small and not significant.

As shown in Figure 17, PBMCs from a HIV-positive patient before or after vaccination were stimulated with DMSO (control), recombinant MVA expressing HIV Gag from GeoVax (MVA GeoVax), Gag peptide from GeoVax (Pep GeoVax, also referred to herein as Gag peptide pool 1) or Gag peptides from JPT (HIV (GAG) Ultra peptide mixture, also referred to herein as Gag peptide pool 2) for 20 hours. IFN γ production was detected by intracellular staining and flow cytometry using standard protocols. Flow cytometry data were gated on CD4 T cells. Numbers captured in boxes are the percentage of total CD4 T cells designated “HIV-specific” on the basis of cytokine response to antigen-specific stimulation.

Example 14: HIV-specific CD4 T cell expansion and lentivirus transduction

Designing and testing methods for enriching PBMC to increase the proportion of HIV-specific CD4 T cells and transducing these cells with AGT103 to produce the cellular product AGT103T. The protocol was designed for ex vivo culture of PBMC (peripheral blood mononuclear cells) from HIV-positive patients who had received a therapeutic HIV vaccine. In this example, the therapeutic vaccine consisted of three doses of plasmid DNA expressing HIV Gag, Pol and Env genes followed by two doses of MVA 62-B (modified vaccinia Ankara number 62-B) expressing the same HIV Gag, Pol, and Env genes. The protocol is not specific for a vaccine product and only requires a sufficient level of HIV-specific CD4+ T cells after immunization. Venous blood was collected and PBMC were purified by Ficoll-Paque density gradient centrifugation. Alternately, PBMC or defined cellular fractions can be prepared by positive or negative selection methods using antibody cocktails and fluorescence activated or magnetic bead sorting. The purified PBMC are washed and cultured in standard medium containing supplements, antibiotics and fetal bovine serum. To these cultures, a pool of

synthetic peptides was added representing possible T cell epitopes within the HIV Gag polyprotein. Cultures are supplemented by adding cytokines interleukin-2 and interleukin-12 that were selected after testing combinations of interleukin-2 and interleukin-12, interleukin 2 and interleukin-7, interleukin 2 and interleukin-15. Peptide stimulation is followed by a culture
5 interval of approximately 12 days. During the 12 days culture, fresh medium and fresh cytokine supplements were added approximately once every four days.

The peptide stimulation interval is designed to increase the frequency of HIV-specific CD4 T cells in the PBMC culture. These HIV-specific CD4 T cells were activated by prior therapeutic immunization and can be re-stimulated and caused to proliferate by synthetic
10 peptide exposure. Our goal is to achieve greater than or equal to 1% of total CD4 T cells being HIV-specific by end of the peptide stimulation culture period.

On approximately day 12 of culture cells are washed to remove residual materials then stimulated with synthetic beads decorated with antibodies against CD4 T cell surface proteins CD3 and CD28. This well-established method for polyclonal stimulation of T cells will
15 reactivate the cells and make them more susceptible for AGT103 lentivirus transduction. The lentivirus transduction is performed on approximately day 13 of culture and uses a multiplicity of infection between 1 and 5. After transduction cells are washed to remove residual lentivirus vector and cultured in media containing interleukin-2 and interleukin-12 with fresh medium and cytokines added approximately once every four days until approximately day 24 of culture.

20 Throughout the culture interval the antiretroviral drug Saquinavir is added at a concentration of approximately 100 nM to suppress any possible outgrowth of HIV.

On approximately day 24 of culture cells are harvested, washed, a sample is set aside for potency and release assay, then the remaining cells are suspended in cryopreservation medium before freezing in single aliquots of approximately 1×10^{10} cells per dose that will
25 contain approximately 1×10^8 HIV-specific CD4 T cells that are transduced with AGT103.

Potency of the cell product (AGT103T) is tested in one of two alternate potency assays. Potency assay 1 tests for the average number of genome copies (integrated AGT103 vector sequences) per CD4 T cell. The minimum potency is approximately 0.5 genome copies per CD4 T cell in order to release the product. The assay is performed by positive selection of CD3
30 positive/CD4 positive T cells using magnetic bead labeled monoclonal antibodies, extracting total cellular DNA and using a quantitative PCR reaction to detect sequences unique to the AGT103 vector. Potency assay 2 tests for the average number of genome copies of integrated AGT103 within the subpopulation of HIV-specific CD4 T cells. This assay is accomplished by

first stimulating the PBMC with the pool of synthetic peptides representing HIV Gag protein. Cells are then stained with a specific antibody reagent capable of binding to the CD4 T cell and also capturing secreted interferon-gamma cytokine. The CD4 positive/interferon-gamma positive cells are captured by magnetic bead selection, total cellular DNA is prepared, and the number of genome copies of AGT103 per cell is determined with a quantitative PCR reaction. Release criterion based on potency using Assay 2 require that greater than or equal to 0.5 genome copies per HIV-specific CD4 T-cell are present in the AGT103 cell product.

Functional test for enriching and transducing HIV-specific CD4 T cells from PBMC of HIV-positive patients that received a therapeutic HIV vaccine. The impact of therapeutic vaccination on the frequency of HIV-specific CD4 T cells was tested by a peptide stimulation assay (Figure 14 panel B). Before vaccination the frequency of HIV-specific CD4 T cells was 0.036% in this representative individual. After vaccination, the frequency of HIV-specific CD4 T cells was increased approximately 2-fold to the value of 0.076%. Responding cells (HIV-specific) identified by accumulation of cytoplasmic interferon-gamma, were only detected after specific peptide stimulation.

We also tested whether peptide stimulation to enrich for HIV-specific CD4 T cells followed by AGT103 transduction would reach our goal of generating approximately 1% of total CD4 T cells in culture that were both HIV-specific and transduced by AGT103. In this case, we used an experimental version of AGT103 that expresses green fluorescence protein (see GFP). In Figure 14, panel C the post-vaccination culture after peptide stimulation (HIV (GAG) Ultra) and AGT103 transduction demonstrated that 1.11% of total CD4 T cells were both HIV-specific (based on expressing interferon-gamma in response to peptide stimulation) and AGT103 transduced (based on expression of GFP).

Several patients from a therapeutic HIV vaccine study were tested to assess the range of responses to peptide stimulation and to begin defining eligibility criteria for entering a gene therapy arm in a future human clinical trial. Figure 18 Panel D shows the frequency of HIV-specific CD4 T cells in 4 vaccine trial participants comparing their pre-and post-vaccination specimens. Importantly, in three cases, the post-vaccination specimens show a value of HIV-specific CD4 T cells that was greater than or equal to 0.076% of total CD4 T cells. The ability to reach this value was not predicted by the pre-vaccination specimens as patient 001-004 and patient 001-006 both started with pre-vaccination values of 0.02% HIV-specific CD4 T cells but one reached an eventual post-vaccination value of 0.12% HIV-specific CD4 T cells while the other individual fail to increase this value after vaccination. The same three patients that

responded well to vaccine, in terms of increasing the frequency of HIV-specific CD4 T cells, also showed substantial enrichment of HIV-specific CD4 T cells after peptide stimulation and culture. In the three cases shown in Figure 18 Panel E, peptide stimulation and subsequent culture generated samples where 2.07%, 0.72% or 1.54% respectively of total CD4 T cells were HIV-specific. These values indicate that a majority of individuals responding to a therapeutic HIV vaccine will have a sufficiently large ex vivo response to peptide stimulation in order to enable our goal of achieving approximately 1% of total CD4 T cells that are HIV-specific and transduced with AGT103 in the final cell product.

As shown in Figure 18, Panel A describes the schedule of treatment. Panel B demonstrates that PBMCs were stimulated with Gag peptide or DMSO control for 20 hours. IFN gamma production was detected by intracellular staining by FACS. CD4⁺ T cells were gated for analysis. Panel C demonstrates CD4⁺ T cells were expanded and transduced with AGT103-GFP using the method as shown in Panel A. Expanded CD4⁺ T cells were rested in fresh medium without any cytokine for 2 days and re-stimulated with Gag peptide or DMSO control for 20 hours. IFN gamma production and GFP expression was detected by FACS. CD4⁺ T cells were gated for analysis. Panel D demonstrates frequency of HIV-specific CD4⁺ T cells (IFN gamma positive, pre- and post-vaccination) were detected from 4 patients as discussed herein. Panel E demonstrates Post-vaccination PBMCs from 4 patients were expanded and HIV-specific CD4⁺ T cells were examined.

Example 15: Dose Response

Vector Construction. A modified version of AGT103 was constructed to test the dose response for increasing AGT103 and its effects on cell surface CCR5 levels. The AGT103 was modified to include a green fluorescent protein (GFP) expression cassette under control of the CMV promoter. Transduced cells expression the miR30CCR5 miR21Vif miR185Tat micro RNA cluster and emit green light due to expressing GFP.

Functional assay for dose response of increasing AGT103-GFP and inhibition of CCR5 expression. CEM-CCR5 T cells were transduced with AGT103-GFP using multiplicity of infection per cell from 0 to 5. Transduced cells were stained with a fluorescently conjugated (APC) monoclonal antibody specific for cell surface CCR5. The intensity of staining is proportional to the number of CCR5 molecules per cell surface. The intensity of green fluorescence is proportional to the number of integrated AGT103-GFP copies per cell.

As shown in Figure 19, Panel A demonstrates the dose response for increasing AGT103-GFP and its effects on cell surface CCR5 expression. At multiplicity of infection equal to 0.4 only 1.04% of cells are both green (indicating transduction) and showing significantly reduced CCR5 expression. At multiplicity of infection equal to 1 the number of CCR5^{low}, GFP⁺ cells increases to 68.1%. At multiplicity of infection equal to 5 the number of CCR5^{low}, GFP⁺ cells increased to 95.7%. These data are presented in histogram form in Figure 19, Panel B that shows a normally distribution population in terms of CCR5 staining, moving toward lower mean fluorescence intensity with increasing doses of AGT103-GFP. The potency of AGT103-GFP is presented in graphical form in Figure 19, Panel C showing the percentage inhibition of CCR5 expression with increasing doses of AGT103-GFP. At multiplicity of infection equal to 5, there was greater than 99% reduction in CCR5 expression levels.

Example 16: AGT103 efficiently transduces primary human CD4⁺ T cells

Transducing primary CD4 T cells with AGT103 lentivirus vector. A modified AGT103 vector containing the green fluorescence protein marker (GFP) was used at multiplicities of infection between 0.2 and 5 for transducing purified, primary human CD4 T cells.

Functional assay for transduction efficiency of AGT103 in primary human CD4 T cells. CD4 T cells were isolated from human PBMC (HIV-negative donor) using magnetic bead labeled antibodies and standard procedures. The purified CD4 T cells were stimulated ex vivo with CD3/CD28 beads and cultured in media containing interleukin-2 for 1 day before AGT103 transduction. The relationship between lentivirus vector dose (the multiplicity of infection) and transduction efficiency is demonstrated in Figure 20, Panel A showing that multiplicity of infection equal to 0.2 resulted in 9.27% of CD4 positive T cells being transduced by AGT103 and that value was increased to 63.1% of CD4 positive T cells being transduced by AGT103 with a multiplicity of infection equal to 5. In addition to achieving efficient transduction of primary CD4 positive T cells it is also necessary to quantify the number of genome copies per cell. In Figure 20, Panel B total cellular DNA from primary human CD4 T cells transduced at several multiplicities of infection were tested by quantitative PCR to determine the number of genome copies per cell. In a multiplicity of infection equal to 0.2 we measured 0.096 genome copies per cell that was in good agreement with 9.27% GFP positive CD4 T cells in panel A. Multiplicity of infection equal to 1 generated 0.691 genome copies per cell and multiplicity of infection equal to 5 generated 1.245 genome copies per cell.

As shown in Figure 20, CD4⁺ T cells isolated from PBMC were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations. After 2 days, beads were removed and CD4⁺ T cells were collected. As shown in Panel A, frequency of transduced cells (GFP positive) were detected by FACS. As shown in Panel B,
 5 the number of vector copies per cell was determined by qPCR. At a multiplicity of infection (MOI) of 5, 63% of CD4⁺ T cells were transduced with an average of 1 vector copy per cell.

Example 17: AGT103 inhibits HIV replication in primary CD4⁺ T cells

Protecting primary human CD4 positive T cells from HIV infection by transducing cells with AGT103. Therapeutic lentivirus AGT103 was used for transducing primary human CD4
 10 positive T cells at multiplicities of infection between 0.2 and 5 per cell. The transduced cells were then challenged with a CXCR4-tropic HIV strain NL4.3 that does not require cell surface CCR5 for penetration. This assay tests the potency of microRNA against Vif and Tat genes of HIV in terms of preventing productive infection in primary CD4 positive T cells, but uses an indirect method to detect the amount of HIV released from infected, primary human CD4 T
 15 cells.

Functional assay for AGT103 protection against CXCR4-tropic HIV infection of primary human CD4 positive T cells. CD4 T cells were isolated from human PBMC (HIV-negative donor) using magnetic bead labeled antibodies and standard procedures. The purified CD4 T cells were stimulated ex vivo with CD3/CD28 beads and cultured in media containing
 20 interleukin-2 for 1 day before AGT103 transduction using multiplicities of infection between 0.2 and 5. Two days after transduction the CD4 positive T cell cultures were challenged with HIV strain NL4.3 that was engineered to express the green fluorescent protein (GFP). The transduced and HIV-exposed primary CD4 T cell cultures were maintained for 7 days before collecting cell-free culture fluids containing HIV. The cell-free culture fluids were used to
 25 infect a highly permissive T cell line C8166 for 2 days. The proportion of HIV-infected C8166 cells was determined by flow cytometry detecting GFP fluorescence. With a mock lentivirus infection, the dose of 0.1 multiplicity of infection for NL4.3 HIV resulted in an amount of HIV being released into culture fluids that was capable of establishing productive infection in 15.4% of C8166 T cells. With the dose 0.2 multiplicity of infection for AGT103, this value for
 30 HIV infection of C8166 cells is reduced to 5.3% and multiplicity of infection equal to 1 for AGT103 resulted in only 3.19% of C8166 T cells being infected by HIV. C8166 infection was reduced further to 0.62% after AGT103 transduction using a multiplicity of infection equal to

5. There is a clear dose response relationship between the amount of AGT103 used for transduction and the amount of HIV released into the culture medium.

As shown in Figure 21, CD4⁺ T cells isolated from PBMC were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations (MOI). After 2 days, beads were removed and CD4⁺ T cells were infected with 0.1 MOI of HIV NL4.3-GFP. 24 hours later, cells were washed 3 times with PBS and cultured with IL-2 (30U/ml) for 7 days. At the end of the culture, supernatant was collected to infect the HIV permissive cell line C8166 for 2 days. HIV-infected C8166 cells (GFP positive) were detected by FACS. There was a reduction in viable HIV with an increase in the multiplicity of infection of AGT103 as observed by less infection of C8166 cells MOI 0.2=65.6%, MOI 1= 79.3%, and MOI 5=96%).

Example 18: AGT103 protects primary human CD4⁺ T cells from HIV-induced depletion

AGT103 transduction of primary human CD4 T cells to protect against HIV-mediated cytopathology and cell depletion. PBMC were obtained from healthy, HIV-negative donors and stimulated with CD3/CD28 beads then cultured for 1 day in medium containing interleukin-2 before AGT103 transduction using multiplicities of infection between 0.2 and 5.

Functional assay for AGT103 protection of primary human CD4 T cells against HIV-mediated cytopathology. AGT103-transduced primary human CD4 T cells were infected with HIV NL 4.3 strain (CXCR4-tropic) that does not require CCR5 for cellular entry. When using the CXCR4-tropic NL 4.3, only the effect of Vif and Tat microRNA on HIV replication is being tested. The dose of HIV NL 4.3 was 0.1 multiplicity of infection. One day after HIV infection, cells were washed to remove residual virus and cultured in medium plus interleukin-2. Cells were collected every three days during a 14-day culture then stained with a monoclonal antibody that was specific for CD4 and directly conjugated to a fluorescent marker to allow measurement of the proportion of CD4 positive T cells in PBMC. Untreated CD4 T cells or CD4 T cells transduced with the control lentivirus vector were highly susceptible to HIV challenge and the proportion of CD4 positive T cells in PBMC fell below 10% by day 14 culture. In contrast, there was a dose-dependent effect of AGT103 on preventing cell depletion by HIV challenge. With a AGT103 dose of 0.2 multiplicity of infection more than 20% of PBMC were CD4 T cells by day 14 of culture and this value increased to more than 50% of PBMC being CD4 positive T cells by day 14 of culture with a AGT103 dose of multiplicity of

infection equal to 5. Again, there is a clear dose response effect of AGT103 on HIV cytopathogenicity in human PBMC.

As shown in Figure 22, PBMCs were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations (MOI). After 2 days, beads
5 were removed and cells were infected with 0.1 MOI of HIV NL4.3. 24 hours later, cells were washed 3 times with PBS and cultured with IL-2 (30U/ml). Cells were collected every 3 days and the frequency of CD4⁺ T cells were analyzed by FACS. After 14 days of exposure to HIV, there was an 87% reduction in CD4⁺ T cells transduced with LV-Control, a 60% reduction with AGT103 MOI 0.2, a 37% reduction with AGT103 MOI 1, and a 17% reduction with
10 AGT103 MOI 5.

Example 19: Generating a Population of CD4⁺ T cells enriched for HIV-Specificity and transduced with AGT103/CMV-GFP

Therapeutic vaccination against HIV had minimal effect on the distribution of CD4⁺,
15 CD8⁺ and CD4⁺/CD8⁺ T cells. As shown in Figure 23A, the CD4 T cell population is shown in the upper left quadrant of the analytical flow cytometry dot plots, and changes from 52% to 57% of total T cells after the vaccination series. These are representative data.

Peripheral blood mononuclear cells from a participant in an HIV therapeutic vaccine trial were cultured for 12 days in medium +/- interleukin-2/interleukin-12 or +/- interleukin-
20 7/interleukin-15. Some cultures were stimulated with overlapping peptides representing the entire p55 Gag protein of HIV-1 (HIV (GAG) Ultra peptide mixture) as a source of epitope peptides for T cell stimulation. These peptides are 10-20 amino acids in length and overlap by 20-50% of their length to represent the entire Gag precursor protein (p55) from HIV-1 BaL strain. The composition and sequence of individual peptides can be adjusted to compensate for
25 regional variations in the predominant circulating HIV sequences or when detailed sequence information is available for an individual patient receiving this therapy. At culture end, cells were recovered and stained with anti-CD4 or anti-CD8 monoclonal antibodies and the CD3⁺ population was gated and displayed here. The HIV (GAG) Ultra peptide mixture stimulation for either pre- or post-vaccination samples was similar to the medium control indicating that
30 HIV (GAG) Ultra peptide mixture was not toxic to cells and was not acting as a polyclonal mitogen. The results of this analysis can be found in Figure 23B.

HIV (GAG) Ultra peptide mixture and interleukin-2/interleukin-12 provided for optimal expansion of antigen-specific CD4 T cells. As shown in the upper panels of Figure

23C, there was an increase in cytokine (interferon-gamma) secreting cells in post-vaccination specimens exposed to HIV (GAG) Ultra peptide mixture. In the pre-vaccination sample, cytokine secreting cells increased from 0.43 to 0.69% as a result of exposure to antigenic peptides. In contrast, the post-vaccination samples showed an increase of cytokine secreting
 5 cells from 0.62 to 1.76% of total CD4 T cells as a result of peptide stimulation. These data demonstrate the strong impact of vaccination on the CD4 T cell responses to HIV antigen.

Finally, AGT103/CMV-GFP transduction of antigen-expanded CD4 T cells produced HIV-specific and HIV-resistant helper CD4 T cells that are needed for infusion into patients as part of a functional cure for HIV (in accordance with other various aspects and embodiments, AGT103 alone is used; for example, clinical embodiments may not include the CMV-GFP
 10 segment). The upper panels of Figure 23C show the results of analyzing the CD4⁺ T cell population in culture. The x axis of Figure 23C shows Green Fluorescent Protein (GFP) emission indicating that individual cells were transduced with the AGT103/CMV-GFP. In the post-vaccination samples 1.11% of total CD4 T cells that were both cytokine secreting was
 15 recovered, indicating that the cells are responding specifically to HIV antigen, and transduced with AGT103/CMV-GFP. This is the target cell population and the clinical product intended for infusion and functional cure of HIV. With the efficiency of cell expansion during the antigen stimulation and subsequent polyclonal expansion phases of ex vivo culture, 4×10^8 antigen-specific, lentivirus transduced CD4 T cells can be produced. This exceeds the target
 20 for cell production by 4-fold and will allow achievement of a count of antigen-specific and HIV-resistant CD4 T cells of approximately 40 cells/microliter of blood or around 5.7% of total circulating CD4 T cells.

Table 4 below shows the results of the *ex vivo* production of HIV-specific and HIV-resistant CD4 T cells using the disclosed vectors and methods.

25

Table 4			
Material/manipulation	Total CD4 T cells	Percentage HIV-specific	Percentage HIV-specific and HIV-resistant
Leukapheresis pack from HIV+ patient	$\sim 7 \times 10^8$	~ 0.12	N/A
Peptide expansion <i>ex</i>	$\sim 8 \times 10^8$	~ 2.4	N/A

<i>vivo</i>			
Mitogen expansion	$\sim 1.5 \times 10^{10}$	~ 2.4	N/A
Lentivirus transduction	$\sim 1.5 \times 10^{10}$	~ 2.4	~ 1.6

Example 20: Clinical Study for Treatment of HIV-Positive Subjects with No Immunization

AGT103T is a genetically modified autologous PBMC containing $\geq 5 \times 10^7$ HIV-specific CD4 T cells that are also transduced with AGT103 lentivirus vector

A Phase I clinical trial will test the safety and feasibility of infusing *ex vivo* modified autologous CD4 T cells (AGT103T) in adult research participants with confirmed HIV infection, CD4+ T-cell counts >600 cells per mm^3 of blood and stable virus suppression below 200 copies per ml of plasma while on cART. All study participants will continue receiving their standard antiretroviral medications throughout the Phase I clinical trial. Study participants are screened by submitting a blood for in vitro testing to measure the frequency of CD4+ T-cells that respond to stimulation with a pool of overlapping, synthetic peptides representing the HIV-1 Gag polyprotein. Subjects with $\geq 0.065\%$ of total CD4 T cells designated as Gag-specific CD4 T cells are enrolled in the gene therapy study and undergo leukapheresis followed by purification of PBMC (using Ficoll density gradient centrifugation or negative selection with antibodies) that are cultured *ex vivo* and stimulated with HIV Gag peptides plus interleukin-2 and interleukin-12 for 12 days, then stimulated again with beads decorated with CD3/CD28 bispecific antibody. The antiretroviral drug Saquinavir is included at 100 nM to prevent emergence of autologous HIV during *ex vivo* culture. One day after CD3/CD28 stimulation cells are transduced with AGT103 at multiplicity of infection between 1 and 10. The transduced cells are cultured for an additional 7-14 days during which time they expand by polyclonal proliferation. The culture period is ended by harvesting and washing cells, setting aside aliquots for potency and safety release assays, and resuspending the remaining cells in cryopreservation medium. A single dose is $\leq 1 \times 10^{10}$ autologous PBMC. The potency assay measures the frequency of CD4 T cells that respond to peptide stimulation by expressing interferon-gamma. Other release criteria include the product must include $\geq 0.5 \times 10^7$ HIV-specific CD4 T cells that are also transduced with AGT103. Another release criterion is that the number of AGT103 genome copies per cell must not exceed 3. Five days before infusion with AGT103T subjects receive one dose of busulfuram (or Cytosan or fludarabine or suitable

drug combinations) conditioning regimen followed by infusion of $\leq 1 \times 10^{10}$ PBMC containing genetically modified CD4 T cells.

A Phase II study will evaluate efficacy of AGT103T cell therapy. Phase II study participants include individuals enrolled previously in our Phase I study who were judged to have successful and stable engraftment of genetically modified, autologous, HIV-specific CD4 T cells and clinical responses defined as positive changes in parameters monitored as described in efficacy assessments (1.3.). Study participants will be asked to add Maraviroc to their existing regimen of antiretroviral medication. Maraviroc is a CCR5 antagonist that will enhance the effectiveness of genetic therapy directed at reducing CCR5 levels. Once the Maraviroc regimen is in place subjects will be asked to discontinue the previous antiretroviral drug regimen and only maintain Maraviroc monotherapy for 28 days or until plasma viral RNA levels exceed 10,000 per ml on 2 sequential weekly blood draws. Persistently high viremia requires participants to return to their original antiretroviral drug regimen with or without Maraviroc according to recommendations of their HIV care physician.

If participants remain HIV suppressed (below 2,000 vRNA copies per ml of plasma) for >28 days on Maraviroc monotherapy, they will be asked to gradually reduce Maraviroc dosing over a period of 4 weeks followed by intensive monitoring for an additional 28 days. Subjects who maintained HIV suppression with Maraviroc monotherapy are considered to have a functional cure. Subjects who maintain HIV suppression even after Maraviroc withdrawal also have a functional cure. Monthly monitoring for 6 months followed by less intensive monitoring will establish the durability of functional cure.

1.1 Patient Selection

Inclusion Criteria:

- Aged between 18 and 60 years.
- Documented HIV infection prior to study entry.
- Must be willing to comply with study-mandated evaluations; including not changing their antiretroviral regimen (unless medically indicated) during the study period.
- CD4+ T-cell count >600 cell per millimeter cubed (cells/mm³)
- CD4+ T-cell nadir of >400 cells/mm³
- HIV viral load >1,000 copies per milliliter (mL)

Exclusion Criteria:

- Any viral hepatitis
- Acute HIV infection
- HIV viral load >1,000,000 copies/mL
- 5 • Active or recent (prior 6 months) AIDS defining complication
- Any change in HIV medications within 12 weeks of entering the study
- Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
- Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled
- 10 • angina or arrhythmias
- History of bleeding problems
- Use of chronic steroids in past 30 days
- Pregnant or breast feeding
- Active drug or alcohol abuse
- 15 • Serious illness in past 30 days
- Currently participating in another clinical trial or any prior gene therapy

1.2 Safety assessments

- Acute infusion reaction
- Post-infusion safety follow-up

20 1.3 Efficacy assessments – Phase I

- Number and frequency of modified CD4 T cells.
- Durability of modified CD4 T cells.
- In vitro response to Gag peptide restimulation (ICS assay) as a measure of memory T cell function.
- 25 • Polyfunctional anti-HIV CD8 T cell responses compare to pre- and post-vaccination time points.
- Frequency of CD4 T cells making doubly spliced HIV mRNA after in vitro stimulation.

1.4 Efficacy assessments – Phase II

- Number and frequency of genetically modified CD4 T cells.
- Maintenance of viral suppression ($< 2,000$ vRNA copies per ml but 2 consecutive weekly draws not exceeding 5×10^4 vRNA copies per ml are permitted) with Maraviroc monotherapy.
- Continued virus suppression during and after Maraviroc withdrawal.
- Stable CD4 T cell count.

Example 21: Generating a Population of CD4+ T cells through Depletion of CD8+ T cells

Prior to Peptide Stimulation

Because CD8+ T cell overgrowth significantly impacted the expansion of target CD4+ T cells, CD8+ T cells were depleted at the beginning of cell expansion to determine whether it would improve CD4+ T cell expansion. Current CD8+ T cell depletion methods require that cells are passed through a magnetic column. To avoid possible impacts of that procedure on antigen presenting cells and CD4+ T cells, the cell depletion was performed after peptide stimulation and before lentivirus transduction when cells were better able to withstand the mechanical stresses.

More specifically, HIV positive human peripheral blood was obtained. PBMCs were separated with Ficoll-Paque PLUS (GE Healthcare, Cat: 17-1440-02). Fresh separated PBMCs (1×10^7) were stimulated with PepMix™ HIV (GAG) Ultra (Cat: PM-HIV-GAG, JPT Peptide Technologies, Berlin, Germany) in 1mL medium in a 24-well plate for 18 hours. CD8+ T cells were depleted with PE anti-human CD8 antibody and anti-PE microbeads. The negatively selected cells were cultured at 2×10^6 /mL in TexMACS GMP medium (Cat: 170-076-309, Miltenyi Biotech, Bergisch Gladbach, Germany) containing IL-7 (170-076-111, Miltenyi Biotech, Bergisch Gladbach, Germany), IL-15 (170-076-114, Miltenyi Biotech, Bergisch Gladbach, Germany) and Saquinavir (Cat: 4658, NIH AIDS Reagent Program, Germantown, MD). Lentivirus AGT103 was added 24 hours later at MOI 5. Fresh medium containing IL-7, IL-15 and Saquinavir were added every 2-3 days during the expansion. The final concentration of IL-7/IL-15 was 10ng/mL. The final concentration of Saquinavir was 100nM. At day 12-16, $2-3 \times 10^6$ cells were collected for peptide restimulation and intracellular cytokine staining (ICS) analysis. A schematic of this depletion protocol is shown in Figure 24.

When CD8⁺ T cells were depleted, HIV-specific CD4 T cell expansion was improved significantly (Figure 25A-C). However, overgrowth by V δ 1 T cells (PTID 01-006) (Figure 25A) and NK cells (PTID 01-008) (Figure 25C) was observed.

Referring to Figure 25A, on day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 44.5%, 55.5%, 0.032%, and 0%, respectively. On day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 44.2%, 55.3%, 0.48%, and 0.053%, respectively. On day 12, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 79.8%, 20.1%, 0.12%, and 0.018%, respectively. On day 12, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix had a fluorescence intensity of 58.9%, 19.2%, 21.2%, and 0.69%, respectively. On day 12, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 64.4%, 35.0%, 0.44%, and 0.14%, respectively. On day 12, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 61.9%, 32.9%, 3.47%, and 1.70%, respectively.

On day 12, with CD8 depletion, gating data was also produced using CD4 and CD8 as variables. The lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant had a fluorescence intensity of 45.5%/45.3%, 44.9%, 9.26%, and 0.35%, respectively. In addition, gating data was produced using V δ 1 and V δ 2 as variables. The lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant had a fluorescence intensity of 16.9%, 82.8%, 0.14%, and 0.12%, respectively.

Referring to Figure 25B, on day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 33.6%, 66.4%, 5.9E-4%, and 1.78E-3, respectively. On day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 33.7%, 66.3%, 0.011%, and 0.016%, respectively. On day 16, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 78.4%, 21.2%, 0.30%, and 0.018%, respectively. On day 16, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the

GagPepMix had a fluorescence intensity of 76.3%, 20.2%, 2.95%, and 0.61%, respectively. On day 16, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 50.9%, 48.7%, 0.36%, and 0.10%, respectively. On day 16, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 51.6%, 44.4%, 0.43%, and 3.60%, respectively.

Referring to Figure 25C, on day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 65.4%, 34.5%, 0.096%, and 7.71E-4, respectively. On day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 65.4%, 34.3%, 0.20%, and 0.10%, respectively. On day 16, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 87.9%, 12.1%, 0.028%, and 6.24E-3%, respectively. On day 16, without CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix had a fluorescence intensity of 82.3%, 12.1%, 5.38%, and 0.23%, respectively. On day 16, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 87.8%, 12.0%, 0.22%, and 0.013%, respectively. On day 16, with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 87.8%, 11.1%, 0.30%, and 0.78%, respectively.

On day 16, with CD8 depletion, gating data was also produced using the variables CD3 and CD4, which showed a fluorescence intensity of 83.1% in the region indicated. In addition, gating data was produced using the variables CD56 and CD4, which showed a fluorescence intensity of 65.7% in the region indicated.

Example 22: Generating a Population of CD4⁺ T cells through Depletion of CD8⁺, $\gamma\delta$, NK, and B Cells Prior to Peptide Stimulation

When CD8⁺ T cells were depleted, $\gamma\delta$ or NK cell overgrowth was observed in multiple patients. Consequently, CD8, $\gamma\delta$, NK or B cells were depleted to test whether it would improve CD4⁺ T cell expansion. Cell depletion was performed after peptide stimulation and before lentivirus transduction.

HIV positive human peripheral blood was obtained. PBMCs were separated with Ficoll-Paque PLUS (GE Healthcare, Cat: 17-1440-02). Fresh separated PBMCs (1×10^7) were stimulated with PepMix™ HIV (GAG) Ultra (Cat: PM-HIV-GAG, JPT Peptide Technologies, Berlin, Germany) in 1mL medium in a 24-well plate for 18 hours. CD8+ T, $\gamma\delta$, NK, or B cells were depleted with PE labeled specific antibodies and anti-PE microbeads. The negative selected cells were cultured at 2×10^6 /mL in TexMACS GMP medium (Cat: 170-076-309, Miltenyi Biotech, Bergisch Gladbach, Germany) containing IL-7 (170-076-111, Miltenyi Biotech, Bergisch Gladbach, Germany), IL-15 (170-076-114, Miltenyi Biotech, Bergisch Gladbach, Germany) and Saquinavir (Cat: 4658, NIH AIDS Reagent Program, Germantown, MD). Lentivirus AGT103 was added 24 hours later at MOI 5. Fresh medium containing IL-7, IL-15 and Saquinavir were added every 2-3 days during the expansion. The final concentration of IL-7/IL-15 was 10ng/mL. At day 12-16, $2-3 \times 10^6$ cells were collected for peptide restimulation and intracellular cytokine staining (ICS) analysis. A schematic of this depletion protocol is shown in Figure 26.

When additional cell subsets were depleted, HIV Gag-specific CD4 T cells were expanded to higher levels (Figure 27A-B). The overgrowth of CD8, $\gamma\delta$, or NK cells appears to inhibit CD4 T cell growth or kill lentivirus-transduced antigen-specific CD4 T cells. This optimized protocol is suitable for scale-up and cell manufacturing.

Referring to Figure 27A, on day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 56.4%, 43.5%, 0.034%, and 7.44E-4%, respectively. On day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 54.8%, 44.8%, 0.30%, and 0.055%, respectively. After 18 hours with no depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 83.9%, 16.0%, 0.061%, and 0.027%, respectively. After 18 hours with no depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 77.6%, 15.4%, 6.39%, and 0.54%, respectively. After 18 hours with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 41.9%, 57.9%, 0.094%, and 0.099%, respectively. After 18 hours with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right

quadrant of the GagPepMix, had a fluorescence intensity of 43.3%, 50.7%, 3.00%, and 2.98%, respectively. After 18 hours with CD8 and $\gamma\delta$ depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 40.4%, 59.3%, 0.12%, and 0.13%, respectively. After 18 hours with CD8 and $\gamma\delta$ depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 38.3%, 54.7%, 3.14%, and 3.86%, respectively. After 18 hours with CD8, $\gamma\delta$, and B depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 46.2%, 53.6%, 0.13%, and 0.080%, respectively. After 18 hours with CD8, $\gamma\delta$, and B depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 42.1%, 48.5%, 4.28%, and 5.06%, respectively.

Referring to Figure 27B, on day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 42.6%, 57.4%, 2.71E-3%, and 0.0%, respectively. On day 0, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 42.5%, 57.4%, 0.031%, and 0.048%, respectively. After 18 hours with no depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 79.5%, 20.5%, 0.017%, and 9.73E-3%, respectively. After 18 hours with no depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 78.9%, 19.5%, 0.93%, and 0.65%, respectively. After 18 hours with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the control, had a fluorescence intensity of 51.4%, 48.4%, 0.11%, and 0.063%, respectively. After 18 hours with CD8 depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 51.7%, 43.0%, 0.22%, and 5.03%, respectively. After 18 hours with CD8, CD56, $\gamma\delta$, and B depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the cells that had no stimulation, had a fluorescence intensity of 12.8%, 87.0%, 0.14%, and 0.10%, respectively. After 18 hours with CD8, CD56, $\gamma\delta$, and B depletion, the lower left quadrant, the lower right quadrant, the upper left quadrant, and the upper right quadrant of the GagPepMix, had a fluorescence intensity of 13.2%, 79.4%, 0.27%, and 7.17%, respectively.

Example 23: Method of Measuring Transduction Efficiency of the AGT103 Lentivirus

To improve the expansion of CD4⁺ T cells, the target cell is lentivirus AGT103-transduced, antigen-specific CD4⁺ T cells. A lentivirus carrying GFP was used to measure transduction efficiency. Because intracellular staining causes significant GFP signal loss, CCS
 5 was used to identify antigen-specific CD4⁺ T cells and GFP positive cells were used to identify the transduced cell subsets.

1x10⁷ PBMCs from HIV positive patients were stimulated with PepMix™ HIV (GAG) Ultra (Cat: PM-HIV-GAG, JPT Peptide Technologies, Berlin, Germany) in 1mL medium in a 24-well plate for 18 hours. CD8, γδ, NK or B cells were depleted with PE labeled specific
 10 antibodies and anti-PE microbeads. The negative selected cells were cultured at 2x10⁶/mL in TexMACS GMP medium (Cat: 170-076-309, Miltenyi Biotech, Bergisch Gladbach, Germany) containing IL-7 (170-076-111, Miltenyi Biotech, Bergisch Gladbach, Germany), IL-15 (170-076-114, Miltenyi Biotech, Bergisch Gladbach, Germany) and Saquinavir (Cat: 4658, NIH AIDS Reagent Program, Germantown, MD). Lentivirus carrying GFP was added 24 hours later
 15 at MOI 5. Fresh medium containing IL-7, IL-15 and Saquinavir were added every 3 days during the expansion. The final concentration of IL-7/IL-15 was 10ng/mL. At day 12-16, 2-3 x10⁶ cells were collected. Peptide restimulation and CCS assay was performed to evaluate IFN-γ-positive antigen-specific CD4⁺ T cells and transduction efficiency with GFP signaling. All experiments were performed following manufacturer's instructions.

20 IFN-γ positive, antigen-specific CD4⁺ T cells showed much better transduction efficiency compared to other cell subsets in the culture (Figure 28). It is reasonable given that antigen-specific CD4⁺ T cells received TCR stimulation, proliferated faster, and were more easily infected by lentivirus. As shown in Figure 28, the lower right quadrant (68.6% fluorescence) and upper right quadrant (12.6% fluorescence), had a GFP transduction
 25 efficiency of 41.5%, and 67.8%, respectively. This is in contrast to the lower left quadrant (9.75% fluorescence) and the upper left quadrant (2.46% fluorescence), which had a GFP transduction efficiency of 35.6% and 43.3%, respectively.

**Example 24: Method of Determining Relationship between percentage of Transduced
 30 Cells and Vector Copy Number**

Because the target cell is AGT103 lentivirus transduced, HIV-specific CD4 T cells, it is important to know how many target cells are included in the final cell product. However, there are no detectable markers included in the clinical grade AGT103 lentivirus. As a result,

transduction efficiency was measured by detecting vector copy number (VCN) by qPCR. By establishing the relationship between percentage of transduced cells and VCN using a lentivirus carrying GFP, the percentage of transduced cells based on VCN in the final cell product can be estimated.

5 1×10^7 PBMCs from HIV positive patients were stimulated with PepMix™ HIV (GAG) Ultra (Cat: PM-HIV-GAG, JPT Peptide Technologies, Berlin, Germany) in 1mL medium in a 24-well plate for 18 hours. CD8, $\gamma\delta$, NK or B cells were depleted with PE labeled specific antibodies and anti-PE microbeads. The negative selected cells were cultured at 2×10^6 /mL in TexMACS GMP medium (Cat: 170-076-309, Miltenyi Biotech, Bergisch Gladbach, Germany) 10 containing IL-7 (170-076-111, Miltenyi Biotech, Bergisch Gladbach, Germany), IL-15 (170-076-114, Miltenyi Biotech, Bergisch Gladbach, Germany) and Saquinavir (Cat: 4658, NIH AIDS Reagent Program, Germantown, MD). Lentivirus carrying GFP was added 24 hours later at MOI 5. Fresh medium containing IL-7, IL-15 and Saquinavir were added every 3 days during the expansion. The final concentration of IL-7/IL-15 was 10ng/mL. The final 15 concentration of Saquinavir was 100nM. At day 12-16, $2-3 \times 10^6$ cells were collected. Peptide restimulation and CCS assay was performed to evaluate antigen-specific CD4+ T cells and transduction efficiency with GFP signaling. QPCR was performed to detect vector copy number. All experiments were performed following manufacturer's instructions.

After testing four samples, a positive correlation between percentage of transduced 20 cells and vector copy number was observed (Figure 29).

Sequences

The following sequences are referred to herein:

SEQ ID NO:	Description	Sequence
1	miR30 CCR5	AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACT GAGCTTGCTCTACTGTGAAGCCACAGATGGGTAGA GCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACT TCAAGGGGCTT
2	miR21 Vif	CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTG TACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAG AAGAACACATCCGCACTGACATTTTGGTATCTTTCA

		TCTGACCA
3	miR185 Tat	GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCT TCTTCCTGCCATAGCGTGG TCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCC CTCCCAATGACCGCGTCTTCGTCTG
4, 64	Elongation Factor-1 alpha (EF1-alpha) promoter	CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGG GAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCC GAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGT CGCCGTGAACGTTCTTTTTTCGCAACGGGTTTGCCGC CAGAACACAGGTAAAGTGCCGTGTGTGGTTCCCGCG GGCCTGGCCTCTTTACGGGTATGGCCCTTGCGTGC CTTGAATTACTTCCACGCCCCTGGCTGCAGTACGTG ATTCTTGATCCCGAGCTTCGGGTGGAAGTGGGTGG GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCG CCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGG GGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCC TGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTAAA ATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCA AGATAGTCTTGTAATGCGGGCCAAGATCTGCACAC TGGTATTTTCGGTTTTTGGGGCCGCGGGCGGCGACGG GGCCCGTGCGTCCCAGCGCACATGTTTCGGCGAGGC GGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGG GGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCT GGCCTCGCGCCGCGGTGTATCGCCCCGCCCTGGGCG GCAAGGCTGGCCCGGTCTGGCACCAAGTTGCGTGAGC GGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGA GCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGG GCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTT TCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGA GTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTC GAGCTTTTGGAGTACGTCTTTAGGTTGGGGGGA GGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG

		GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGAT GTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGA TCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAA AGTTTTTTTCTTCCATTTCAGGTGTCGTGA
5	CCR5 target sequence	GAGCAAGCTCAGTTTACA
6	Vif target sequence	GGGATGTGTACTTCTGAACTT
7	Tat target sequence	TCCGCTTCTTCCTGCCATAG
8	TAR decoy sequence	CTTGCAATGATGTCGTAATTTGCGTCTTACCTCGTTC TCGACAGCGACCAGATCTGAGCCTGGGAGCTCTCTG GCTGTCAGTAAGCTGGTACAGAAGGTTGACGAAAA TTCTTACTGAGCAAGAAA
9	Rev/Tat target sequence	GCGGAGACAGCGACGAAGAGC
10	Rev/Tat shRNA sequence	GCGGAGACAGCGACGAAGAGCTTCAAGAGAGCTCT TCGTCGCTGTCTCCGCTTTTT
11	Gag target sequence	GAAGAAATGATGACAGCAT
12	Gag shRNA sequence	GAAGAAATGATGACAGCATTTC AAGAGAATGCTGT CATCATTCTTCTTTTT
13	Pol target sequence	CAGGAGCAGATGATACAG
14	Pol shRNA sequence	CAGGAGATGATACAGTTCAAGAGACTGTATCATCTG CTCCTGTTTTT
15	CCR5 target sequence #1	GTGTCAAGTCCAATCTATG
16	CCR5 shRNA sequence #1	GTGTCAAGTCCAATCTATGTTCAAGAGACATAGATT GGACTTGACACTTTTT
17	CCR5 target sequence #2	GAGCATGACTGACATCTAC

18	CCR5 shRNA sequence #2	GAGCATGACTGACATCTACTTCAAGAGAGTAGATGT CAGTCATGCTCTTTTT
19	CCR5 target sequence #3	GTAGCTCTAACAGGTTGGA
20	CCR5 shRNA sequence #3	GTAGCTCTAACAGGTTGGATTCAAGAGATCCAACCT GTTAGAGCTACTTTTT
21	CCR5 target sequence #4	G TTCAGAAACTACCTCTTA
22	CCR5 shRNA sequence #4	G TTCAGAAACTACCTCTTATTCAAGAGATAAGAGGT AGTTTCTGAACTTTTT
23	CCR5 target sequence #5	GAGCAAGCTCAGTTTACACC
24	CCR5 shRNA sequence #5	GAGCAAGCTCAGTTTACACCTTCAAGAGAGGTGTA AACTGAGCTTGCTCTTTTT
25	Homo sapiens CCR5 gene, sequence 1	ATGGATTATCAAGTGTCAAGTCCAATCTATGACATC AATTATTATACATCGGAGCCCTGCCAAAAAATCAAT GTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCGCTC TACTCACTGGTGTTCATCTTTGGTTTTGTGGGC
26	Homo sapiens CCR5 gene, sequence 2	AACATGCTGGTCATCCTCATCCTGATAAACTGCAAA AGGCTGAAGAGCATGACTGACATCTACCTGCTCAAC CTGGCCATCTCTGACCTGTTTTTCCTTCTTACTGTCC CCTTCTGGGCTCACTATGCTGCCGCCAGTGGGACT TTGGAAATACAATGTGTCAACTCTTGACAGGGCTCT ATTTTATAGGCTTCTTCTCTGGAATCTTCTTCATCAT CCTCCTGACAATCGATAGGTACCTGGCTGTCGTCCA TGCTGTGTTTGCTTTAAAAGCCAGGACGGTCACCTT TGGGGTGGTGACAAGTGTGATCACTTGGGTGGTGGC TGTGTTTGCGTCTCTCCCAGGAATCATCTTTACCAG ATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTC TCATTTTCCATACAGTCAGTATCAATTCTGGAAGAA TTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGT CCTGCCGCTGCTTGTCATGGTCATCTGCTACTCGGG

		AATCCTAAAAACTCTGCTTCGGTGTCGAAATGAGAA GAAGAGGCACAGGGCTGTGAGGCTTATCTTCACCAT CATGATTGTTTATTTTCTCTTCTGGGCTCCCTACAAC ATTGTCCTTCTCCTGAAC
27	Homo sapiens CCR5 gene, sequence 3	ACCTTCCAGGAATTCTTTGGCCTGAATAATTGCAGT AGCTCTAACAGGTTGGACCAAGCTATGCAGGTGA
28	Homo sapiens CCR5 gene, sequence 4	CAGAGACTCTTGGGATGACGCACTGCTGCATCAACC CCATCATCTATGCCTTTGTCGGGGAGAAGTTCAGAA ACTACCTCTTAGTCTTCTTCCAAAAGCACATTGCCA AACGCTTCTGCAAATGCTGTTCTATTTTCCAG
29	Homo sapiens CCR5 gene, sequence 5	CAAGAGGCTCCCGAGCGAGCAAGCTCAGTTTACAC CCGATCCACTGGGGAGCAGGAAATATCTGTGGGCTT GTGA
30	CD4 promoter sequence	TGTTGGGGTTCAAATTTGAGCCCCAGCTGTTAGCCC TCTGCAAAGAAAAAAAAAAAAAAAAAAGAACAAA GGGCCTAGATTTCCTTCTGAGCCCCACCCTAAGAT GAAGCCTCTTCTTTCAAGGGAGTGGGGTTGGGGTGG AGGCGGATCCTGTCAGCTTTGCTCTCTCTGTGGCTG GCAGTTTCTCCAAAGGGTAACAGGTGTCAGCTGGCT GAGCCTAGGCTGAACCCTGAGACATGCTACCTCTGT CTTCTCATGGCTGGAGGCAGCCTTTGTAAGTCACAG AAAGTAGCTGAGGGGCTCTGGAAAAAAGACAGCCA GGGTGGAGGTAGATTGGTCTTTGACTCCTGATTAA GCCTGATTCTGCTTAACTTTTTCCCTTGACTTTGGCA TTTTCACCTTGACATGTTCCCTGAGAGCCTGGGGGG TGGGGAACCCAGCTCCAGCTGGTGACGTTTGGGGCC GGCCCAGGCCTAGGGTGTGGAGGAGCCTTGCCATC GGGCTTCCTGTCTCTCTTCATTAAAGCACGACTCTGC AGA
31	miR30- CCR5/miR21-	AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACT GAGCTTGCTCTACTGTGAAGCCACAGATGGGTAGA

	Vif/miR185 Tat microRNA cluster sequence	GCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACT TCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCA CCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTG AATCTCATGGAGTTCAGAAGAACACATCCGCACTG ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGC CTGGCTCGAGCAGGGGGGCGAGGGATTCCGCTTCTTC CTGCCATAGCGTGGTCCCCCTCCCCTATGGCAGGCAG AAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGT C
32	Long WPRE sequence	AATCAACCTCTGATTACAAAATTTGTGAAAGATTGA CTGGTATTCTTA ACTATGTTGCTCCTTTTACGCTATG TGGATACGCTGCTTTAATGCCTTTGTATCATGCTATT GCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATA AATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGC CCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGT TTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCA CCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCC CCTCCCTATTGCCACGGCGGAACATCGCCGCCTG CCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGG CACTGACAATTCCGTGGTGTGTCGGGGAAATCATC GTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGG ATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTG CTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTC GCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCT CCCCGCCT
33	Elongation Factor-1 alpha (EF1-alpha) promoter; miR30CCR5; miR21Vif;	CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGG GAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCC GAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGT CGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGC CAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCG GGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGC

	miR185 Tat	CTTGAATTACTTCCACGCCCCTGGCTGCAGTACGTG ATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGG GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCCTTCG CCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGG GGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCC TGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAA ATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCA AGATAGTCTTGTAATGCGGGCCAAGATCTGCACAC TGGTATTTTCGGTTTTTTGGGGCCGCGGGCGGGCGACGG GGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGC GGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGG GGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCT GGCCTCGCGCCGCGGTGTATCGCCCCGCCCTGGGCG GCAAGGCTGGCCCCGGTCGGCACCAGTTGCGTGAGC GGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGA GCTCAAAATGGAGGACGCGGGCGCTCGGGAGAGCGG GCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTT TCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGA GTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTC GAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGA GGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGAT GTAATTCTCCTTGGAATTTGCCCTTTTTTGAGTTTGGA TCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAA AGTTTTTTTCTTCCATTTTCAGGTGTCGTGATGTACA <u>AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACT</u> <u>GAGCTTGCTCTACTGTGAAGCCACAGATGGGTTAGA</u> <u>GCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACT</u> <u>TCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCA</u> <u>CCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTG</u> <u>AATCTCATGGAGTTCAGAAGAACACATCCGCACTG</u> <u>ACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGC</u>
--	------------	--

		<u>CTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTC</u> <u>CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCAG</u> <u>AAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGT</u> <u>C</u>
34	Rous Sarcoma virus (RSV) promoter	GTAGTCTTATGCAATACTCTTGTAGTCTTGCAACAT GGTAACGATGAGTTAGCAACATGCCTTACAAGGAG AGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTA AGGTGGTACGATCGTGCCTTATTAGGAAGGCAACA GACGGGTCTGACATGGATTGGACGAACCACTGAAT TGCCGCATTGCAGAGATATTGTATTTAAGTGCCTAG CTCGATAACAATAAACG
35	5' Long terminal repeat (LTR)	GGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGC TCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTC AATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTG CCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCC TCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA
36	Psi Packaging signal	TACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGG AGAGAG
37	Rev response element (RRE)	AGGAGCTTTGTTTCCTTGGGTCTTGGGAGCAGCAGG AAGCACTATGGGCGCAGCCTCAATGACGCTGACGG TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGC AGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAA CAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAG CAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATA CCTAAAGGATCAACAGCTCC
38	Central polypurine tract (cPPT)	TTTTAAAAGAAAAGGGGGGATTGGGGGGGTACAGTG CAGGGGAAAGAATAGTAGACATAATAGCAACAGAC ATACAAACTAAAGAATTACAAAAACAAATTACAAA ATTCAAAATTTTA
39, 102	3' delta LTR	TGGAAGGGCTAATTCACCTCCCAACGAAGATAAGAT CTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACC AGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGA

		ACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAG TGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACT CTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAG TGTGGAAAATCTCTAGCAGTAGTAGTTCATGTCA
40, 49	Helper/Rev; CMV early (CAG) enhancer; Enhance Transcription	TAGTTATTAATAGTAATCAATTACGGGGTCATTAGT TCATAGCCCATATATGGAGTTCCGCGTTACATAACT TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACG ACCCCCGCCCATTGACGTCAATAATGACGTATGTTC CCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGACTATTTACGGTAAACTGCCCACTTGG CAGTACATCAAGTGTATCATATGCCAAGTACGCCCC CTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTA CTTGGCAGTACATCTACGTATTAGTCATC
41, 50	Helper/Rev; Chicken beta actin (CAG) promoter; Transcription	GCTATTACCATGGGTGCGAGGTGAGCCCCACGTTCTG CTTCACTCTCCCCATCTCCCCCCCCCTCCCCACCCCA ATTTTGTATTTATTTATTTTAAATTATTTTGTGCAGC GATGGGGGCGGGGGGGGGGGGGGGGGCGCGCGCCAGG CGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCG AGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG CGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCG GCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGC GGGCG
42, 51	Helper/Rev; Chicken beta actin intron; Enhance gene expression	GGAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTC CGCGCCGCCTCGCGCCGCCCCGGCTCTGACTG ACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGG CCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAA TGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGC CTAAAGGGCTCCGGGAGGGCCCTTTGTGCGGGGG GGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGC GTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGC GGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTG

		TGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGG GGGCGGTGCCCCGCGGTGCGGGGGGGCTGCGAGGG GAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGG GGTGAGCAGGGGGTGTGGGCGCGGCGGTTCGGGCTG TAACCCCCCTGCACCCCCCTCCCCGAGTTGCTGA GCACGGCCCGGCTTCGGGTGCGGGGGCTCCGTGCGG GGCGTGGCGCGGGGGCTCGCCGTGCCGGGCGGGGGG TGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCC GCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCG GCGGCCCCGGAGCGCCGGCGGCTGTTCGAGGCGCGG CGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCG AGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGGC GGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCT CTAGCGGGCGCGGGGCGAAGCGGTGCGGCGCCGGCA GGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCG CCGCGCCGCGTCCCCTTCTCCATCTCCAGCCTCGG GGCTGCCGCAGGGGGACGGCTGCCTTCGGGGGGGA CGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGAC CGGCGG
43, 52	Helper/Rev; HIV Gag; Viral capsid	ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGA ATTAGATCGATGGGAAAAAATTCGGTTAAGGCCAG GGGGAAAGAAAAAATATAAATTAAAACATATAGTA TGGGCAAGCAGGGAGCTAGAACGATTTCGCAGTTAA TCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACA AATACTGGGACAGCTACAACCATCCCTTCAGACAG GATCAGAAGAACTTAGATCATTATATAATACAGTAG CAACCCTCTATTGTGTGCATCAAAGGATAGAGATAA AAGACACCAAGGAAGCTTTAGACAAGATAGAGGAA GAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAG CAGCAGCTGACACAGGACACAGCAATCAGGTCAGC CAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAA

		TGCATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCA GCCCAGAAGTGATACCCATGTTTTTCAGCATTATCAG AAGGAGCCACCCCACAAGATTTAACACCATGCTA AACACAGTGGGGGGACATCAAGCAGCCATGCAAAT GTTAAAAGAGACCATCAATGAGGAAGCTGCAGAAT GGGATAGAGTGCATCCAGTGCATGCAGGGCCTATT GCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGA CATAGCAGGAACTACTAGTACCCTTCAGGAACAAA TAGGATGGATGACACATAATCCACCTATCCCAGTAG GAGAAATCTATAAAAGATGGATAATCCTGGGATTA AATAAAATAGTAAGAATGTATAGCCCTACCAGCATT CTGGACATAAGACAAGGACCAAAGGAACCCTTTAG AGACTATGTAGACCGATTCTATAAAACTCTAAGAGC CGAGCAAGCTTCACAAGAGGTAAAAAATTGGATGA CAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATT GTAAGACTATTTTAAAAGCATTGGGACCAGGAGCG ACACTAGAAGAAATGATGACAGCATGTCAGGGAGT GGGGGGACCCGGCCATAAAGCAAGAGTTTTTGGCTG AAGCAATGAGCCAAGTAACAAATCCAGCTACCATA ATGATACAGAAAGGCAATTTTAGGAACCAAAGAAA GACTGTTAAGTGTTTCAATTGTGGCAAAGAAGGGCA CATAGCCAAAAAATTGCAGGGCCCCTAGGAAAAAAGG GCTGTTGGAAATGTGGAAAGGAAGGACACCAAATG AAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGG AAGATCTGGCCTTCCCACAAGGGAAGGCCAGGGAA TTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACC AGAAGAGAGCTTCAGGTTTGGGGAAGAGACAACAA CTCCCTCTCAGAAGCAGGAGCCGATAGACAAGGAA CTGTATCCTTTAGCTTCCCTCAGATCACTCTTTGGCA GCGACCCCTCGTCACAATAA
44, 53	Helper/Rev; HIV Pol; Protease and	ATGAATTTGCCAGGAAGATGGAAACCAAAAATGAT AGGGGGAATTGGAGGTTTTATCAAAGTAGGACAGT

	reverse transcriptase	ATGATCAGATACTCATAGAAATCTGCGGACATAAA GCTATAGGTACAGTATTAGTAGGACCTACACCTGTC AACATAATTGGAAGAAATCTGTTGACTCAGATTGGC TGCAC TT TAAATTTTCCCATTAGTCCTATTGAGACTG TACCAGTAAAATTAAAGCCAGGAATGGATGGCCCA AAAGTTAAACAATGGCCATTGACAGAAGAAAAAAT AAAAGCATTAGTAGAAATTTGTACAGAAATGGAAA AGGAAGGAAAAATTTCAAAAATTGGGCCTGAAAAT CCATACAATACTCCAGTATTTGCCATAAAGAAAAAA GACAGTACTAAATGGAGAAAATTAGTAGATTTCAG AGAACTTAATAAGAGAACTCAAGATTTCTGGGAAG TTCAATTAGGAATACCACATCCTGCAGGGTTAAAAC AGAAAAAATCAGTAACAGTACTGGATGTGGGCGAT GCATATTTTTCAGTTCCCTTAGATAAAGACTTCAGG AAGTATACTGCATTTACCATACCTAGTATAACAAT GAGACACCAGGGATTAGATATCAGTACAATGTGCTT CCACAGGGATGGAAAGGATCACCAGCAATATTCCA GTGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAA ACAAAATCCAGACATAGTCATCTATCAATACATGGA TGATTTGTATGTAGGATCTGACTTAGAAATAGGGCA GCATAGAACAAAAATAGAGGAACTGAGACAACATC TGTTGAGGTGGGGATTTACCACACCAGACAAAAAA CATCAGAAAGAACCTCCATTCCTTTGGATGGGTAT GAACTCCATCCTGATAAATGGACAGTACAGCCTATA GTGCTGCCAGAAAAGGACAGCTGGACTGTCAATGA CATACAGAAATTAGTGGGAAAATTGAATTGGGCAA GTCAGATTTATGCAGGGATTAAAGTAAGGCAATTAT GTAAACTTCTTAGGGGAACCAAAGCACTAACAGAA GTAGTACCACTAACAGAAGAAGCAGAGCTAGAACT GGCAGAAAACAGGGAGATTCTAAAAGAACCGGTAC ATGGAGTGTATTATGACCCATCAAAGACTTAATAG CAGAAATACAGAAGCAGGGGGCAAGGCCAATGGACA
--	--------------------------	--

		TATCAAATTTATCAAGAGCCATTTAAAAATCTGAAA ACAGGAAAATATGCAAGAATGAAGGGTGCCACAC TAATGATGTGAAACAATTAACAGAGGCAGTACAAA AAATAGCCACAGAAAGCATAGTAATATGGGGAAAG ACTCCTAAATTTAAATTACCCATACAAAAGGAAACA TGGGAAGCATGGTGGACAGAGTATTGGCAAGCCAC CTGGATTCCTGAGTGGGAGTTTGTCAATACCCCTCC CTTAGTGAAGTTATGGTACCAGTTAGAGAAAGAAC CCATAATAGGAGCAGAACTTTCTATGTAGATGGG GCAGCCAATAGGGAACTAAATTAGGAAAAGCAGG ATATGTAAGTACAGAGGAAGACAAAAAGTTGTCC CCCTAACGGACACAACAAATCAGAAGACTGAGTTA CAAGCAATTCATCTAGCTTTGCAGGATTCGGGATTA GAAGTAAACATAGTGACAGACTCACAATATGCATT GGGAATCATTCAAGCACAACCAGATAAGAGTGAAT CAGAGTTAGTCAGTCAAATAATAGAGCAGTTAATA AAAAAGGAAAAAGTCTACCTGGCATGGGTACCAGC ACACAAAGGAATTGGAGGAAATGAACAAGTAGATG GGTTGGTCAGTGCTGGAATCAGGAAAGTACTA
45, 54	Helper Rev; HIV Integrase; Integration of viral RNA	TTTTTAGATGGAATAGATAAGGCCCAAGAAGAACA TGAGAAATATCACAGTAATTGGAGAGCAATGGCTA GTGATTTTAACTACCACCTGTAGTAGCAAAAGAAA TAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGG GAAGCCATGCATGGACAAGTAGACTGTAGCCCAGG AATATGGCAGCTAGATTGTACACATTTAGAAGGAA AAGTTATCTTGGTAGCAGTTCATGTAGCCAGTGGAT ATATAGAAGCAGAAGTAATTCCAGCAGAGACAGGG CAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGA AGATGGCCAGTAAAAACAGTACATACAGACAATGG CAGCAATTTACCAGTACTACAGTTAAGGCCGCCTG TTGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCC CTACAATCCCCAAAGTCAAGGAGTAATAGAATCTAT

		GAATAAAGAATTAAAGAAAATTATAGGACAGGTAA GAGATCAGGCTGAACATCTTAAGACAGCAGTACAA ATGGCAGTATTCATCCACAATTTTAAAAGAAAAGG GGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAG TAGACATAATAGCAACAGACATACAAACTAAAGAA TTACAAAAACAAATTACAAAAATTCAAAATTTTCGG GTTTATTACAGGGACAGCAGAGATCCAGTTTGGA AGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGG CAGTAGTAATACAAGATAATAGTGACATAAAAGTA GTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTA TGGAAAACAGATGGCAGGTGATGATTGTGTGGCAA GTAGACAGGATGAGGATTAA
46, 55	Helper/Rev; HIV RRE; Binds Rev element	AGGAGCTTTGTTCTTGGGTCTTGGGAGCAGCAGG AAGCACTATGGGCGCAGCGTCAATGACGCTGACGG TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGC AGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAA CAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAG CAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATA CCTAAAGGATCAACAGCTCCT
47, 57, 58	Helper/Rev; HIV Rev; Nuclear export and stabilize viral mRNA	ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAAC TCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATC AAAGCAACCCACCTCCCAATCCCGAGGGGACCCGA CAGGCCCCGAAGGAATAGAAGAAGAAGGTGGAGAG AGAGACAGAGACAGATCCATTCGATTAGTGAACGG ATCCTTAGCACTTATCTGGGACGATCTGCGGAGCCT GTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACT CTTGATTGTAACGAGGATTGTGGAACCTTCTGGGACG CAGGGGGTGGGAAGCCCTCAAATATTGGTGGAAATC TCCTACAATATTGGAGTCAGGAGCTAAAGAATAG
48, 56	Helper/Rev; Rabbit beta globin poly A;	AGATCTTTTCCCTCTGCCAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATA AAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAA

	RNA stability	TTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAG GGCAAATCATTTAAAACATCAGAATGAGTATTTGGT TTAGAGTTTGGCAACATATGCCATATGCTGGCTGCC ATGAACAAAGGTGGCTATAAAGAGGGTCATCAGTAT ATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCAT AGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTTATA TTTTGTTTTGTGTTATTTTTTTTCTTTAACATCCCTAAA ATTTTCCTTACATGTTTTTACTAGCCAGATTTTTTCCTC CTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTC TCTTATGAAGATC
59, 63	Rev; Rabbit beta globin poly A; RNA stability	AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCCTTGAGCATCTGACTTCTGGCTAATA AAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAA TTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAG GGCAAATCATTTAAAACATCAGAATGAGTATTTGGT TTAGAGTTTGGCAACATATGCCCATATGCTGGCTGC CATGAACAAAGGTTGGCTATAAAGAGGGTCATCAGT ATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCC ATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATA TATTTTGTTTTGTGTTATTTTTTTTCTTTAACATCCCTA AAATTTTCCTTACATGTTTTTACTAGCCAGATTTTTCC TCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCT TCTCTTATGGAGATC
60	Envelope; CMV promoter; Transcription	ACATTGATTATTGACTAGTTATTAATAGTAATCAAT TACGGGGTCATTAGTTCATAGCCCATATATGGAGTT CCGCGTTACATAACTTACGGTAAATGGCCCGCCTGG CTGACCGCCCAACGACCCCCGCCCATTGACGTCAAT AATGACGTATGTTCCCATAGTAACGCCAATAGGGAC TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTA AACTGCCCACCTTGGCAGTACATCAAGTGTATCATAT GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAA ATGGCCCGCCTGGCATTATGCCCAGTACATGACCTT

		ATGGGACTTTCCTACTTGGCAGTACATCTACGTATT AGTCATCGCTATTACCATGGTGATGCGGTTTTGGCA GTACATCAATGGGCGTGGATAGCGGTTTGACTCACG GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGG GAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCC AAAATGTCGTAACAACCTCCGCCCCATTGACGCAAAT GGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA GC
61	Envelope; Beta globin intron; Enhance gene expression	GTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCG CTATTGTAAAATTCATGTTATATGGAGGGGGCAAAG TTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCT TGTATCACCATGGACCCTCATGATAATTTTGTTTCTT TCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTT ATTTTCTTTTCATTTTCTGTAACCTTTTTCGTTAAACTT TAGCTTGCATTTGTAAACGAATTTTAAATTCATTTT GTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCAC TTTTTTTTCAAGGCAATCAGGGTATATTATATTGTAC TTCAGCACAGTTTTAGAGAACAATTGTTATAATTAA ATGATAAGGTAGAATATTTCTGCATATAAATTCTGG CTGGCGTGGAAATATTCTTATTGGTAGAAACAATA CACCTGGTCATCATCCTGCCTTTCTCTTTATGGTTA CAATGATATACACTGTTTGAGATGAGGATAAAATAC TCTGAGTCCAAACCGGGCCCCCTCTGCTAACCATGTT CATGCCTTCTTCTCTTTCCTACAG
62	Envelope; VSV- G; Glycoprotein envelope-cell entry	ATGAAGTGCCTTTTGTACTTAGCCTTTTTATTATTG GGGTGAATTGCAAGTTCACCATAGTTTTTCCACACA ACCAAAAAGGAACTGGAAAAATGTTCTTCTAATT ACCATTATTGCCCGTCAAGCTCAGATTTAAATTGGC ATAATGACTTAATAGGCACAGCCTTACAAGTCAAA ATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGG TTGGATGTGTCATGCTTCCAAATGGGTCACTACTTG TGATTTCCGCTGGTATGGACCGAAGTATATAACACA

		TTCCATCCGATCCTTCACTCCATCTGTAGAACAATG CAAGGAAAGCATTGAACAAACGAAACAAGGAACTT GGCTGAATCCAGGCTTCCCTCCTCAAAGTTGTGGAT ATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCC AGGTGACTCCTCACCATGTGCTGGTTGATGAATACA CAGGAGAATGGGTTGATTACAGTTCATCAACGGA AAATGCAGCAATTACATATGCCCCACTGTCCATAAC TCTACAACCTGGCATTCTGACTATAAGGTCAAAGGG CTATGTGATTCTAACCTCATTTCCATGGACATCACCT TCTTCTCAGAGGACGGAGAGCTATCATCCCTGGGAA AGGAGGGCACAGGGTTCAGAAGTAACTACTTTGCTT ATGAAACTGGAGGCAAGGCCTGCAAAATGCAATAC TGCAAGCATTGGGGAGTCAGACTCCCATCAGGTGTC TGGTTCGAGATGGCTGATAAGGATCTCTTTGCTGCA GCCAGATTCCCTGAATGCCCAGAAGGGTCAAGTATC TCTGCTCCATCTCAGACCTCAGTGGATGTAAGTCTA ATTCAGGACGTTGAGAGGATCTTGGATTATTCCCTC TGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCT TCCAATCTCTCCAGTGGATCTCAGCTATCTTGCTCCT AAAAACCCAGGAACCGGTCCTGCTTTCACCATAATC AATGGTACCCTAAAATACTTTGAGACCAGATACATC AGAGTCGATATTGCTGCTCCAATCCTCTCAAGAATG GTCGGAATGATCAGTGGAACCTACCACAGAAAGGGA ACTGTGGGATGACTGGGCACCATATGAAGACGTGG AAATTGGACCCAATGGAGTTCTGAGGACCAGTTCA GGATATAAGTTTCCTTTATACATGATTGGACATGGT ATGTTGGACTCCGATCTTCATCTTAGCTCAAAGGCT CAGGTGTTTCGAACATCCTCACATTCAAGACGCTGCT TCGCAACTTCCTGATGATGAGAGTTTATTTTTTGGTG ATACTGGGCTATCCAAAAATCCAATCGAGCTTGTAG AAGGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCCT CTTTTTTCTTTATCATAGGGTTAATCATTGGACTATT
--	--	--

		CTTGGTTCTCCGAGTTGGTATCCATCTTTGCATTAAA TTAAAGCACACCAAGAAAAGACAGATTTATACAGA CATAGAGATGA
65	Promoter; PGK	GGGGTTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGG GTTTGCGCAGGGACGCGGCTGCTCTGGGCGTGGTTC CGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGCA CATTCTTCACGTCCGTTTCGCAGCGTCACCCGGATCT TCGCCGCTACCCTTGTGGGGCCCCCGGCGACGCTTC CTGCTCCGCCCCCTAAGTCGGGAAGGTTCTTGCGGT TCGCGGCGTGCCGGACGTGACAAACGGAAGCCGCA CGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAG GGAGCAATGGCAGCGCGCCGACCGCGATGGGCTGT GGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGA GCAGCGGCCGGGAAGGGGCGGTGCGGGAGGCGGG GTGTGGGGCGGTAGTGTGGGGCCCTGTTCTTGCCCGC GCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCAC GTCGGCAGTCGGCTCCCTCGTTGACCGAATCACCGA CCTCTCTCCCCAG
66	Promoter; UbC	GCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCCCT CCTCACGGCGAGCGCTGCCACGTCAGACGAAGGGC GCAGGAGCGTTCCTGATCCTTCCGCCCGGACGCTCA GGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAG AACCCCAGTATCAGCAGAAGGACATTTTAGGACGG GACTTGGGTGACTCTAGGGCACTGGTTTTCTTTCCA GAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCT CGGCGATTCTGCGGAGGGATCTCCGTGGGGCGGTG AACGCCGATGATTATATAAGGACGCGCCGGGTGTG GCACAGCTAGTTCCGTCGCAGCCGGGATTTGGGTGCG CGGTTCTTGTTTGTGGATCGCTGTGATCGTCACTTGG TGAGTTGCGGGCTGCTGGGCTGGCCGGGGCTTTCGT GGCCGCCGGGCCGCTCGGTGGGACGGAAGCGTGTG GAGAGACCGCCAAGGGCTGTAGTCTGGGTCCGCGA

		GCAAGGTTGCCCTGAACTGGGGGTTGGGGGGAGCG CACAAAATGGCGGCTGTTCCCGAGTCTTGAATGGAA GACGCTTGTAAGGCGGGCTGTGAGGTCGTTGAAAC AAGGTGGGGGGGCATGGTGGGCGGCAAGAACCCAAG GTCTTGAGGCCTTCGCTAATGCGGGAAAGCTCTTAT TCGGGTGAGATGGGCTGGGGCACCATCTGGGGACC CTGACGTGAAGTTTGTCACTGACTGGAGAACTCGGG TTTGTCGTCTGGTTGCGGGGGGCGGCAGTTATGCGGT GCCGTTGGGCAGTGCACCCGTACCTTTGGGAGCGCG CGCCTCGTCGTGTCGTGACGTCACCCGTTCTGTTGG CTTATAATGCAGGGTGGGGCCACCTGCCGGTAGGTG TGCGGTAGGCTTTTCTCCGTCGCAGGACGCAGGGTT CGGGCCTAGGGTAGGCTCTCCTGAATCGACAGGCG CCGGACCTCTGGTGAGGGGAGGGATAAGTGAGGCG TCAGTTTCTTTGGTCGGTTTTTATGTACCTATCTTCTT AAGTAGCTGAAGCTCCGGTTTTTGAACATATGCGCTCG GGGTTGGCGAGTGTGTTTTGTGAAGTTTTTTAGGCA CCTTTTGAAATGTAATCATTGTTGGGTCAATATGTAAT TTTCAGTGTTAGACTAGTAAA
67	Poly A; SV40	GTTTATTGCAGCTTATAATGGTTACAAATAAAGCAA TAGCATCACAAATTTACAAATAAAGCATTTTTTTTC ACTGCATTCTAGTTGTGGTTTTGTCCAAACTCATCAA TGTATCTTATCA
68	Poly A; bGH	GACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC CCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC ACTCCCCTGTCCTTTCCTAATAAAAATGAGGAAATT GCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTG GGGGGTGGGGTGGGGCAGGACAGCAAGGGGGGAGG ATTGGGAAGACAATAGCAGGCATGCTGGGGATGCG GTGGGCTCTATGG
69	HIV Gag; Bal	ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGGAGA ATTAGATAGGTGGGAAAAAATTCGGTTAAGGCCAG

		GGGGAAAGAAAAAATATAGATTA AAAACATATAGTA TGGGCAAGCAGGGAACTAGAAAGATTCGCAGTCAA TCCTGGCCTGTTAGAAACATCAGAAGGCTGCAGAC AAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGA ACTTAGATCATTATATAATACAGTA GCAACCCTCTATTGTGTACATCAAAAGATAGAGGTA AAAGACACCAAGGAAGCTTTAGACAAAATAGAGGA AGAGCAAAACAAATGTAAGAAAAAGGCACAGCAA GCAGCAGCTGACACAGGAAACAGCGGTCAGGTCAG CCAAAATTTCCCTATAGTGCAGAACCTCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAA TGCATGGGTAAAAGTAATAGAAGAGAAAGCTTTCA GCCCAGAAGTAATACCCATGTTTTTCAGCATTATCAG AAGGAGCCACCCCACAAGATTTAAACACCATGCTA AACACAGTGGGGGGACATCAAGCAGCCATGCAAAT GTTAAAAGAACCCATCAATGAGGAAGCTGCAAGAT GGGATAGATTGCATCCCGTGCAGGCAGGGCCTGTTG CACCAGGCCAGATAAGAGATCCAAGGGGAAGTGAC ATAGCAGGAACTACCAGTACCCTTCAGGAACAAAT AGGATGGATGACAAGTAATCCACCTATCCCAGTAG GAGAAATCTATAAAAGATGGATAATCCTGGGATTA AATAAAATAGTAAGGATGTATAGCCCTACCAGCATT TTGGACATAAGACAAGGACCAAAGGAACCCTTTAG AGACTATGTAGACCGGTTCTATAAAACTCTAAGAGC CGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGA CAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATT GTAAGACTATTTTAAAAGCATTGGGACCAGCAGCTA CACTAGAAGAAATGATGACAGCATGTCAGGGAGTG GGAGGACCCAGCCATAAAGCAAGAATTTTGGCAGA AGCAATGAGCCAAGTAACAAATTCAGCTACCATAA TGATGCAGAAAGGCAATTTTAGGAACCAAAGAAAG ATTGTTAAATGTTTCAATTGTGGCAAAGAAGGGCAC
--	--	--

		ATAGCCAGAACTGCAGGGCCCCTAGGAAAAGGGG CTGTTGGAAATGTGGAAAGGAAGGACACCAAATGA AAGACTGTACTGAGAGACAGGCTAATTTTTTAGGGA AAATCTGGCCTTCCCACAAAGGAAGGCCAGGGAAT TTCCTTCAGAGCAGACCAGAGCCAACAGCCCCACC AGCCCCACCAGAAGAGAGCTTCAGGTTTGGGGAAG AGACAACAACCTCCCTCTCAGAAGCAGGAGCTGATA GACAAGGAACTGTATCCTTTAGCTTCCCTCAGATCA CTCTTTGGCAACGACCCCTCGTCACAATAA
70	HIV Pol; Bal	ATGAATTTGCCAGGAAGATGGAAACCAAAAATGAT AGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGT ATGATCAGATACTCATAGAAATCTGTGGACATAAA GCTATAGGTACAGTATTAATAGGACCTACACCTGTC AACATAATTGGAAGAAATCTGTTGACTCAGATTGGT TGCACTTTAAATTTTCCCATTAGTCCTATTGAAACTG TACCAGTAAAATTAAAACCAGGAATGGATGGCCCA AAAGTTAAACAATGGCCACTGACAGAAGAAAAAAT AAAAGCATTAAATGGAAATCTGTACAGAAATGGAAA AGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAAT CCATACAATACTCCAGTATTTGCCATAAAGAAAAAA GACAGTACTAAATGGAGAAAATTAGTAGATTTCAG AGAACTTAATAAGAAAACTCAAGACTTCTGGGAAG TACAATTAGGAATACACATCCCGCAGGGGGTTAAAA AAGAAAAAATCAGTAACAGTACTGGATGTGGGTGA TGCATATTTTTTCAGTTCCCTTAGATAAAGAATTCAG GAAGTATACTGCATTTACCATACCTAGTATAAACAA TGAAACACCAGGGATCAGATATCAGTACAATGTAC TTCCACAGGGATGGAAAGGATCACCAGCAATATTTC AAAGTAGCATGACAAGAATCTTAGAGCCTTTTAGA AAACAAAATCCAGAAATAGTGATCTATCAATACAT GGATGATTTGTATGTAGGATCTGACTTAGAAATAGG GCAGCATAGAACAAAAATAGAGGAACTGAGACAAC

		ATCTGTTGAGGTGGGGATTTACCACACCAGACAAA AAACATCAGAAAGAACCTCCATTCCTTTGGATGGGT TATGAACTCCATCCTGATAAATGGACAGTACAGCCT ATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAA TGACATACAGAAGTTAGTGGGAAAATTGAATTGGG CAAGTCAGATTTACCCAGGAATTAAAGTAAAGCAA TTATGTAGGCTCCTTAGGGGAACCAAGGCATTAACA GAAGTAATACCACTAACAAAAGAAACAGAGCTAGA ACTGGCAGAGAACAGGGGAAATTCTAAAAGAACCAG TACATGGGGTGTATTATGACCCATCAAAAGACTTAA TAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGG ACATATCAAATTTATCAAGAGCCATTTAAAAATCTG AAAACAGGAAAATATGCAAGAATGAGGGGGTGCCCA CACTAATGATGTAAAACAATTAACAGAGGCAGTGC AAAAAATAACCACAGAAAGCATAGTAATATGGGGA AAGACTCCTAAATTTAAACTACCCATACAAAAAGA AACATGGGAAACATGGTGGACAGAGTATTGGCAAG CCACCTGGATTCCTGAGTGGGAGTTTGTCAATACCC CTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAG AACCATAATAGGAGCAGAAACATTCTATGTAGAT GGAGCAGCTAACCGGGAGACTAAATTAGGAAAAGC AGGATATGTTACTAACAGAGGAAGACAAAAAGTTG TCTCCCTAACTGACACAACAAATCAGAAGACTGAGT TACAAGCAATTCATCTAGCTTTACAAGATTCAGGAT TAGAAGTAAACATAGTAACAGACTCACAATATGCA TTAGGAATCATTCAAGCACAACCAGATAAAAGTGA ATCAGAGTTAGTCAGTCAAATAATAGAACAGTTAAT AAAAAAGGAAAAGGTCTACCTGGCATGGGTACCAG CGCACAAAGGAATTGGAGGAAATGAACAAGTAGAT AAATTAGTCAGTACTGGAATCAGGAAAGTACTA
71	HIV Integrase; Bal	TTTTTAGATGGAATAGATATAGCCCAAGAAGAACAT GAGAAATATCACAGTAATTGGAGAGCAATGGCTAG

		TGATTTTAAACCTGCCACCTGTGGTAGCAAAAGAAAT AGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAG AAGCCATGCATGGACAAGTAGACTGTAGTCCAGGA ATATGGCAACTAGATTGTACACATTTAGAAGGAAA AATTATCCTGGTAGCAGTTCATGTAGCCAGTGGATA TATAGAAGCAGAAGTTATTCCAGCAGAGACAGGGC AGGAAACAGCATACTTTCTCTTAAAATTAGCAGGAA GATGGCCAGTAAAAACAATACATACAGACAATGGC AGCAATTTCACTAGTACTACAGTCAAGGCCGCCTGT TGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCC CTACAATCCCCAAAGTCAGGGAGTAGTAGAATCTAT AAATAAAGAATTAAAGAAAATTATAGGACAGGTAA GAGATCAGGCTGAACATCTTAAAACAGCAGTACAA ATGGCAGTATTCATCCACAATTTTAAAAGAAAAGG GGGGATTGGGGGGGTATAGTGCAGGGGAAAGAATAG TAGACATAATAGCAACAGACATACAACTAAAGAA TTACAAAAACAAATTACAAAAATTCAAATTTTCGG GTTTATTACAGGGACAGCAGAGATCCACTTTGGAAA GGACCAGCAAAGCTTCTCTGGAAAGGTGAAGGGGC AGTAGTAATACAAGATAATAGTGACATAAAAGTAG TACCAAGAAGAAAAGCAAAGATCATTAGGGATTAT GGAAAACAGATGGCAGGTGATGATTGTGTGGCAAG TAGACAGGATGAGGATTAG
72	Envelope; RD114	ATGAAACTCCCAACAGGAATGGTCATTTTATGTAGC CTAATAATAGTTCGGGCAGGGTTTGACGACCCCCGC AAGGCTATCGCATTAGTACAAAAACAACATGGTAA ACCATGCGAATGCAGCGGAGGGCAGGTATCCGAGG CCCCACCGAACTCCATCCAACAGGTAACTTGCCCAG GCAAGACGGCCTACTTAATGACCAACCAAAAATGG AAATGCAGAGTCACTCCAAAAAATCTCACCCCTAGC GGGGGAGAACTCCAGAACTGCCCCTGTAACACTTTC CAGGACTCGATGCACAGTTCTTGTTATACTGAATAC

		CGGCAATGCAGGGCGAATAATAAGACATACTACAC GGCCACCTTGCTTAAAATACGGTCTGGGAGCCTCAA CGAGGTACAGATATTACAAAACCCCAATCAGCTCCT ACAGTCCCCTTGTAGGGGCTCTATAAATCAGCCCGT TTGCTGGAGTGCCACAGCCCCCATCCATATCTCCGA TGGTGGAGGACCCCTCGATACTAAGAGAGTGTGGA CAGTCCAAAAAAGGCTAGAACAAATTCATAAGGCT ATGCATCCTGAACTTCAATACCACCCCTTAGCCCTG CCCAAAGTCAGAGATGACCTTAGCCTTGATGCACGG ACTTTTGATATCCTGAATACCACTTTTAGGTTACTCC AGATGTCCAATTTTAGCCTTGCCCAAGATTGTTGGC TCTGTTTAAAACTAGGTACCCCTACCCCTCTTGCGA TACCCACTCCCTCTTTAACCTACTCCCTAGCAGACTC CCTAGCGAATGCCTCCTGTCAGATTATACCTCCCCT CTTGGTTCAACCGATGCAGTTCTCCAACCTCGTCCTG TTTATCTTCCCCTTTCATTAACGATACGGAACAAAT AGACTTAGGTGCAGTCACCTTTACTAACTGCACCTC TGTAGCCAATGTCAGTAGTCCTTTATGTGCCCTAAA CGGGTCAGTCTTCCTCTGTGGAAATAACATGGCATA CACCTATTTACCCCAAAACTGGACAGGACTTTGCGT CCAAGCCTCCCTCCTCCCCGACATTGACATCATCCC GGGGGATGAGCCAGTCCCCATTCTGCCATTGATCA TTATATACATAGACCTAAACGAGCTGTACAGTTCAT CCCTTTACTAGCTGGACTGGGAATCACCGCAGCATT CACCACCGGAGCTACAGGCCTAGGTGTCTCCGTCAC CCAGTATACAAAATTATCCCATCAGTTAATATCTGA TGTCCAAGTCTTATCCGGTACCATAACAAGATTTACA AGACCAGGTAGACTCGTTAGCTGAAGTAGTTCTCCA AAATAGGAGGGGACTGGACCTACTAACGGCAGAAC AAGGAGGAATTTGTTTAGCCTTACAAGAAAAATGCT GTTTTTATGCTAACAAGTCAGGAATTGTGAGAAACA AAATAAGAACCCTACAAGAAGAATTACAAAAACGC
--	--	--

		AGGGAAAGCCTGGCATCCAACCCTCTCTGGACCGG GCTGCAGGGCTTTCTTCCGTACCTCCTACCTCTCCTG GGACCCCTACTCACCTCCTACTCATACTAACCATT GGGCCATGCGTTTTCAATCGATTGGTCCAATTTGTT AAAGACAGGATCTCAGTGGTCCAGGCTCTGGTTTTG ACTCAGCAATATCACCAGCTAAAACCCATAGAGTA CGAGCCATGA
73	Envelope; GALV	ATGCTTCTCACCTCAAGCCCGCACCCACCTTCGGCAC CAGATGAGTCCTGGGAGCTGGAAAAGACTGATCAT CCTCTTAAGCTGCGTATTCGGAGACGGCAAAACGA GTCTGCAGAATAAGAACCCCCACCAGCCTGTGACCC TCACCTGGCAGGTACTGTCCCAAACCTGGGGACGTTG TCTGGGACAAAAAGGCAGTCCAGCCCCTTTGGACTT GGTGGCCCTCTCTTACACCTGATGTATGTGCCCTGG CGGCCGGTCTTGAGTCCTGGGATATCCCGGGATCCG ATGTATCGTCCTCTAAAAGAGTTAGACCTCCTGATT CAGACTATACTGCCGCTTATAAGCAAATCACCTGGG GAGCCATAGGGTGCAGCTACCCTCGGGCTAGGACC AGGATGGCAAATTCCCCCTTCTACGTGTGTCCCCGA GCTGGCCGAACCCATTCAGAAGCTAGGAGGTGTGG GGGGCTAGAATCCCTATACTGTAAAGAATGGAGTT GTGAGACCACGGGTACCGTTTATTGGCAACCCAAGT CCTCATGGGACCTCATAACTGTAAAATGGGACCAA AATGTGAAATGGGAGCAAAAATTTCAAAGTGTGA ACAAACCGGCTGGTGTAACCCCCTCAAGATAGACTT CACAGAAAAAGGAAAACTCTCCAGAGATTGGATAA CGGAAAAAACCTGGGAATTAAGGTTCTATGTATATG GACACCCAGGCATACAGTTGACTATCCGCTTAGAGG TCACTAACATGCCGGTTGTGGCAGTGGGCCCAGACC CTGTCCTTGCGGAACAGGGACCTCCTAGCAAGCCCC TCACTCTCCCTCTCTCCCCACGGAAAGCGCCGCCCA CCCCTCTACCCCCGGCGGCTAGTGAGCAAACCCCTG

		CGGTGCATGGAGAACTGTTACCCTAAACTCTCCGC CTCCCACCAGTGGCGACCGACTCTTTGGCCTTGTGC AGGGGGCCTTCCTAACCTTGAATGCTACCAACCCAG GGGCCACTAAGTCTTGCTGGCTCTGTTTGGGCATGA GCCCCCCTTATTATGAAGGGATAGCCTCTTCAGGAG AGGTCGCTTATACCTCCAACCATAACCCGATGCCACT GGGGGGCCCAAGGAAAGCTTACCCTCACTGAGGTC TCCGGACTCGGGTCATGCATAGGGAAGGTGCCTCTT ACCCATCAACATCTTTGCAACCAGACCTTACCCATC AATTCCTCTAAAAACCATCAGTATCTGCTCCCCTCA AACCATAGCTGGTGGGCCTGCAGCACTGGCCTCACC CCCTGCCTCTCCACCTCAGTTTTTTAATCAGTCTAAAG ACTTCTGTGTCCAGGTCCAGCTGATCCCCCGCATCT ATTACCATTCTGAAGAAACCTTGTTACAAGCCTATG ACAAATCACCCCCCAGGTTTAAAAGAGAGCCTGCCT CACTTACCCTAGCTGTCTTCCTGGGGTTAGGGATTG CGGCAGGTATAGGTACTGGCTCAACCGCCCTAATTA AAGGGCCCATAGACCTCCAGCAAGGCCTAACCAGC CTCCAAATCGCCATTGACGCTGACCTCCGGGGCCCTT CAGGACTCAATCAGCAAGCTAGAGGACTCACTGAC TTCCCTATCTGAGGTAGTACTCCAAAATAGGAGAGG CCTTGACTTACTATTCCTTAAAGAAGGAGGCCTCTG CGCGGCCCTAAAAGAAGAGTGCTGTTTTTTATGTAGA CCACTCAGGTGCAGTACGAGACTCCATGAAAAAAC TTAAAGAAAGACTAGATAAAAGACAGTTAGAGCGC CAGAAAAACCAAAACTGGTATGAAGGGTGGTTCAA TAACTCCCCTTGGTTTACTACCCTACTATCAACCATC GCTGGGCCCCTATTGCTCCTCCTTTTGTTACTCACTC TTGGGGCCCTGCATCATCAATAAATTAATCCAATTCA TCAATGATAGGATAAGTGCAGTCAAATTTTAGTCC TTAGACAGAAATATCAGACCCTAGATAACGAGGAA AACCTTTAA
--	--	--

74	Envelope; FUG	ATGGTTCCGCAGGTTCTTTTGTTTGTACTCCTTCTGG GTTTTTCGTTGTGTTTCGGGAAGTTCCCCATTTACAC GATACCAGACGAACTTGGTCCCTGGAGCCCTATTGA CATACACCATCTCAGCTGTCCAAATAACCTGGTTGT GGAGGATGAAGGATGTACCAACCTGTCCGAGTTCTC CTACATGGAACTCAAAGTGGGATACATCTCAGCCAT CAAAGTGAACGGGTTCACTTGCACAGGTGTTGTGAC AGAGGCAGAGACCTACACCAACTTTGTTGGTTATGT CACAACCACATTCAAGAGAAAGCATTTCGCCCCAC CCCAGACGCATGTAGAGCCGCGTATAACTGGAAGA TGGCCGGTGACCCCAGATATGAAGAGTCCCTACAC AATCCATACCCCGACTACCACTGGCTTCGAACTGTA AGAACCACCAAAGAGTCCCTCATTATCATATCCCCA AGTGTGACAGATTTGGACCCATATGACAAATCCCTT CACTCAAGGGTCTTCCCTGGCGGAAAGTGCTCAGGA ATAACGGTGTCTCTACCTACTGCTCAACTAACCAT GATTACACCATTTGGATGCCCCGAGAATCCGAGACCA AGGACACCTTGTGACATTTTTTACCAATAGCAGAGGG AAGAGAGCATCCAACGGGAACAAGACTTGCGGCTT TGTGGATGAAAGAGGCCTGTATAAGTCTCTAAAAG GAGCATGCAGGCTCAAGTTATGTGGAGTTCTTGGAC TTAGACTTATGGATGGAACATGGGTGCGGATGCAA ACATCAGATGAGACCAAATGGTGCCCTCCAGATCA GTTGGTGAATTTGCACGACTTTCGCTCAGACGAGAT CGAGCATCTCGTTGTGGAGGAGTTAGTTAAGAAAA GAGAGGAATGTCTGGATGCATTAGAGTCCATCATG ACCACCAAGTCAGTAAGTTTCAGACGTCTCAGTCAC CTGAGAAAACCTTGTCCTCAGGGTTTGGAAAAGCATAT ACCATATTCAACAAAACCTTGATGGAGGCTGATGCT CACTACAAGTCAGTCCGGACCTGGAATGAGATCATC CCCTCAAAGGGTGTTTGAAAGTTGGAGGAAGGTG CCATCCTCATGTGAACGGGGTGTTTTTCAATGGTAT
----	---------------	--

		AATATTAGGGCCTGACGACCATGTCCTAATCCCAGA GATGCAATCATCCCTCCTCCAGCAACATATGGAGTT GTTGGAATCTTCAGTTATCCCCCTGATGCACCCCCT GGCAGACCCTTCTACAGTTTTTCAAAGAAGGTGATGA GGCTGAGGATTTTGTGGAAGTTCACCTCCCCGATGT GTACAAACAGATCTCAGGGGGTTGACCTGGGTCTCCC GAACTGGGGAAAGTATGTATTGATGACTGCAGGGG CCATGATTGGCCTGGTGTTGATATTTTCCCTAATGA CATGGTGCAGAGTTGGTATCCATCTTTGCATTAAAT TAAAGCACACCAAGAAAAGACAGATTTATACAGAC ATAGAGATGAACCGACTTGGAAAGTAA
75	Envelope; LCMV	ATGGGTCAGATTGTGACAATGTTTGAGGCTCTGCCT CACATCATCGATGAGGTGATCAACATTGTCATTATT GTGCTTATCGTGATCACGGGTATCAAGGCTGTCTAC AATTTTGCCACCTGTGGGATATTCGCATTGATCAGT TTCCTACTTCTGGCTGGCAGGTCCTGTGGCATGTAC GGTCTTAAGGGACCCGACATTTACAAAGGAGTTTAC CAATTTAAGTCAGTGGAGTTTGATATGTCACATCTG AACCTGACCATGCCCAACGCATGTTTCAGCCAACAAC TCCCACCATTACATCAGTATGGGGACTTCTGGACTA GAATTGACCTTCACCAATGATTCCATCATCAGTCAC AACTTTTGCAATCTGACCTCTGCCTTCAACAAAAAG ACCTTTGACCACACACTCATGAGTATAGTTTCGAGC CTACACCTCAGTATCAGAGGGAACTCCAACATAAG GCAGTATCCTGCGACTTCAACAATGGCATAACCATC CAATACAACCTTGACATTCTCAGATCGACAAAGTGCT CAGAGCCAGTGTAGAACCTTCAGAGGTAGAGTCCT AGATATGTTTAGAACTGCCTTCGGGGGGGAAATACAT GAGGAGTGGCTGGGGCTGGACAGGCTCAGATGGCA AGACCACCTGGTGTAGCCAGACGAGTTACCAATAC CTGATTATACAAAATAGAACCTGGGAAAACCACTG CACATATGCAGGTCCTTTTGGGATGTCCAGGATTCT

		CCTTTCCCAAGAGAAGACTAAGTTCTTCACTAGGAG ACTAGCGGGCACATTCACCTGGACTTTGTCAGACTC TTCAGGGGTGGAGAATCCAGGTGGTTATTGCCTGAC CAAATGGATGATTCTTGCTGCAGAGCTTAAGTGTTT CGGGAACACAGCAGTTGCGAAATGCAATGTAAATC ATGATGCCGAATTCTGTGACATGCTGCGACTAATTG ACTACAACAAGGCTGCTTTGAGTAAGTTCAAAGAG GACGTAGAATCTGCCTTGCACTTATTCAAAACAACA GTGAATTCTTTGATTTTCAGATCAACTACTGATGAGG AACCACCTTGAGAGATCTGATGGGGGTGCCATATTGC AATTACTCAAAGTTTTTGGTACCTAGAACATGCAAAG ACCGGCGAAACTAGTGTCCCAAGTGCTGGCTTGTC ACCAATGGTTCTTACTTAAATGAGACCCACTTCAGT GATCAAATCGAACAGGAAGCCGATAACATGATTAC AGAGATGTTGAGGAAGGATTACATAAAGAGGCAGG GGAGTACCCCCCTAGCATTGATGGACCTTCTGATGT TTTCCACATCTGCATATCTAGTCAGCATCTTCCTGCA CCTTGTCAAAATACCAACACACAGGCACATAAAAG GTGGCTCATGTCCAAAGCCACACCGATTAACCAACA AAGGAATTTGTAGTTGTGGTGCATTTAAGGTGCCTG GTGTAAAAACCGTCTGGAAAAGACGCTGA
76	Envelope; FPV	ATGAACACTCAAATCCTGGTTTTTCGCCCTTGTGGCA GTCATCCCCACAAATGCAGACAAAATTTGTCTTGGA CATCATGCTGTATCAAATGGCACCAAAGTAAACAC ACTCACTGAGAGAGGAGTAGAAGTTGTCAATGCAA CGGAAACAGTGGAGCGGACAAACATCCCCAAAATT TGCTCAAAGGGGAAAAGAACCACTGATCTTGGCCA ATGCGGACTGTTAGGGACCATTACCGGACCACCTCA ATGCGACCAATTTCTAGAATTTTCAGCTGATCTAAT AATCGAGAGACGAGAAGGAAATGATGTTTGTTACC CGGGGAAGTTTGTTAATGAAGAGGCATTGCGACAA ATCCTCAGAGGATCAGGTGGGATTGACAAAGAAAC

		AATGGGATTACATATAGTGGAATAAGGACCAACG GAACAACTAGTGCATGTAGAAGATCAGGGTCTTCAT TCTATGCAGAAATGGAGTGGCTCCTGTCAAATACAG ACAATGCTGCTTTCCACAAATGACAAAATCATACA AAACACAAGGAGAGAATCAGCTCTGATAGTCTGG GGAATCCACCATTTCAGGATCAACCACCGAACAGAC CAAACCTATATGGGAGTGGAAATAAACTGATAACAG TCGGGAGTTCCAAATATCATCAATCTTTTGTGCCGA GTCCAGGAACACGACCGCAGATAAATGGCCAGTCC GGACGGATTGATTTTCATTGGTTGATCTTGGATCCC AATGATACAGTTACTTTTAGTTTCAATGGGGCTTTC ATAGCTCCAAATCGTGCCAGCTTCTTGAGGGGAAAG TCCATGGGGATCCAGAGCGATGTGCAGGTTGATGCC AATTGCGAAGGGGAATGCTACCACAGTGGAGGGAC TATAACAAGCAGATTGCCTTTTCAAACATCAATAG CAGAGCAGTTGGCAAATGCCCAAGATATGTAAAAC AGGAAAGTTTATTATTGGCAACTGGGATGAAGAAC GTTCCCGAACCTTCCAAAAAAGGAAAAAAGAGG CCTGTTTGGCGCTATAGCAGGGTTTATTGAAAATGG TTGGGAAGGTCTGGTCGACGGGTGGTACGGTTTCAG GCATCAGAATGCACAAGGAGAAGGAACTGCAGCAG ACTACAAAAGCACCCAATCGGCAATTGATCAGATA ACCGGAAAGTTAAATAGACTCATTGAGAAAACCAA CCAGCAATTTGAGCTAATAGATAATGAATTCAGTGA GGTGGAAAAGCAGATTGGCAATTTAATTAAGTGA CCAAAGACTCCATCACAGAAGTATGGTCTTACAATG CTGAACTTCTTGTGGCAATGGAAAACCAGCACACTA TTGATTTGGCTGATTCAGAGATGAACAAGCTGTATG AGCGAGTGAGGAAACAATTAAGGGAAAATGCTGAA GAGGATGGCACTGGTTGCTTTGAAATTTTTCATAAA TGTGACGATGATTGTATGGCTAGTATAAGGAACAAT ACTTATGATCACAGCAAATACAGAGAAGAAGCGAT
--	--	--

		GCAAAATAGAATACAAATTGACCCAGTCAAATTGA GTAGTGGCTACAAAGATGTGATACTTTGGTTTAGCT TCGGGGGCATCATGCTTTTTTGCTTCTTGCCATTGCAAT GGGCCTTGTTTTTCATATGTGTGAAGAACGGAAACAT GCGGTGCACTATTTGTATATAA
77, 78	Envelope; RRV	AGTGTAACAGAGCACTTTAATGTGTATAAGGCTACT AGACCATACCTAGCACATTGCGCCGATTGCGGGGA CGGGTACTTCTGCTATAGCCCAGTTGCTATCGAGGA GATCCGAGATGAGGCGTCTGATGGCATGCTTAAGAT CCAAGTCTCCGCCCAAATAGGTCTGGACAAGGCAG GCACCCACGCCCACACGAAGCTCCGATATATGGCTG GTCATGATGTTTCAGGAATCTAAGAGAGATTTCCTTGA GGGTGTACACGTCCGCAGCGTGCTCCATACATGGGA CGATGGGACACTTCATCGTCGCACACTGTCCACCAG GCGACTACCTCAAGGTTTCGTTCGAGGACGCAGATT CGCACGTGAAGGCATGTAAGGTCCAATACAAGCAC AATCCATTGCCGGTGGGTAGAGAGAAGTTCGTGGTT AGACCACACTTTGGCGTAGAGCTGCCATGCACCTCA TACCAGCTGACAACGGCTCCCACCGACGAGGAGAT TGACATGCATACACCGCCAGATATACCGGATCGCAC CCTGCTATCACAGACGGCGGGCAACGTCAAATAA CAGCAGGCGGCAGGACTATCAGGTACAACCTGTACC TGCGGCCGTGACAACGTAGGCACTACCAGTACTGA CAAGACCATCAACACATGCAAGATTGACCAATGCC ATGCTGCCGTCACCAGCCATGACAAATGGCAATTTA CCTCTCCATTTGTTCCCAGGGCTGATCAGACAGCTA GGAAAGGCAAGGTACACGTTCCGTTCCCTCTGACTA ACGTCACCTGCCGAGTGCCGTTGGCTCGAGCGCCGG ATGCCACCTATGGTAAGAAGGAGGTGACCCTGAGA TTACACCCAGATCATCCGACGCTCTTCTCCTATAGG AGTTTAGGAGCCGAACCGCACCCGTACGAGGAATG GGTTGACAAGTTCTCTGAGCGCATCATCCAGTGAC

		GGAAGAAGGGATTGAGTACCAGTGGGGCAACAACC CGCCGGTCTGCCTGTGGGCGCAACTGACGACCGAG GGCAAACCCCATGGCTGGCCACATGAAATCATTCA GTACTATTATGGACTATACCCCGCCGCCACTATTGC CGCAGTATCCGGGGCGAGTCTGATGGCCCTCCTAAC TCTGGCGGCCACATGCTGCATGCTGGCCACCGCGAG GAGAAAGTGCCTAACACCGTACGCCCTGACGCCAG GAGCGGTGGTACCGTTGACACTGGGGCTGCTTTGCT GCGCACCGAGGGGCGAATGCA
79	Envelope; Ebola	ATGGGTGTTACAGGAATATTGCAGTTACCTCGTGAT CGATTCAAGAGGACATCATTCTTTCTTTGGGTAAAT ATCCTTTTCCAAAGAACATTTTCCATCCCACCTTGGA GTCATCCACAATAGCACATTACAGGTTAGTGATGTC GACAAACTGGTTTGCCGTGACAAACTGTCATCCACA AATCAATTGAGATCAGTTGGACTGAATCTCGAAGG GAATGGAGTGGCAACTGACGTGCCATCTGCAACTA AAAGATGGGGCTTCAGGTCCGGTGTCCCACCAAAG GTGGTCAATTATGAAGCTGGTGAATGGGCTGAAAA CTGCTACAATCTTGAAATCAAAAAACCTGACGGGA GTGAGTGTCTACCAGCAGCGCCAGACGGGATTTCGG GGCTTCCCCCGGTGCCGGTATGTGCACAAAGTATCA GGAACGGGACCGTGTGCCGGAGACTTTGCCTTCCAC AAAGAGGGTGCTTTCTTCCTGTATGACCGACTTGCT TCCACAGTTATCTACCGAGGAACGACTTTCGCTGAA GGTGTGCGTTGCATTTCTGATACTGCCCCAAGCTAAG AAGGACTTCTTCAGCTCACACCCCTTGAGAGAGCCG GTCAATGCAACGGAGGACCCGTCTAGTGGCTACTAT TCTACCACAATTAGATATCAAGCTACCGGTTTTGGA ACCAATGAGACAGAGTATTTGTTCGAGGTTGACAAT TTGACCTACGTCCAACCTTGAATCAAGATTCACACCA CAGTTTCTGCTCCAGCTGAATGAGACAATATATACA AGTGGGAAAAGGAGCAATACCACGGGAAAACCTAAT

		TTGGAAGGTCAACCCCGAAATTGATACAACAATCG GGGAGTGGGCCTTCTGGGAAACTAAAAAACCTCA CTAGAAAAATTTCGCAGTGAAGAGTTGTCTTTCACAG CTGTATCAAACAGAGCCAAAAACATCAGTGGTCAG AGTCCGGCGCGAACTTCTTCCGACCCAGGGACCAAC ACAACAACCTGAAGACCACAAAATCATGGCTTCAGA AAATTCCTCTGCAATGGTTCAAGTGCACAGTCAAGG AAGGGAAGCTGCAGTGTCTGCATCTGACAACCCTTGC CACAATCTCCACGAGTCCTCAACCCCCCACAACCAA ACCAGGTCCGGACAACAGCACCCACAATACACCCG TGTATAAACTTGACATCTCTGAGGCAACTCAAGTTG AACAAACATCACCGCAGAACAGACAACGACAGCACA GCCTCCGACACTCCCCCGCCACGACCGCAGCCGGA CCCCTAAAAGCAGAGAACACCAACACGAGCAAGGG TACCGACCTCCTGGACCCCGCCACCACAACAAGTCC CCAAAACCACAGCGAGACCGCTGGCAACAACAACA CTCATCACCAAGATACCGGAGAAGAGAGTGCCAGC AGCGGGAAGCTAGGCTTAATTACCAATACTATTGCT GGAGTCGCAGGACTGATCACAGGCGGGAGGAGAGC TCGAAGAGAAGCAATTGTCAATGCTCAACCCAAAT GCAACCCTAATTTACATTACTGGACTACTCAGGATG AAGGTGCTGCAATCGGACTGGCCTGGATACCATATT TCGGGCCAGCAGCCGAGGGAATTTACATAGAGGGG CTGATGCACAATCAAGATGGTTTAATCTGTGGGTG AGACAGCTGGCCAACGAGACGACTCAAGCTCTTCA ACTGTTCCCTGAGAGCCACAACCGAGCTACGCACCTT TTCAATCCTCAACCGTAAGGCAATTGATTTCTTGCT GCAGCGATGGGGCGGCACATGCCACATTTTGGGAC CGGACTGCTGTATCGAACCACATGATTGGACCAAG AACATAACAGACAAAATTGATCAGATTATTCATGAT TTTGTTGATAAAACCCTTCCGGACCAGGGGGACAAT GACAATTGGTGGACAGGATGGAGACAATGGATACC
--	--	--

		GGCAGGTATTGGAGTTACAGGCGTTATAATTGCAGT TATCGCTTTATTCTGTATATGCAAATTTGTCTTTTAG
80	Short WPRE sequence	AATCAACCTCTGGATTACAAAATTTGTGAAAGATTG ACTGATATTCTTAACTATGTTGCTCCTTTTACGCTGT GTGGATATGCTGCTTTAATGCCTCTGTATCATGCTAT TGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTAT AAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGG CCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTG TTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCC ACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCC CCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCT GCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGG GCACTGATAATTCCGTGGTGTGTC
81	Primer	TAAGCAGAATTC ATGAATTTGCCAGGAAGAT
82	Primer	CCATACAATGAATGGACACTAGGCGGCCGCACGAA T
83	Gag, Pol, Integrase fragment	GAATTCATGAATTTGCCAGGAAGATGGAAACCAAA AATGATAGGGGGAATTGGAGGTTTTATCAAAGTAA GACAGTATGATCAGATACTCATAGAAATCTGCGGA CATAAAGCTATAGGTACAGTATTAGTAGGACCTACA CCTGTCAACATAATTGGAAGAAATCTGTTGACTCAG ATTGGCTGCACTTTAAATTTTCCCATTAGTCCTATTG AGACTGTACCAGTAAAATTAAAGCCAGGAATGGAT GGCCCAAAAGTTAAACAATGGCCATTGACAGAAGA AAAAATAAAAGCATTAGTAGAAATTTGTACAGAAA TGGAAAAGGAAGGAAAAATTTCAAAAATTGGGCCT GAAAATCCATACAATACTCCAGTATTTGCCATAAAG AAAAAAGACAGTACTAAATGGAGAAAATTAGTAGA TTTCAGAGAACTTAATAAGAGAACTCAAGATTTCTG GGAAGTTCAATTAGGAATACCACATCCTGCAGGGTT AAAACAGAAAAAATCAGTAACAGTACTGGATGTGG GCGATGCATATTTTTCAGTTCCCTTAGATAAAGACT

		TCAGGAAGTATACTGCATTTACCATACCTAGTATAA ACAATGAGACACCAGGGATTAGATATCAGTACAAT GTGCTTCCACAGGGATGGAAAGGATCACCAGCAAT ATTCCAGTGTAGCATGACAAAAATCTTAGAGCCTTT TAGAAAACAAAATCCAGACATAGTCATCTATCAAT ACATGGATGATTTGTATGTAGGATCTGACTTAGAAA TAGGGCAGCATAGAACAAAAATAGAGGAACTGAGA CAACATCTGTTGAGGTGGGGATTTACCACACCAGAC AAAAAACATCAGAAAGAACCTCCATTCCTTTGGATG GGTTATGAACTCCATCCTGATAAATGGACAGTACAG CCTATAGTGCTGCCAGAAAAGGACAGCTGGACTGT CAATGACATACAGAAATTAGTGGGAAAATTGAATT GGGCAAGTCAGATTTATGCAGGGATTAAAGTAAGG CAATTATGTAACTTCTTAGGGGAACCAAAGCACTA ACAGAAGTAGTACCACTAACAGAAGAAGCAGAGCT AGAACTGGCAGAAAACAGGGAGATTCTAAAAGAAC CGGTACATGGAGTGTATTATGACCCATCAAAGACT TAATAGCAGAAATACAGAAGCAGGGGGCAAGGCCAA TGGACATATCAAATTTATCAAGAGCCATTTAAAAAT CTGAAAACAGGAAAGTATGCAAGAATGAAGGGTGC CCACACTAATGATGTGAAACAATTAACAGAGGCAG TACAAAAAATAGCCACAGAAAGCATAGTAATATGG GGAAAGACTCCTAAATTTAAATTACCCATACAAAA GGAAACATGGGAAGCATGGTGGACAGAGTATTGGC AAGCCACCTGGATTCCTGAGTGGGAGTTTGTCAATA CCCCTCCCTTAGTGAAGTTATGGTACCAGTTAGAGA AAGAACCCATAATAGGAGCAGAACTTTCTATGTA GATGGGGCAGCCAATAGGGAAACTAAATTAGGAAA AGCAGGATATGTAACTGACAGAGGAAGACAAAAAG TTGTCCCCCTAACGGACACAACAAATCAGAAGACT GAGTTACAAGCAATTCATCTAGCTTTGCAGGATTCG GGATTAGAAGTAAACATAGTGACAGACTCACAATA
--	--	--

		TGCATTGGGAATCATTCAAGCACAAACCAGATAAGA GTGAATCAGAGTTAGTCAGTCAAATAATAGAGCAG TTAATAAAAAAAGGAAAAAAGTCTACCTGGCATGGGT ACCAGCACACAAAGGAATTGGAGGAAATGAACAAG TAGATAAATTGGTCAGTGCTGGAATCAGGAAAGTA CTATTTTTTAGATGGAATAGATAAGGCCCAAGAAGA ACATGAGAAATATCACAGTAATTGGAGAGCAATGG CTAGTGATTTTAACCTACCACCTGTAGTAGCAAAAG AAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAA GGGGAAGCCATGCATGGACAAGTAGACTGTAGCCC AGGAATATGGCAGCTAGATTGTACACATTTAGAAG GAAAAGTTATCTTGGTAGCAGTTCATGTAGCCAGTG GATATATAGAAGCAGAAGTAATTCCAGCAGAGACA GGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCA GGAAGATGGCCAGTAAAAACAGTACATACAGACAA TGGCAGCAATTTACACCAGTACTACAGTTAAGGCCGC CTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCA TTCCCTACAATCCCCAAAGTCAAGGAGTAATAGAAT CTATGAATAAAGAATTAAAGAAAATTATAGGACAG GTAAGAGATCAGGCTGAACATCTTAAGACAGCAGT ACAAATGGCAGTATTCATCCACAATTTTAAAAGAAA AGGGGGGATTGGGGGGGTACAGTGCAGGGGAAAGA ATAGTAGACATAATAGCAACAGACATACAACTAA AGAATTACAAAAACAAATTACAAAAATTCAAAATT TTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTT GGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAA GGGGCAGTAGTAATACAAGATAATAGTGACATAAA AGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGG ATTATGGAAAACAGATGGCAGGTGATGATTGTGTG GCAAGTAGACAGGATGAGGATTAA
84	DNA Fragment containing Rev,	TCTAGAATGGCAGGAAGAAGCGGAGACAGCGACGA AGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCT

	RRE and rabbit beta globin poly A	CTATCAAAGCAACCCACCTCCCAATCCCGAGGGGA CCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGG AGAGAGAGACAGAGACAGATCCATTCGATTAGTGA ACGGATCCTTGGCACTTATCTGGGACGATCTGCGGA GCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACT TACTCTTGATTGTAACGAGGATTGTGGAAC TTCTGG GACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGG AATCTCCTACAATATTGGAGTCAGGAGCTAAAGAAT AGAGGAGCTTTGTTCCCTTGGGTTCTTGGGAGCAGCA GGAAGCACTATGGGCGCAGCGTCAATGACGCTGAC GGTACAGGCCAGACAATTATTGTCTGGTATAGTGCA GCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGC AACAGCATCTGTTGCAACTCACAGTCTGGGGCATCA AGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGA TACCTAAAGGATCAACAGCTCCTAGATCTTTTTCCC TCTGCCAAAAATTATGGGGACATCATGAAGCCCCTT GAGCATCTGACTTCTGGCTAATAAAGGAAATTTATT TTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCT CACTCGGAAGGACATATGGGAGGGCAAATCATTTA AAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCA ACATATGCCATATGCTGGCTGCCATGAACAAAGGTG GCTATAAAGAGGTCATCAGTATATGAAACAGCCCC CTGCTGTCCATTCCCTTATTCCATAGAAAAGCCTTGA CTTGAGGTTAGATTTTTTTTATATTTTGTTTTGTGTT ATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACAT GTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTAC TCCCAGTCATAGCTGTCCCTCTTCTCTTATGAAGATC CCTCGACCTGCAGCCCAAGCTTGGCGTAATCATGGT CATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAC AATTCCACACAACATACGAGCCGGAAGCATAAAGT GTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTC ACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCCAG
--	---	---

		TCGGGAAACCTGTCGTGCCAGCGGATCCGCATCTCA ATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGC CCATCCCGCCCCCTAACTCCGCCCAGTTCCGCCCATT CTCCGCCCCCATGGCTGACTAATTTTTTTTATTTATGC AGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCA GAAGTAGTGAGGAGGCTTTTTTTGGAGGCCTAGGCTT TTGCAAAAAGCTAACTTGTTTATTGCAGCTTATAAT GGTTACAAATAAAGCAATAGCATCACAAATTTAC AAATAAAGCATTTTTTTTCACTGCATTCTAGTTGTGGT TTGTCCAAACTCATCAATGTATCTTATCAGCGGCCG CCCCGGG
85	DNA fragment containing the CAG enhancer/promot er/intron sequence	ACGCGTTAGTTATTAATAGTAATCAATTACGGGGTGC ATTAGTTCATAGCCCATATATGGAGTTCCGCGTTAC ATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCCGCCCATTGACGTCAATAATGACGTA TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTG ACGTCAATGGGTGGACTATTTACGGTAAACTGCCCA CTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC CTGGCATTATGCCCAGTACATGACCTTATGGGACTT TCCTACTTGGCAGTACATCTACGTATTAGTCATCGC TATTACCATGGGTGCGAGGTGAGCCCCACGTTCTGCT TCACTCTCCCCATCTCCCCCCCCCTCCCCACCCCCAAT TTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCG ATGGGGGCGGGGGGGGGGGGGGGGGCGCGCGCCAGGC GGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGA GGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGC GCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGG CGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCG GGCGGGAGTCGCTGCGTTGCCTTCGCCCCGTGCCCC GCTCCGCGCCGCCTCGCGCCGCCCGCCCCGGCTCTG ACTGACCGCGTTACTCCACAGGTGAGCGGGCGGG

		ACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGG TTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGA AAGCCTTAAAGGGCTCCGGGAGGGCCCTTTGTGCG GGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGT GTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCC CGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGC TTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGC CGGGGGCGGTGCCCGCGGTGCGGGGGGGGCTGCGA GGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGG GGGGGTGAGCAGGGGGTGTGGGCGCGGCGGTCTGGG CTGTAACCCCCCTGCACCCCCCTCCCCGAGTTGC TGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGC GGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGG GGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGG CCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCG CGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGC GGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTG CGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTG GCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCC CTCTAGCGGGCGCGGGCGAAGCGGTGCGGCGCCGG CAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGT CGCCGCGCCGCCGTCCCCTTCTCCATCTCCAGCCTC GGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGGG GACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTG ACCGGCGGGAATTC
86	DNA fragment containing VSV- G	GAATTCATGAAGTGCCTTTTGTACTTAGCCTTTTTAT TCATTGGGGTGAATTGCAAGTTCACCATAGTTTTTC CACACAACCAAAAAGGAAACTGGAAAAATGTTTCCT TCTAATTACCATTATTGCCCCGTCAAGCTCAGATTTA AATTGGCATAATGACTTAATAGGCACAGCCTTACAA GTCAAATGCCCAAGAGTCACAAGGCTATTCAAGC AGACGGTTGGATGTGTCATGCTTCCAAATGGGTCAC

		TACTTGTGATTTCCGCTGGTATGGACCGAAGTATAT AACACATTCCATCCGATCCTTCACTCCATCTGTAGA ACAATGCAAGGAAAGCATTGAACAAACGAAACAAG GAACTTGGCTGAATCCAGGCTTCCCTCCTCAAAGTT GTGGATATGCAACTGTGACGGATGCCGAAGCAGTG ATTGTCCAGGTGACTCCTCACCATGTGCTGGTTGAT GAATACACAGGAGAATGGGTTGATTCACAGTTCATC AACGGAAAATGCAGCAATTACATATGCCCCACTGTC CATAACTCTACAACCTGGCATTCTGACTATAAGGTC AAAGGGCTATGTGATTCTAACCTCATTTCCATGGAC ATCACCTTCTTCTCAGAGGACGGAGAGCTATCATCC CTGGGAAAGGAGGGGCACAGGGTTCAGAAGTAACTA CTTTGCTTATGAAACTGGAGGCAAGGCCTGCAAAAT GCAATACTGCAAGCATTGGGGAGTCAGACTCCCATC AGGTGTCTGGTTCGAGATGGCTGATAAGGATCTCTT TGCTGCAGCCAGATTCCCTGAATGCCCAGAAGGGTC AAGTATCTCTGCTCCATCTCAGACCTCAGTGGATGT AAGTCTAATTCAGGACGTTGAGAGGATCTTGGATTA TTCCCTCTGCCAAGAAACCTGGAGCAAAATCAGAG CGGGTCTTCCAATCTCTCCAGTGGATCTCAGCTATC TTGCTCCTAAAAACCCAGGAACCGGTCCTGCTTTCA CCATAATCAATGGTACCCTAAAATACTTTGAGACCA GATACATCAGAGTCGATATTGCTGCTCCAATCCTCT CAAGAATGGTCGGAATGATCAGTGGAACCTACCACA GAAAGGGAACTGTGGGATGACTGGGGCACCATATGA AGACGTGGAAATTGGACCCAATGGAGTTCTGAGGA CCAGTTCAGGATATAAGTTTCCTTTATACATGATTG GACATGGTATGTTGGACTCCGATCTTCATCTTAGCT CAAAGGCTCAGGTGTTCTGAACATCCTCACATTCAAG ACGCTGCTTCGCAACTTCCTGATGATGAGAGTTTAT TTTTTGGTGATACTGGGCTATCCAAAATCCAATCG AGCTTGTAGAAGGTTGGTTCAGTAGTTGGAAAAGCT
--	--	--

		CTATTGCCTCTTTTTTCTTTATCATAGGGTTAATCAT TGGACTATTCTTGGTTCTCCGAGTTGGTATCCATCTT TGCATTAAATTAAAGCACACCAAGAAAAGACAGAT TTATACAGACATAGAGATGAGAATTC
87	Helper plasmid containing RRE and rabbit beta globin poly A	TCTAGAAGGAGCTTTGTTCTTGGGTTCTTGGGAGC AGCAGGAAGCACTATGGGCGCAGCGTCAATGACGC TGACGGTACAGGCCAGACAATTATTGTCTGGTATAG TGCAGCAGCAGAACAATTTGCTGAGGGGCTATTGAG GCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGC ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGA AAGATACCTAAAGGATCAACAGCTCCTAGATCTTTT TCCCTCTGCCAAAAATTATGGGGACATCATGAAGCC CCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATT TATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGT CTCTCACTCGGAAGGACATATGGGAGGGCAAATCA TTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTT GGCAACATATGCCATATGCTGGCTGCCATGAACAA AGGTGGCTATAAAGAGGTCATCAGTATATGAAACA GCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGC CTTGACTTGAGGTTAGATTTTTTTTATATTTTGTTTT GTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCT TACATGTTTTTACTAGCCAGATTTTTTCCTCCTCTCCTG ACTACTCCCAGTCATAGCTGTCCCTCTTCTCTTATGA AGATCCCTCGACCTGCAGCCCAAGCTTGGCGTAATC ATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCC GCTCACAATTCCACACAACATACGAGCCGGAAGCA TAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGC TAACTCACATTAATTGCGTTGCGCTCACTGCCCCGCT TTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGC ATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAA CTCCGCCCATCCCGCCCCCTAACTCCGCCCAGTTCCG CCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTAT

		TTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCT ATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT AGGCTTTTGCAAAAAGCTAACTTGTTTATTGCAGCT TATAATGGTTACAAATAAAGCAATAGCATCACAAA TTTCACAAATAAAGCATTTTTTTTCCTGCACTTCTAGT TGTGGTTTGTCCAAACTCATCAATGTATCTTATCACC CGGG
88	RSV promoter and HIV Rev	CAATTGCGATGTACGGGCCAGATATACGCGTATCTG AGGGGACTAGGGTGTGTTTAGGCGAAAAGCGGGGC TTCGGTTGTACGCGGTTAGGAGTCCCCTCAGGATAT AGTAGTTTCGCTTTTGCATAGGGAGGGGGAAATGTA GTCTTATGCAATACACTTGTAGTCTTGCAACATGGT AACGATGAGTTAGCAACATGCCTTACAAGGAGAGA AAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGG TGGTACGATCGTGCCTTATTAGGAAGGCAACAGAC AGGTCTGACATGGATTGGACGAACCACTGAATTCCG CATTGCAGAGATAATTGTATTTAAGTGCCTAGCTCG ATACAATAAACGCCATTTGACCATTACACCATTTGG TGTGCACCTCCAAGCTCGAGCTCGTTTAGTGAACCG TCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGA CCTCCATAGAAGACACCGGGACCGATCCAGCCTCCC CTCGAAGCTAGCGATTAGGCATCTCCTATGGCAGGA AGAAGCGGAGACAGCGACGAAGAACTCCTCAAGGC AGTCAGACTCATCAAGTTTCTCTATCAAAGCAACCC ACCTCCCAATCCCGAGGGGACCCGACAGGCCCGAA GGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAG ACAGATCCATTTCGATTAGTGAACGGATCCTTAGCAC TTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCA GCTACCACCGCTTGAGAGACTTACTCTTGATTGTAA CGAGGATTGTGGAACCTTCTGGGACGCAGGGGGTGG GAAGCCCTCAAATATTGGTGGAATCTCCTACAATAT TGGAGTCAGGAGCTAAAGAATAGTCTAGA

89	Target sequence	ATGGCAGGAAGAAGCGGAG
90	shRNA sequence	ATGGCAGGAAGAAGCGGAGTTCAAGAGACTCCGCT TCTTCCTGCCATTTTTT
91	H1 promoter and shRT sequence	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCAGTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGAC AGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTA TGTGTTCTGGGAAATCACCATAAACGTGAAATGTCT TTGGATTTGGGAATCTTATAAGTTCTGTATGAGACC ACTTGGATCCGCGGAGACAGCGACGAAGAGCTTCA AGAGAGCTCTTCGTCGCTGTCTCCGCTTTTT
92	H1 CCR5 sequence	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCAGTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGAC AGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTA TGTGTTCTGGGAAATCACCATAAACGTGAAATGTCT TTGGATTTGGGAATCTTATAAGTTCTGTATGAGACC ACTTGGATCCGTGTCAAGTCCAATCTATGTTCAAGA GACATAGATTGGACTTGACACTTTTT
93	CCR5 Forward Primer	AGGAATTGATGGCGAGAAGG
94	CCR5 Reverse Primer	CCCCAAAGAAGGTCAAGGTAATCA
95	Actin Forward Primer	AGCGCGGCTACAGCTTCA
96	Actin Reverse Primer	GGCGACGTAGCACAGCTTCT
97	AGT103 CCR5 miR30	TGTAAACTGAGCTTGCTCTA
98	AGT103-R5-1	TGTAAACTGAGCTTGCTCGC
99	AGT103-R5-2	CATAGATTGGACTTGACAC
100	CAG promoter	TAGTTATTAATAGTAATCAATTACGGGGGTCATTAGT

		TCATAGCCCATATATGGAGTTCCGCGTTACATAACT TACGGTAAATGGCCCGCCTGGCTGACCGCCCAACG ACCCCGCCCATTGACGTCAATAATGACGTATGTTC CCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGACTATTTACGGTAAACTGCCCACTTGG CAGTACATCAAGTGTATCATATGCCAAGTACGCCCC CTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTA CTTGGCAGTACATCTACGTATTAGTCATCGCTATTA CCATGGGTGCGAGGTGAGCCCCACGTTCTGCTTCACT CTCCCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGT ATTTATTTATTTTTTTAATTATTTTGTGCAGCGATGGG GGCGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGC GGGGCGGGGCGAGGGGGCGGGGGCGGGGGCGAGGCGG AGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCG GCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCG
101	H1 element	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGAC AGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTA TGTGTTCTGGGAAATCACCATAAACGTGAAATGTCT TTGGATTTGGGAATCTTATAAGTTCTGTATGAGACC ACTT
103	7SK promoter	CTGCAGTATTTAGCATGCCCCACCCATCTGCAAGGC ATTCTGGATAGTGTCAAACAGCCGGAAATCAAGT CCGTTTATCTCAAACTTTAGCATTTTGGGAATAAAT GATATTTGCTATGCTGGTTAAATTAGATTTTAGTTA AATTCCTGCTGAAGCTCTAGTACGATAAGCAACTT GACCTAAGTGTAAGTTGAGATTCCTTCAGGTTTA TATAGCTTGTGCGCCGCCTGGCTACCTC
104	miR155 Tat	CTGGAGGCTTGCTGAAGGCTGTATGCTGTCCGCTTC

		TTCCTGCCATAGGGTTTTGGCCACTGACTGACCCTA TGGGGAAGAAGCGGACAGGACACAAGGCCTGTTAC TAGCACTCACATGGAACAAATGGCC
--	--	--

While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the
5 scope and spirit of the present invention.

CLAIMS**WHAT IS CLAIMED IS:**

1. A method of treating cells infected with HIV, the method comprising:
 - (a) contacting peripheral blood mononuclear cells (PBMC) isolated from a subject infected with HIV with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out *ex vivo*;
 - (b) transducing the PBMC *ex vivo* with a viral delivery system encoding at least one genetic element; and
 - (c) culturing the transduced PBMC for at least 1 day.
2. The method of claim 1, wherein the transduced PBMC are cultured from about 1 to about 35 days.
3. The method of claim 1, further comprising infusing the transduced PBMC into a subject.
4. The method of claim 3, wherein the subject is a human.
5. The method of claim 1, wherein the stimulatory agent comprises a peptide.
6. The method of claim 5, wherein the peptide comprises a gag peptide.
7. The method of claim 1, wherein the stimulatory agent comprises a vaccine.
8. The method of claim 7, wherein the vaccine comprises a HIV vaccine.
9. The method of claim 8, wherein the HIV vaccine comprises a MVA/HIV62B vaccine or a variant thereof.
10. The method of claim 1, wherein the viral delivery system comprises a lentiviral particle.
11. The method of claim 1, wherein the at least one genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence.
12. The method of claim 1, wherein the at least one genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence.
13. The method of claim 11 or 12, wherein the HIV RNA sequence comprises a HIV Vif sequence, a HIV Tat sequence, or a variant thereof.
14. The method of claim 11 or 12, wherein the at least one genetic element comprises a microRNA or a shRNA.

15. The method of claim 14, wherein the at least one genetic element comprises a microRNA cluster.
16. The method of claim 14, wherein the at least one genetic element comprises a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTT (SEQ ID NO: 1).
17. The method of claim 14, wherein the at least one genetic element comprises:
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTT (SEQ ID NO: 1).
18. The method of claim 14, wherein the at least one genetic element comprises a microRNA having:
- at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAAC
TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or
 - at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
GGGCCTGGCTCGAGCAGGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).
19. The method of claim 14, wherein the at least one genetic element comprises:
- CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAAC
TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or
 - GGGCCTGGCTCGAGCAGGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).
20. The method of claim 15, wherein the microRNA cluster comprises a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
 GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
 GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
 GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
 TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
 GAGCAGGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
 CCTATGGCAGGCAGAAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
 (SEQ ID NO: 31).

21. The method of claim 15, wherein the microRNA cluster comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
 GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
 GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
 GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
 TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
 GAGCAGGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
 CCTATGGCAGGCAGAAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
 (SEQ ID NO: 31).

22. A method of treating HIV infection in a subject, the method comprising:

- (a) removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC);
- (b) contacting the PBMC *ex vivo* with a therapeutically effective amount of a stimulatory agent;
- (c) transducing the PBMC *ex vivo* with a viral delivery system encoding at least one genetic element; and
- (d) culturing the transduced PBMC for at least 1 day.

23. The method of claim 22, wherein the transduced PBMC are cultured from about 1 to about 35 days.

24. The method of claim 22, further comprising infusing the transduced PBMC into the subject.

25. The method of any one of claims 22-24, wherein the subject is a human.

26. The method of claim 22, wherein the stimulatory agent comprises a peptide.

27. The method of claim 26, wherein the stimulatory agent comprises a gag peptide.

28. The method of claim 22, wherein the stimulatory agent comprises a vaccine.

29. The method of claim 28, wherein the vaccine comprises a HIV vaccine.
30. The method of claim 29, wherein the HIV vaccine comprises a MVA/HIV62B vaccine or a variant thereof.
31. The method of claim 22, wherein the viral delivery system comprises a lentiviral particle.
32. The method of claim 22, wherein the at least one genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence.
33. The method of claim 22, the at least one genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence.
34. The method of claim 32 or 33, wherein the HIV RNA sequence comprises a HIV Vif sequence, a HIV Tat sequence, or a variant thereof.
35. The method of claim 32 or 33, wherein the at least one genetic element comprises a microRNA or a shRNA.
36. The method of claim 35, wherein the at least one genetic element comprises a microRNA cluster.
37. The method of claim 35, wherein the at least one genetic element comprises a microRNA having:
- a. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCC
TACTGCCTCGGACTTCAAGGGGCTT (SEQ ID NO: 1).
38. The method of claim 35, wherein the at least one genetic element comprises:
- AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTT (SEQ ID NO: 1).
39. The method of claim 35, wherein the at least one genetic element comprises a microRNA having:
- a. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAAC

TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or

- b. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity
with

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

40. The method of claim 35, wherein the at least one genetic element comprises:

- a. CATCTCCATGGCTGTACCACCTTGTCTGGGGGATGTGTACTTCTGAAC
TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or
- b. GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

41. The method of claim 36, wherein the microRNA cluster comprises a sequence having
at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
GAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
CCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
(SEQ ID NO: 31).

42. The method of claim 36, wherein the microRNA cluster comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
GAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
CCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
(SEQ ID NO: 31).

43. A lentiviral vector comprising at least one encoded genetic element, wherein the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence, wherein the HIV RNA sequence comprises a HIV Vif sequence, a HIV Tat sequence, or variant thereof.
44. A lentiviral vector comprising at least one encoded genetic element, wherein the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence, wherein the HIV RNA sequence comprises a HIV Vif sequence, HIV Tat sequence, or a variant thereof.
45. The lentiviral vector of claim 43 or 44, wherein the at least one encoded genetic element comprises a microRNA or a shRNA.
46. The lentiviral vector of claim 45, wherein the at least one encoded genetic element comprises a microRNA cluster.
47. The lentiviral vector of claim 45, wherein the at least one encoded genetic element comprises a microRNA having:
- a. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT
ACTGTGAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCC
TACTGCCTCGGACTTCAAGGGGCTT (SEQ ID NO: 1).
48. The lentiviral vector of claim 47, wherein the at least one encoded genetic element comprises:
AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTT (SEQ ID NO: 1).
49. The lentiviral vector of claim 45, wherein the at least one encoded genetic element comprises a microRNA having:
- a. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with
CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAAC
TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or

- b. at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with

GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

50. The lentiviral vector of claim 45, wherein the at least one encoded genetic element comprises:

- a. CATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAAC
TTGTGTTGAATCTCATGGAGTTCAGAAGAACACATCCGCACTGACAT
TTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or
- b. GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCAT
AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC
CAATGACCGCGTCTTCGTCG (SEQ ID NO: 3).

51. The lentiviral vector of claim 46, wherein the microRNA cluster comprises a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
GAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
CCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
(SEQ ID NO: 31).

52. The lentiviral vector of claim 46, wherein the microRNA cluster comprises:

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT
GAAGCCACAGATGGGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCG
GACTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGG
GATGTGTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGAACACA
TCCGCACTGACATTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCTGGCTC
GAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCTCC
CCTATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC
(SEQ ID NO: 31).

53. A lentiviral vector system for expressing a lentiviral particle, the system comprising:
- a. a lentiviral vector according to any one of claims 43-52;
 - b. an envelope plasmid for expressing an envelope protein optimized for infecting a cell; and
 - c. at least one helper plasmid for expressing gag, pol, and rev genes, wherein when the lentiviral vector, the envelope plasmid, and the at least one helper plasmid are transfected into a packaging cell line, a lentiviral particle is produced by the packaging cell line, wherein the lentiviral particle is capable of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA sequence.
54. The lentiviral vector system of claim 53, wherein the system comprises a first helper plasmid for expressing the gag and pol genes, and a second plasmid for expressing the rev gene.
55. A lentiviral particle capable of infecting a cell, the lentiviral particle comprising an envelope protein optimized for infecting a cell, and a lentiviral vector according to any one of claims 43-52.
56. The lentiviral particle of claim 55, wherein the envelope protein is optimized for infecting a T cell.
57. The lentiviral particle of claim 56, wherein the envelope protein is optimized for infecting a CD4⁺ T cell.
58. A modified cell comprising a CD4⁺ T cell, wherein the CD4⁺ T cell has been infected with a lentiviral particle according to any one of claims 55-57.
59. The modified cell of claim 58, wherein the CD4⁺ T cell also recognizes an HIV antigen.
60. The modified cell of claim 59, wherein the HIV antigen comprises a gag antigen.
61. The modified cell of claim 58, wherein the CD4⁺ T cell expresses a decreased level of CCR5 following infection with the lentiviral particle.
62. A method of selecting a subject for a therapeutic treatment regimen, the method comprising:
- (a) removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC) and determining a first quantifiable measurement associated with at least one factor associated with the PBMC; and

- (b) contacting the PBMC *ex vivo* with a therapeutically effective amount of a second stimulatory agent, and determining a second measurement associated with the at least one factor associated with the PBMC, whereby when the second quantifiable measurement is higher than the first quantifiable measurement, the subject is selected for the treatment regimen.
63. The method of claim 62, whereby the at least one factor associated with the PBMC is T cell proliferation.
64. The method of claim 62, wherein the at least one factor is IFN gamma production.
65. The method of claim 1, further comprising depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes.
66. The method of claim 65, wherein the depleting occurs after removing the leukocytes.
67. The method of claim 65, wherein the depleting occurs at the same time as removing the leukocytes.
68. The method of claim 22, further comprising depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes.
69. The method of claim 68, wherein the depleting occurs after removing the leukocytes.
70. The method of claim 68, wherein the depleting occurs at the same time as removing the leukocytes.
71. The method of claim 62, further comprising depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, $\gamma\delta$ cells, NK cells, B cells, neutrophils, basophils, eosinophils, T regulatory cells, NKT cells, and erythrocytes.
72. The method of claim 71, wherein the depleting occurs after removing the leukocytes.
73. The method of claim 71, wherein the depleting occurs at the same time as removing the leukocytes.

1/33




Figure 1

2/33




Figure 2




Figure 3





Figure 4

**Figure 5**

6/33

Elongation Factor-1 alpha (EF1-alpha) promoter

CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTT
 TTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTTCGCAA
 CGGGTTTGCCGCCAGAACACAGGTAAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGG
 GTTATGGCCCTTGCGTGCCTTGAATTACTTCCACGCCCCCTGGCTGCAGTACGTGATTCTTGATCC
 CGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTTCGAGGCCTTGCGCTTAAGGAGCCCCCTTCGCCTC
 GTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCGCGTGCGAATCTGGTGGCACCTTCGC
 GCCTGTCTCGCTGCTTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCT
 TTTTTTCTGGCAAGATAGTCTTGTAATGCGGGCCAAGATCTGCACACTGGTATTTTCGGTTTTTG
 GGGCCGCGGGCGGCGACGGGGCCCCGTGCGTCCCAGCGCACATGTTTCGGCGAGGCGGGGCCTGCGA
 GCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCT
 CGCGCCGCGGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCCGGTCGGCACCCAGTTGCGTGAG
 CGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGA
 GAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATG
 TGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGT
 CGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACT
 GAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATC
 TTGGTTTCAATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTTCTTCCATTTTCAGGTGTCGTGAT
 GTACA

miR30 CCR5

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCCACAGATG
GGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAAGGGGCTT

miR21 Vif





CCCGGGCATCTCCATGGCTGTACCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTGTTGAATC
TCATGGAGTTCAGAAGAACACATCCGCACTGACATTTTGGTATCTTTCATCTGACCA

miR185 Tat

GCTAGCGGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTCCCC
TCCCCATATGGCAGGCAGAAGCGGCACCTTCCCTCCCAATGACCGCGTCTTCGTC

Figure 6

7/33

Vector 1**Vector 2****Vector 3****Vector 4****Vector 5****Vector 6****Vector 7****Vector 8****Vector 9****Figure 7**




Figure 8

9/33




Figure 9

10/33




Figure 10

11/33




Figure 11





Figure 12




Figure 13

14/33




Figure 14




Figure 15

16/33




Figure 16




Figure 17




Figure 18




Figure 19





Figure 20




Figure 21




Figure 22




Figure 23




Figure 23 Cont'd

25/33




Figure 24




Figure 25




Figure 25 Cont'd






Figure 26




Figure 27




Figure 27 Cont'd




Figure 28

A

PTID	Mean of Vector copy number-NC	Using ACH2 as 1	GFP percentage among total cells (%)	GFP percentage among IFNG+ CD4+ cells (%)
01-006	0.225	0.139	9.17	41.7
01-007	0.23	0.142	21.6	48.4
01-009	0.596	0.368	34	72.8
01-009-2	0.927	0.572	43.8	67.8

B




Figure 29




Figure 17